ANTIMICROBIAL PEPTIDES AND METHODS OF USE

Abstract: The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention furthe rprovides recombinant expression cassettes, host cells, and transgenic plants.

Description: ANTIMICROBIAL PEPTIDES AND METHODS OF USE TECHNICAL FIELD The present invention relates generally to plant molecular biology. More specifically, it relates to nucleic acids and methods for modulating their expression in plants and to transforming genes into plants in order to enhance disease resistance. BACKGROUND OF THE INVENTION Disease in plants results from biotic and abiotic causes. Biotic causes include fungi, viruses, insects, bacteria, and nematodes. Of these, fungi are the most frequent causative agents of disease in plants. Abiotic causes of disease in plants include extremes of temperature, water, oxygen, and soil pH, plus nutrient-element deficiencies and imbalances, excess heavy metals, and air pollution. A host of cellular processes enables plants to defend themselves from disease caused by pathogenic agents. These processes apparently form an integrated set of resistance mechanisms that is activated by initial infection and then limits further spread ofthe invading pathogenic microorganism. Subsequent to recognition of a potentially pathogenic microbe, plants can activate an array of biochemical responses. Generally, the plant responds by inducing several local responses in the cells immediately surrounding the infection site. The most common resistance response observed in both nonhost and race-specific interactions is termed the "hypersensitive response" (HR). In the hypersensitive response, cells contacted by the pathogen, and often neighboring cells, rapidly collapse and dry in a necrotic fleck. Other responses include the deposition of callose, the physical thickening of cell walls by lignification, and the synthesis of various antibiotic small molecules and proteins. Genetic factors in both the host and the pathogen determine the specificity of these local responses, which can be very effective in limiting the spread of infection. As noted, among the causative agents of infectious disease of crop plants, the phytopathogenic fungi play the dominant role. Phytopathogenic fungi cause devastating epidemics as well as significant annual crop yield losses. Pathogenic fungi attack all ofthe approximately 300,000 species of flowering plants. However, a single plant species can be host to only a few fungal species, and similarly, most fungi usually have a limited host range. The antimicrobial peptide, snakin-1 has been isolated from potato tubers and found to be active against bacterial and fungal pathogens from potato and other plant species. Snakin-1 causes aggregation of both gram-positive and gram-negative bacteria. The protein is homologous to amino acid sequences deduced from cDNAs that encode gibberellin-inducible rnRNAs. The protein also shares sequence motifs with kistrin and other hemotoxic snake venoms. Plant disease outbreaks have resulted in catastrophic crop failures that have triggered famines and caused major social change. Generally, the best strategy for plant disease control is to use resistant cultivars selected or developed by plant breeders for this purpose. However, the potential for serious crop disease epidemics persists today, as evidenced by outbreaks ofthe Victoria blight of oats and southern corn leaf blight. Accordingly, molecular methods are needed to supplement traditional breeding methods to protect plants from pathogen attack. SUMMARY OF THE INVENTION Generally, it is the object ofthe present invention to provide nucleic acids and proteins relating to disease resistance, particularly antimicrobial and antifungal compositions. Such compositions are generally herein referred to as KCP-like (lysine- and cysteine-rich peptides or nucleic acids encoding these peptides). The present invention provides transgenic plants and seeds comprising the nucleic acids of the present invention, as well as transgenic plants and seeds modified to express a KCP-like polynucleotide. It is another object ofthe present invention to provide methods for modulating, in a transgenic plant, the expression ofthe nucleic acids of the present invention. In one aspect, the present invention relates to an isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of: (a) a polynucleotide that encodes a polypeptide of SEQ ID NOS:37-72; (b) a polynucleotide comprising at least 20 contiguous bases of SEQ ID OS: 1-36; (c) a polynucleotide having at least 70% sequence identity to any of SEQ ID NOS: 1-36, wherein said polynucleotide encodes a polypeptide having KCP-like activity; (d) a polynucleotide at least 25 nucleotides in length that hybridizes to a polynucleotide having the sequence set forth in SEQ ID NOS: 1-36, wherein said polynucleotide encodes a polypeptide having KCP-like activity; (e) a polynucleotide comprising the sequence set forth in any of SEQ ID NOS: 1-36; and, (f) a polynucleotide complementary to a polynucleotide of (a) through (e). The isolated nucleic acid can be DNA. The isolated nucleic acid can also be RNA. In another aspect, the present invention relates to vectors comprising the polynucleotides ofthe present invention. Also the present invention relates to recombinant expression cassettes, comprising a nucleic acid ofthe present invention operably linked to a promoter. In another aspect, the present invention is directed to a host cell into which has been introduced the recombinant expression cassette. In yet another aspect, the present invention relates to a transgenic plant or plant cell comprising a recombinant expression cassette with a promoter operably linked to any ofthe isolated nucleic acids ofthe present invention. Plants containing the recombinant expression cassette ofthe present invention include but are not limited to maize, soybean, sunflower, sorghum, canola, wheat, alfalfa, cotton, rice barley, or millet. The present invention also provides transgenic seed from the transgenic plant. In another aspect, the present invention relates to an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) an amino acid sequence comprising at least 25 contiguous amino acids ofthe sequence set forth in SEQ ID NOS:37-72; (b) an amino acid sequence having at least 75% sequence identity to the sequence set forth in SEQ ID NOS:37-72, wherein said polypeptide retains KCP-like activity; and, (c) an amino acid sequence comprising the sequences set forth in SEQ ID NOS:37-72. In a further aspect, the present invention relates to a method of modulating the level of protein in a plant by introducing into a plant cell a recombinant expression cassette comprising a polynucleotide ofthe present invention operably linked to a promoter, culturing the plant cell under plant growing conditions to produce a regenerated plant, and inducing expression ofthe polynucleotide for a time sufficient to modulate the protein ofthe present invention in the plant. Plants ofthe present invention include but are not limited to maize, soybean, sunflower, sorghum, canola, wheat, alfalfa, cotton, rice, barley, or millet. The level of protein in the plant can either be increased or decreased. In yet another aspect, the present invention is directed to a method for identifying KCP-like proteins, said method comprising: (a) searching at least one protein database with a pattern selected from the group consisting of: i) a pattern representing a compound having the formula (SEQ ID NO:97) C-X(2)-C-C-X(2)- [CS]-X(1,2)-C-V-P-[PSATK]-[GR]-X(2)-[GAQR], wherein: C is cysteine; X(2) is any two amino acids selected independently from one another; [CS] is one amino acid selected from the group consisting of cysteine and serine; X(l,2) is X(l) or X(2) wherein X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; V is valine; P is proline; [PSATK] is one amino acid selected from the group consisting of proline, serine, alanine, threonine, and lysine; [GR] is one amino acid selected from the group consisting of glycine and arginine; and [GAQR] is one amino acid selected from the group consisting of glycine, alanine, glutamine and arginine; and ii) a pattern for a compound having the formula (SEQ ID NO:98) [CS]-[PSQAG]-X(0,2)-C-Y-X(4)-[TNSM]-X(5,8)-K, wherein [CS] is one amino acid selected from the group consisting of cysteine and serine; [PSQAG] is one amino acid selected from the group consisting of proline, serine, glutamine, alanine, and glycine; X(0,2) is X(0) or X(l) or X(2) wherein X(0) is no amino acid, X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; C is cysteine; Y is tyrosine; X(4) is any four amino acids selected independently from one another; [TNSM] is one amino acid selected from the group consisting of threonine, asparagine, serine, and methionine; X(5,8) is X(5) or X(6) or X(7) or X(8) wherein X(5) is any five amino acids selected independently from one another, X(6) is any six amino acids selected independently from one another, X(7) is any seven amino acids selected independently from one another, and X(8) is any eight amino acids selected independently from one another; and K is lysine; and, (b) selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by at least one formula selected from said group. In one manifestation, searching is performed utilizing PHI-BLAST or PHI-PSI-BLAST under parameters comprising a default Expectation value (E) of 10, a gap opening cost with a default value of 11 , and a gap extension cost with a default value of 1. In another manifestation, the PHI-BLAST or PHI-PSI-BLAST is further used with BLOSUM62 substitution matrix. DETAILED DESCRIPTION OF THE INVENTION Overview Novel nucleic acid molecules and polypeptide sequences from maize, rice, wheat, and soybean are provided. These polypeptides are related to the potato snakin antimicrobial protein and GASA4 or GASA5 or GAST1 homologs in plants, and are referred to as KCP-like (lysine- and cysteine-rich peptides or nucleic acids encoding these peptides). The KCP-like proteins ofthe invention are generally lysine- and cysteine-rich; and the last three amino acids, which are universally conserved in the proteins ofthe invention, are K, C, and P, in that order. Generally, the KCP-like polypeptides ofthe invention are natural plant protection proteins. The KCP-like polypeptides ofthe invention are "antimicrobial," by which is intended antibacterial, antiviral, and antifungal. Additionally, the polypeptides ofthe invention may enhance resistance to insects and nematodes. Consequently, the sequences ofthe invention are "anti-pathogenic: and therefore find use in the prevention and control of disease in plants. The invention provides ectopic constitutive or inducible expression ofthe nucleotide sequences to enhance disease resistance in plants. In this manner, expression ofthe protein can be controlled such that the protein is expressed in the tissue or developmental stages to encounter the pathogen where it is most likely to strike. The proteins also find use in controlling plant pathogens such as bacteria, fungi, insects, nematodes, and the like. The KCP-like polypeptides ofthe invention can also be used for any application including coating surfaces to target microbes. In this manner, the target microbes include human pathogens or microorganisms. Surfaces that might be coated with the KCP-like polypeptides ofthe invention include carpets and sterile medical facilities. Polymer bound polypeptides ofthe invention may be used to coat surfaces. Methods for incorporating compositions with anti-microbial properties into polymers are known in the art. See U.S. Patent No. 5,847,047, herein incorporated by reference. Another embodiment involves the use ofthe compositions ofthe invention in the treatment and preservation of textiles. Insect pests devalue and destroy textiles and fabrics including, but not limited to, carpets, draperies, clothing, blankets, and bandages. The compositions ofthe invention may be applied to finished textile products or may be expressed in plants yielding fibers that are incorporated into fabrics. Insect pests that attack textiles include, but are not limited to, webbing clothes moths and carpet beetles. Thirty six novel nucleotide sequences are provided, including nine maize sequences, nine wheat sequences, two rice sequences, and twenty-one soybean sequences. Also provided are the polypeptides encoded by these nucleotide sequences. Nine sequences from Zea mays are provided (designated "Zm"). Zm-KCPl is a 730 nucleotide (nt) sequence (set forth in SEQ ID NO:l) that includes a 31 nt polyA tail (nt 700-730) and 699 nt exclusive ofthe polyA tail. Nucleotides 1 -96 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 97-441 and a 3 nontranslated region at nt 442-699. The predicted polypeptide sequence encoded by SEQ ID NO: 1 is set forth in SEQ ID NO:37. Zm-KCP2 is a 549 nucleotide sequence (set forth in SEQ ID NO:2). Nucleotides 1-241 correspond to a 5 nontranslated leader, with the coding region (ATG — stop) at nt 242-529 and a 3 nontranslated region at nt 530-549. The predicted polypeptide sequence encoded by SEQ ID NO:2 is set forth in SEQ ID NO:38. Zm-KCP3 is a 691 nucleotide (nt) sequence (set forth in SEQ ID NO:3) including a 10 nt polyA tail (nt 682-691) and 681 nt exclusive ofthe polyA tail. Nucleotides 1-156 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 157-504 and a 3 nontranslated region at nt 505-681. The predicted polypeptide sequence encoded by SEQ ID NO:3 is set forth in SEQ ID NO:39. Zm-KCP4 is a 831 nucleotide sequence (set forth in SEQ ID NO:4) that includes an 18 nt polyA tail (nt 814-831) and 813 nt exclusive ofthe polyA tail. Nucleotides 1-143 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 144-446 and a 3' nontranslated region at nt 447-813. The predicted polypeptide sequence encoded by SEQ ID NO:4 is set forth in SEQ ID NO:40. Zm-KCP5 is a 621 nucleotide sequence (set forth in SEQ ID NO: 5) that includes a 27 nt polyA tail (nt 595-621) and 594 nt exclusive ofthe polyA tail. Nucleotides 1-136 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 137-523 and a 3 nontranslated region at nt 524-594. The predicted polypeptide sequence encoded by SEQ ID NO:5 is set forth in SEQ ID NO:41. Zm-KCP6 is a 648 nucleotide sequence (set forth in SEQ ID NO:6) that includes an 18 nt polyA tail (nt 631-648) and 630 nt exclusive ofthe polyA tail. Nucleotides 1-141 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 142-432 and a 3 nontranslated region at nt 433-630. The predicted polypeptide sequence encoded by SEQ ID NO:6 is set forth in SEQ ID NO:42. Zm-KCP7 is an 806 nucleotide sequence (set forth in SEQ ID NO:7) that includes a 33 nt polyA tail (nt 774-806) and 773 nt exclusive ofthe polyA tail. Nucleotides 1-135 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 136-525 and a 3 nontranslated region at nt 526-773. The predicted polypeptide sequence encoded by SEQ ID NO:7 is set forth in SEQ ID NO:43. Zm-KCP8 is a 720 nucleotide sequence (set forth in SEQ ID NO:8) includes a 21 nt polyA tail (nt 700-720) and 699 nt exclusive ofthe polyA tail. Nucleotides 1- 118 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 119-403 and a 3 nontranslated region at nt 404-699. The predicted polypeptide sequence encoded by SEQ ID NO:8 is set forth in SEQ ID NO:44. Zm-KCP9 is a 754 nucleotide (nt) sequence (set forth in SEQ ID NO:9). Nucleotides 1-101 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 102-539 and a 3 nontranslated region at nt 540-754. The predicted polypeptide sequence encoded by SEQ ID NO:9 is set forth in SEQ ID NO:45. Nine sequences from Triticum aestivum are provided (designated "Ta..."). Ta-KCPl is a 594 nucleotide (nt) sequence (set forth in SEQ ID NO JO) that includes a 34 nt polyA tail (nt 561-594) and 560 nt exclusive ofthe polyA tail. Nucleotides 1-110 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 111-344 and a 3 nontranslated region at nt 345-560. The predicted polypeptide sequence encoded by SEQ ID NO: 10 is set forth in SEQ ID NO:46. Ta-KCP2 is a 677 nucleotide sequence (set forth in SEQ ID NO:l 1) including an 18 nt polyA tail (nt 660-677) and 659 nt exclusive ofthe polyA tail. Nucleotides 1-79 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 80-364 and a 3 nontranslated region at nt 365-659. The predicted polypeptide sequence encoded by SEQ ID NO: 11 is set forth in SEQ ID NO:47. Ta-KCP3 is a 639 nucleotide sequence (set forth in SEQ ID NO: 12) including a 27 nt polyA tail (nt 613-639) and 612 nt exclusive ofthe polyA tail. Nucleotides 1- 80 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 81-377 and a 3 ' nontranslated region at nt 378-612. The predicted polypeptide sequence encoded by SEQ ID NO:12 is set forth in SEQ ID NO:48. Ta-KCP4 is a 506 nucleotide sequence (set forth in SEQ ID NO: 13). Nucleotide 1 corresponds to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 2-325 and a 3 nontranslated region at nt 326-506. The predicted polypeptide sequence encoded by SEQ ID NO: 13 is set forth in SEQ ID NO:49. Ta-KCP5 is a 506 nucleotide sequence (set forth in SEQ ID NO: 14). Nucleotides 1-78 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 79-375 and a 3 nontranslated region at nt 376-506. The predicted polypeptide sequence encoded by SEQ ID NO: 14 is set forth in SEQ ID NO:50. Ta-KCP6 is a 769 nucleotide sequence (set forth in SEQ ID NO: 15) that includes a 20 nt polyA tail (nt 750-769) and 749 nt exclusive ofthe polyA tail. Nucleotides 1-55 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 56-400 and a 3 nontranslated region at nt 401-749. The predicted polypeptide sequence encoded by SEQ ID NO: 15 is set forth in SEQ ID NO:51. Ta-KCP7 is a 692 nucleotide sequence (set forth in SEQ ID NO: 16) that includes a 7 nt polyA tail (nt 686-692) and 685 nt exclusive ofthe polyA tail. Nucleotides 1-136 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 137-448 and a 3 nontranslated region at nt 449-685. The predicted polypeptide sequence encoded by SEQ ID NO: 16 is set forth in SEQ ID NO:52. Two Ory∑a sativa sequences are provided (designated "Os..."). Os-KCP3 is a 685 nucleotide sequence (set forth in SEQ ID NO: 17). Nucleotides 1-87 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 88-405, a 3 nontranslated region at nt 406-666, and a 19 nt polyA tail. The predicted polypeptide sequence encoded by SEQ ID NO: 17 is set forth in SEQ ID NO:53. Os-KCP4 is a 660 nucleotide sequence (set forth in SEQ ID NO: 18) that includes a 4 nt polyA tail (nt 657-660) and 656 nt exclusive ofthe polyA tail. Nucleotides 1-75 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 76-330 and a 3 nontranslated region at nt 331 -656. The predicted polypeptide sequence encoded by SEQ ID NO: 18 is set forth in SEQ ID NO:54. Twenty-one Glycine max sequences are provided (designated "Gm..."). Gm-KCPl is a 677 nucleotide (nt) sequence (set forth in SEQ ID NO: 19) that includes a 30 nt polyA tail (nt 648-677) and 647 nt exclusive ofthe polyA tail. Nucleotides 1-144 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 145-411 and a 3 nontranslated region at nt 412-647. The predicted polypeptide sequence encoded by SEQ ID NO: 19 is set forth in SEQ ID NO:55. Gm-KCP2 is a 756 nucleotide sequence (set forth in SEQ ID NO:20) that includes a 42 nt polyA tail (nt 715 -756) and 714 nt exclusive of the poly tail . Nucleotides 1-146 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 147-413 and a 3 nontranslated region at nt 414-714. The predicted polypeptide sequence encoded by SEQ ID NO:20 is set forth in SEQ ID NO:56. Gm-KCP3 is a 579 nucleotide sequence (set forth in SEQ ID NO:21) that includes a 24 nt polyA tail (nt 556-579) and 555 nt exclusive ofthe polyA tail. Nucleotides 1-82 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 83-349 and a 3 nontranslated region at nt 350-555. The predicted polypeptide sequence encoded by SEQ ID NO:21 is set forth in SEQ ID NO:57. Gm-KCP4 is a 509 nucleotide sequence (set forth in SEQ ID NO:22) that includes a 19 nt polyA tail (nt 491-509) and 490 nt exclusive ofthe polyA tail. Nucleotides 1-51 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 52-324 and a 3 nontranslated region at nt 325-490. The predicted polypeptide sequence encoded by SEQ ID NO:22 is set forth in SEQ ID NO: 58. Gm-KCP5 is a 439 nucleotide sequence (set forth in SEQ ID NO:23) that includes an 18 nt polyA tail (nt 422-439) and 421 nt exclusive ofthe polyA tail. Nucleotides 1-16 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 17-289 and a 3 ' nontranslated region at nt 290-421. The predicted polypeptide sequence encoded by SEQ ID NO:23 is set forth in SEQ ID NO:59. Gm-KCP6 is a 783 nucleotide sequence (set forth in SEQ ID NO:24) that includes a 19 nt polyA tail (nt 765-783) and 764 nt exclusive ofthe polyA tail. Nucleotides 1-54 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 55-345 and a 3 nontranslated region at nt 346-764. The predicted polypeptide sequence encoded by SEQ ID NO:24 is set forth in SEQ ID NO:60. Gm-KCP7 is a 607 nucleotide sequence (set forth in SEQ ID NO:25) that includes a 21 nt polyA tail (nt 587-607) and 586 nt exclusive ofthe polyA tail. Nucleotides 1-38 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 39-386 and a 3 ' nontranslated region at nt 387-586. The predicted polypeptide sequence encoded by SEQ ID NO:25 is set forth in SEQ ID NO:61. Gm-KCP8 is a 788 nucleotide sequence (set forth in SEQ ID NO:26) that includes a 19 nt polyA tail (nt 770-788) and 769 nt exclusive ofthe polyA tail. Nucleotides 1-159 correspond to a 5 nontranslated leader, with the coding region (ATG- stop) at nt 160-513 and a 3 nontranslated region at nt 514-769. The predicted polypeptide sequence encoded by SEQ ID NO:26 is set forth in SEQ ID NO:62. Gm-KCP9 is a 996 nucleotide sequence (set forth in SEQ ID NO:27) that includes a 62 nt polyA tail (nt 935-996) and 934 nt exclusive ofthe polyA tail. Nucleotides 1-313 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 314-673 and a 3 nontranslated region at nt 674-934. The predicted polypeptide sequence encoded by SEQ ID NO:27 is set forth in SEQ ID NO:63. Gm-KCPIO is a 615 nucleotide sequence (set forth in SEQ ID NO:28) that includes a 22 nt polyA tail (nt 594-615) and 593 nt exclusive ofthe polyA tail. Nucleotides 1-63 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 64-363 and a 3 nontranslated region at nt 364-593. The predicted polypeptide sequence encoded by SEQ ID NO:28 is set forth in SEQ ID NO:64. Gm-KCPl 1 is a 628 nucleotide sequence (set forth in SEQ ID NO:29) that includes a 21 nt polyA tail (nt 608-628) and 607 nt exclusive ofthe polyA tail. Nucleotides 1-48 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 49-396 and a 3 nontranslated region nt 397-607. The predicted polypeptide sequence encoded by SEQ ID NO:29 is set forth in SEQ ID NO:65. Gm-KCPl 4 is a 1066 nucleotide sequence (set forth in SEQ ID NO:30) that includes a 17 nt polyA tail (nt 1050-1066) and 1049 nt exclusive ofthe polyA tail. Nucleotides 1-188 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 189-764 and a 3 ' nontranslated region at nt 765-1049. The predicted polypeptide sequence encoded by SEQ ID NO:30 is set forth in SEQ ID NO:66. Gm-KCP15 is a 697 nucleotide sequence (set forth in SEQ ID NO:31) that includes a 40 nt polyA tail (nt 658-697) and 657 nt exclusive ofthe polyA tail. Nucleotides 1-109 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 110-433 and a 3 ' nontranslated region at nt 434-657. The predicted polypeptide sequence encoded by SEQ ID NO:31 is set forth in SEQ ID NO: 67. Gm-KCP16 is a 692 nucleotide sequence (set forth in SEQ ID NO:32) that includes a 17 nt polyA tail (nt 676-692) and 675 nt exclusive ofthe polyA tail. Nucleotides 1-113 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 114-437 and a 3 nontranslated region at nt 438-675. The predicted polypeptide sequence encoded by SEQ ID NO:32 is set forth in SEQ ID NO:68. Gm-KCP17 is a 702 nucleotide sequence (set forth in SEQ ID NO:33) that includes a 22 nt polyA tail (nt 681 -702) and 680 nt exclusive of the polyA tail. Nucleotides 1-86 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 87-419 and a 3 nontranslated region at nt 420-680. The predicted polypeptide sequence encoded by SEQ ID NO:33 is set forth in SEQ ID NO: 69. Gm-KCPl 8 is a 783 nucleotide sequence (set forth in SEQ ID NO:34) that includes a 53 nt polyA tail (nt 731-783) and 730 nt exclusive ofthe polyA tail. Nucleotides 1-120 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 121-441 and a 3 nontranslated region at nt 442-730. The predicted polypeptide sequence encoded by SEQ ID NO:34 is set forth in SEQ ID NO:70. Gm-KCPl 9 is a 742 nucleotide sequence (set forth in SEQ ID NO:35) including a 47 nt polyA tail (nt 696-742) and 695 nt exclusive ofthe polyA tail. Nucleotides 1-206 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 207-578 and a 3 nontranslated region at nt 579-695. The predicted polypeptide sequence encoded by SEQ ID NO:35 is set forth in SEQ ID NO:71. Gm-KCP20 is a 652 nucleotide sequence (set forth in SEQ ID NO:36) that includes a 32 nt polyA tail (nt 621-652) and 620 nt exclusive ofthe polyA tail. Nucleotides 1-93 correspond to a 5 nontranslated leader, with the coding region (ATG - stop) at nt 94-387 and a 3 nontranslated region at nt 388-620. The predicted polypeptide sequence encoded by SEQ ID NO:36 is set forth in SEQ ID NO: 72. The KCP-like family of sequences appear to be conserved among dicot and monocot plants. There is nearly as great diversity of genes within species as between species. There are multiple genes for the sequences within a single plant species. Gamier structure predictions indicate that the proteins are disposed towards Turn (T) structures, as expected of proteins having cysteine cross-linkages. The presence of signal or transit peptides was determined for all the KCP-like sequences. Most ofthe KCP-like proteins ofthe invention predict a transit peptide, indicating that the proteins are secreted and extracellular, although a few may be localized intracellularly. Generally, the KCP-like proteins are small, averaging about 6979 Daltons and about 64 amino acids. All ofthe KCP-like proteins are about the same length in the mature peptide bioactive region. The cysteine content averages 18.2%) (molar percent). This small variation reflects the slight differences in size; the conserved cysteines are present in all ofthe proteins. The KCP-like proteins are high in lysine, with an average lysine content of 10.8%. The few proteins with low lysine content all had very high arginine content, arginine being another positively charged amino acid (and thus a conservative amino acid change). All the proteins are basic with an average pi of 8.55, indicating that the proteins are cationic. Thus, the proteins are small cysteine-rich, lysine-rich and cationic, all characteristics of many known antimicrobial proteins. The KCP-like proteins ofthe invention can be used in combination with other antimicrobial proteins, such as defensin, thionin, chitinases, glucanases, and the like. Further, the activity ofthe polypeptides may be synergistic when used with such other antimicrobial proteins. The present invention provides, among other things, compositions and methods for modulating {i.e., increasing or decreasing) the level of polynucleotides and polypeptides ofthe present invention in plants or any other host cell. In particular, the polynucleotides and polypeptides ofthe present invention can be expressed temporally or spatially, e.g., at developmental stages, in tissues, and or in quantities, which are uncharacteristic of non-recombinantly engineered plants. The present invention also provides isolated nucleic acid comprising polynucleotides of sufficient length and complementarity to a gene ofthe present mvention to use as probes or amplification primers in the detection, quantitation, or isolation of gene transcripts. For example, isolated nucleic acids ofthe present invention can be used as probes in detecting deficiencies in the level of mRNA in screenings for desired transgenic plants, for detecting mutations in the gene {e.g., substitutions, deletions, or additions), for monitoring upregulation of expression or changes in enzyme activity in compound screening assays, for detection of any number of allelic variants (polymorphisms), orthologs, or paralogs ofthe gene, or for site-directed mutagenesis in eukaryotic cells (see, e.g., U.S. patent No. 5,565,350). The isolated nucleic acids ofthe present invention can also be used for recombinant expression of their encoded polypeptides, or for use as immunogens in the preparation and/or screening of antibodies. The isolated nucleic acids ofthe present invention can also be employed for use in sense or antisense suppression of one or more genes of the present invention in a host cell, tissue, or plant. Attachment of chemical agents, which bind, intercalate, cleave and/or crosslink to the isolated nucleic acids ofthe present invention can also be used to modulate transcription or translation. The present invention also provides isolated proteins comprising a polypeptide ofthe present invention {e.g., preproenzyme, proenzyme, or enzymes). The isolated nucleic acids and proteins ofthe present invention can be used over a broad range of plant types, particularly monocots such as the species ofthe family Gramineae, including species ofthe genera. Sorghum {e.g. S. bicolor), Oryzα, Avenα, Hordeum, Secαle, Triticum and Zeα mays, and dicots such as Glycine. The isolated nucleic acid and proteins ofthe present invention can also be used in species from the genera: Cucurbita, Rosa, Vitis, Juglans, Fragaria, Lotus, Medicago, Onobrychis, Trifolium, Trigonella, Vigna, Citrus, Linum, Geranium, Manihot, Daucus, Arabidopsis, Brassica, Raphanus, Sinapis, Atropa, Capsicum, Datura, Hyoscyamus, Ly coper sicon, Nicotiana, Solanum, Petunia, Digitalis, Majorana, Ciahorium, Helianthus, Lactuca, Bromus, Asparagus, Antirrhinum, Heterocallis, Nemesis, Pelargonium, Panieum, Pennisetum, Ranunculus, Senecio, Salpiglossis, Cucumis, Browaalia, Pisum, Phaseolus, Lolium, andAllium. Other examples of plant species of interest include, but are not limited to, Brassica sp. (e.g., B. napus, B. rapa, B.junced), particularly those Brassica species useful as sources of seed oil, alfalfa {Medicago sativa), rice {Oryza sativa), rye {Secale cereale), sorghum {Sorghum vulgare), millet (e.g., pearl millet {Pennisetum glaucum), proso millet {Panieum miliaceum), foxtail millet {Setaria italica), finger millet {Eleusine coracanάj), sunflower {Helianthus annuus), safflower {Carthamus tinctorius), wheat {Triticum aestivum), soybean {Glycine max), tobacco {Nicotiana tabacum), potato {Solanum tuber osum), peanuts {Arachis hypogaea), cotton {Gossypium barbadense, Gossypium hirsutum), sweet potato {Ipomoea batatus), cassava {Manihot esculenta), coffee {Coffea spp.), coconut {Cocos nucifera), pineapple {Ananas comosus), citrus trees {Citrus spp.), cocoa {Theobroma cacao), tea {Camellia sinensis), banana {Musa spp.), avocado {Persea americana), fig {Ficus casica), guava {Psidium guajava), mango {Mangifera indica), olive {Olea europaea), papaya {Car ica papaya), cashew {Anacardium occidentale), macadamia {Macadamia integrifolia), almond {Prunus amygdalus), sugar beets {Beta vulgaris), sugarcane {Saccharum spp.), oats, barley, vegetables, ornamentals, and conifers. Vegetables include tomatoes {Lycopersicon esculentum), lettuce (e.g., Lactuca sativa), green beans {Phaseolus vulgaris), lima beans {Phaseolus limensis), peas {Lathyrus spp.), and members ofthe genus Cucumis such as cucumber (C. sativus), cantaloupe (C. cantalupensis), and musk melon (C. melo). Ornamentals include azalea {Rhododendron spp.), hydrangea {Macrophylla hydrangea), hibiscus {Hibiscus rosasanensis), roses {Rosa spp.), tulips {Tulipa spp.), daffodils {Narcissus spp.), petunias {Petunia hybridά), carnation {Dianthus caryophyllus), poinsettia {Euphorbia pulcherrima), and chrysanthemum. Conifers that may be employed in practicing the present invention include, for example, pines such as loblolly pine {Pinus taeda), slash pine {Pinus elliotii), ponderosa pine {Pinus ponderosa), lodgepole pine {Pinus contorta), and Monterey pine {Pinus radiata); Douglas-fir {Pseudotsuga menziesii); Western hemlock {Tsuga canadensis); Sitka spruce {Picea glauca); redwood {Sequoia sempervirens); true firs such as silver fir {Abies amabilis) and balsam fir {Abies balsamea); and cedars such as Western red cedar {Thuja plicata) and Alaska yellow-cedar {Chamaecyparis nootkatensis). Preferably, plants ofthe present invention are crop plants (for example, corn, alfalfa, sunflower, Brassica, soybean, cotton, safflower, peanut, sorghum, wheat, millet, tobacco, etc.), more preferably corn and soybean plants, yet more preferably corn plants. Other plants of interest include grain plants that provide seeds of interest, oil- seed plants, and leguminous plants. Seeds of interest include grain seeds, such as corn, wheat, barley, rice, sorghum, rye, etc. Oil-seed plants include cotton, soybean, safflower, sunflower, Brassica, maize, alfalfa, palm, coconut, etc. Leguminous plants include beans and peas. Beans include guar, locust bean, fenugreek, soybean, garden beans, cowpea, mungbean, lima bean, fava bean, lentils, chickpea, etc. The invention is drawn to compositions and methods for inducing resistance in a plant to plant pests. Accordingly, the compositions and methods are also useful in protecting plants against fungal pathogens, viruses, nematodes, insects and the like. By "disease resistance" is intended that the plants avoid the disease symptoms that are the outcome of plant-pathogen interactions. That is, pathogens are prevented from causing plant diseases and the associated disease symptoms, or alternatively, the disease symptoms caused by the pathogen is minimized or lessened. By "antipathogenic compositions" is intended that the compositions ofthe invention have antipathogenic activity and thus are capable of suppressing, controlling, and/or killing the invading pathogenic organism. An antipathogenic composition ofthe invention will reduce the disease symptoms resulting from pathogen challenge by at least about 5% to about 50%, at least about 10% to about 60%), at least about 30% to about 70%, at least about 40% to about 80%, or at least about 50% to about 90% or greater. Hence, the methods ofthe invention can be utilized to protect plants from disease, particularly those diseases that are caused by plant pathogens. Assays that measure antipathogenic activity are commonly known in the art, as are methods to quantitate disease resistance in plants following pathogen infection. See, for example, U.S. Patent No. 5,614,395, herein incorporated by reference. Such techniques include, measuring over time, the average lesion diameter, the pathogen biomass, and the overall percentage of decayed plant tissues. For example, a plant either expressing an antipathogenic polypeptide or having an antipathogenic composition applied to its surface shows a decrease in tissue necrosis {i.e., lesion diameter) or a decrease in plant death following pathogen challenge when compared to a control plant that was not exposed to the antipathogenic composition. Alternatively, antipathogenic activity can be measured by a decrease in pathogen biomass. For example, a plant expressing an antipathogenic polypeptide or exposed to an antipathogenic composition is challenged with a pathogen of interest. Over time, tissue samples from the pathogen-inoculated tissues are obtained and RNA is extracted. The percent of a specific pathogen RNA transcript relative to the level of a plant specific transcript allows the level of pathogen biomass to be determined. See, for example, Thomma et /. {1998) Plant Biology 95:15107-15111, herein incorporated by reference. Furthermore, in vitro antipathogenic assays include, for example, the addition of varying concentrations ofthe antipathogenic composition to paper disks and placing the disks on agar containing a suspension ofthe pathogen of interest. Following incubation, clear inhibition zones develop around the discs that contain an effective concentration ofthe antipathogenic polypeptide (Liu et al. (1994) Plant Biology 91 : 1888-1892, herein incorporated by reference). Additionally, microspectrophotometrical analysis can be used to measure the in vitro antipathogenic properties of a composition (Hu et al. (1997) Plant Mol. Biol. 34:949-959, and Cammue et al. (1992) J. Biol. Chem. 267: 2228-2233, both of which are herein incorporated by reference). Pathogens ofthe invention include, but are not limited to, viruses or viroids, bacteria, insects, nematodes, fungi, and the like. Viruses include any plant virus, for example, tobacco or cucumber mosaic virus, ringspot virus, necrosis virus, maize dwarf mosaic virus, etc. Specific fungal and viral pathogens for the major crops include: Soybeans: Phytophthora megasperma fsp. glycinea, Macrophomina phaseolina, Rhizoctonia solani, Sclerotinia sclerotiorum, Fusarium oxysporum, Diaporthe phaseolorum var. sojae (Phomopsis sojae), Diaporthe phaseolorum var. caulivora, Sclerotium rolfsii, Cercospora kikuchii, Cercospora sojina, Peronospora manshurica, Colletotrichum dematium (Colletotichum truncatum), Corynespora cassiicola, Septoria glycines, Phyllosticta sojicola, Alternaria alternata, Pseudomonas syringae p.v. glycinea, Xanthomonas campestris p.v.phaseoli, Microsphaera diffusa, Fusarium semitectum, Phialophora gregata, Soybean mosaic virus, Glomerella glycines, Tobacco Ring spot virus, Tobacco Streak virus, Phakopsora pachyrhizi, Pythium aphanidermatum, Pythium ultimum, Pythium debaryanum, Tomato spotted wilt virus, Heterodera glycines Fusarium solani; Canola: Albugo Candida, Alternaria brassicae, Leptosphaeria maculans, Rhizoctonia solani, Sclerotinia sclerotiorum, Mycosphaerella brassiccola, Pythium ultimum, Peronospora parasitica, Fusarium roseum, Alternaria alternata; Alfalfa: Clavibater michiganese subsp. insidiosum, Pythium ultimum, Pythium irregulare, Pythium splendens, Pythium debaryanum, Pythium aphanidermatum, Phytophthora megasperma, Peronospora trifoliorum, Phoma medicaginis var. medicaginis, Cercospora medicaginis, Pseudopeziza medicaginis, Leptotrochila medicaginis, Fusarium, Xanthomonas campestris p.v. alfalfae, Aphanomyces euteiches, Stemphylium herbarum, Stemphylium alfalfae; Wheat: Pseudomonas syringae p.v. atrofaciens, Urocystis agropyri, Xanthomonas campestris p.v. translucens, Pseudomonas syringae p.v. syringae, Alternaria alternata, Cladosporium herbarum, Fusarium graminearum, Fusarium avenaceum, Fusarium culmorum, Ustilago tritici, Ascochyta tritici, Cephalosporium gramineum, Collotetrichum graminicola, Erysiphe graminis f.sp. tritici, Puccinia graminis f.sp. tritici, Puccinia recondita f.sp. tritici, Puccinia striiformis, Pyrenophora tritici-repentis, Septoria nodorum, Septoria tritici, Septoria avenae, Pseudocercosporella herpotrichoides, Rhizoctonia solani, Rhizoctonia cerealis, Gaeumannomyces graminis var. tritici, Pythium aphanidermatum, Pythium arrhenomanes, Pythium ultimum, Bipolaris sorokiniana, Barley Yellow Dwarf Virus, Brome Mosaic Virus, Soil Borne Wheat Mosaic Virus, Wheat Streak Mosaic Virus, Wheat Spindle Streak Virus, American Wheat Striate Virus, Claviceps purpurea, Tilletia tritici, Tilletia laevis, Ustilago tritici, Tilletia indica, Rhizoctonia solani, Pythium arrhenomannes, Pythium gramicola, Pythium aphanidermatum, High Plains Virus, European wheat striate virus; Sunflower: Plasmophora halstedii, Sclerotinia sclerotiorum, Aster Yellows, Septoria helianthi, Phomopsis helianthi, Alternaria helianthi, Alternaria zinniae, Botrytis cinerea, Phoma macdonaldii, Macrophomina phaseolina, Erysiphe cichoracearum, Rhizopus oryzae, Rhizopus arrhizus, Rhizopus stolonifer, Puccinia helianthi, Verticillium dahliae, Erwinia carotovorum pv. carotovora, Cephalosporium acremonium, Phytophthora cryptogea, Albugo tragopogonis; Corn: Fusarium monϊliforme var. subglutinans, Erwinia stewartii, Fusarium moniliforme, Gibberella zeae (Fusarium graminearum), Stenocarpella maydi (Diplodia maydis), Pythium irregulare, Pythium debaryanum, Pythium graminicola, Pythium splendens, Pythium ultimum, Pythium aphanidermatum, Aspergillus flavus, Bipolaris maydis O, T (Cochliobolus heterostrophus) , Helminthosporium carbonum I, II & III (Cochliobolus carbonum), Exserohilum turcicum I, II & III, Helminthosporium pedicellatum, Physoderma maydis, Phyllosticta maydis, Kabatiella maydis, Cercospora sorghi, Ustilago maydis, Puccinia sorghi, Puccinia polysora, Macrophomina phaseolina, Penicillium oxalicum, Nigrospora oryzae, Cladosporium herbarum, Curvularia lunata, Curvularia inaequalis, Curvularia pallescens, Clavibacter michiganense subsp. nebraskense, Trichoderma viride, Maize Dwarf Mosaic Virus A & B, Wheat Streak Mosaic Virus, Maize Chlorotic Dwarf Virus, Claviceps sorghi, Pseudonomas avenae, Erwinia chrysanthemi pv. zea, Erwinia carotovora, Corn stunt spiroplasma, Diplodia macrospora, Sclerophthora macrospora, Peronosclerospora sorghi, Peronosclerosporaphilippinensis, Peronosclerospora maydis, Peronosclerospora sacchari, Sphacelotheca reiliana, Physopella zeae, Cephalosporium maydis, Cephalosporium acremonium, Maize Chlorotic Mottle Virus, High Plains Virus, Maize Mosaic Virus, Maize Rayado Fino Virus, Maize Streak Virus, Maize Stripe Virus, Maize Rough Dwarf Virus; Sorghum: Exserohilum turcicum, Colletotrichum graminicola (Glomerella graminicola), Cercospora sorghi, Gloeocercospora sorghi, Ascochyta sorghina, Pseudomonas syringae p.v. syringae, Xanthomonas campestris p.v. holcicola, Pseudomonas andropogonis, Puccinia purpurea, Macrophomina phaseolina, Perconia circinata, Fusarium moniliforme, Alternaria alternata, Bipolaris sorghicola, Helminthosporium sorghicola, Curvularia lunata, Phoma insidiosa, Pseudomonas avenae (Pseudomonas alboprecipitans), Ramulispora sorghi, Ramulispora sorghicola, Phyllachara sacchari, Sporisorium reilianum (Sphacelotheca reiliana), Sphacelotheca cruenta, Sporisorium sorghi, Sugarcane mosaic H, Maize Dwarf Mosaic Virus A & B, Claviceps sorghi, Rhizoctonia solani, Acremonium strictum, Sclerophthona macrospora, Peronosclerospora sorghi, Peronosclerospora philippinensis, Sclerospora graminicola, Fusarium graminearum, Fusarium oxysporum, Pythium arrhenomanes, Pythium graminicola, etc. Nematodes include parasitic nematodes such as root-knot, cyst, and lesion nematodes, including Heterodera and Globodera spp; particularly Globodera rostochiensis and globodera pailida (potato cyst nematodes); Heterodera glycines (soybean cyst nematode); Heterodera schachtii (beet cyst nematode); and Heterodera avenae (cereal cyst nematode). Insect pests include insects selected from the orders Coleoptera, Diptera, Hymenoptera, Lepidoptera, Mallophaga, Homoptera, Hemiptera, Orthoptera, Thysanoptera, Dermaptera, Isoptera, Anoplura, Siphonaptera, Trichoptera, etc., particularly Coleoptera and Lepidoptera. Insect pests ofthe invention for the major crops include: Maize: Ostrinia nubilalis, European corn borer; Agrotis ipsilon, black cutworm; Helicoverpa zea, corn earworm; Spodoptera frugiperda, fall armyworm; Diatraea grandiosella, southwestern corn borer; Elasmopalpus lignosellus, lesser cornstalk borer; Diatraea saccharalis, surgarcane borer; Diabrotica virgifera, western corn rootworm; Diabrotica longicornis barberi, northern corn rootworm; Diabrotica undecimpunctata howardi, southern corn rootworm; Melanotus spp., wire worms; Cyclocephala borealis, northern masked chafer (white grub); Cyclocephala immaculata, southern masked chafer (white grub); Popillia japonica, Japanese beetle; Chaetocnema pulicaria, corn flea beetle; Sphenophorus maidis, maize billbug; Rhopalosiphum maidis, corn leaf aphid; Anur aphis maidiradicis, corn root aphid; Blissus leucopterus leucopterus, chinch bug; Melanoplus femurrubrum, redlegged grasshopper; Melanoplus sanguinipes, migratory grasshopper; Hylemya platura, seedcorn maggot; Agromyza parvicornis, corn blot leafminer; Anaphothrips obscrurus, grass thrips; Solenopsis milesta, thief ant; Tetranychus urticae, twospotted spider mite; Sorghum: Chilo partellus, sorghum borer; Spodopterafrugiperda, fall armyworm; Helicoverpa zea, corn earworm; Elasmopalpus lignosellus, lesser cornstalk borer; Feltia subterranea, granulate cutworm; Phyllophaga crinita, white grub; Eleodes, Conoderus, and Aeolus spp., wireworms; Oulema melanopus, cereal leaf beetle; Chaetocnema pulicaria, corn flea beetle; Sphenophorus maidis, maize billbug; Rhopalosiphum maidis; corn leaf aphid; Siphaflava, yellow sugarcane aphid; Blissus leucopterus leucopterus, chinch bug; Contarinia sorghicola, sorghum midge; Tetranychus cinnabarinus, carmine spider mite; Tetranychus urticae, twospotted spider mite; Wheat: Pseudaletia unipunctata, army worm; Spodopterafrugiperda, fall armyworm; Elasmopalpus lignosellus, lesser cornstalk borer; Agrotis orthogonia, western cutworm; Elasmopalpus lignosellus, lesser cornstalk borer; Oulema melanopus, cereal leaf beetle; Hypera punctata, clover leaf weevil; Diabrotica undecimpunctata howardi, southern corn rootworm; Russian wheat aphid; Schizaphis graminum, greenbug; Macrosiphum avenae, English grain aphid; Melanoplus femurrubrum, redlegged grasshopper; Melanoplus differ entialis, differential grasshopper; Melanoplus sanguinipes, migratory grasshopper; Mayetiola destructor, Hessian fly; Sitodiplosis mosellana, wheat midge; Meromyza amerϊcana, wheat stem maggot; Hylemya coarctata, wheat bulb fly; Frankliniella fusca, tobacco thrips; Cephus cinctus, wheat stem sawfly; Aceria tulipae, wheat curl mite; Sunflower: Suleima helianthana, sunflower bud moth; Homoeosoma electellum, sunflower moth; zygogramma exclamationis, sunflower beetle; Bothyrus gibbosus, carrot beetle; Neolasioptera murtfeldtiana, sunflower seed midge; Cotton: Heliothis virescens, cotton budworm; Helicoverpa zea, cotton bollworm; Spodoptera exigua, beet armyworm; Pectinophora gossypiella, pink bollworm; Anthonomus grandis grandis, boll weevil; Aphis gossypii, cotton aphid; Pseudatomoscelis seriatus, cotton fleahopper; Trialeurodes abutilonea, bandedwinged whitefly; Lygus lineolaris, tarnished plant bug; Melanoplus femurrubrum, redlegged grasshopper; Melanoplus differ entialis, differential grasshopper; Thrips tabaci, onion thrips; Franklinkiella fusca, tobacco thrips; Tetranychus cinnabarinus, carmine spider mite; Tetranychus urticae, twospotted spider mite; Rice: Diatraea saccharalis, sugarcane borer; Spodopterafrugiperda, fall armyworm; Helicoverpa zea, corn earworm; Colaspis brunnea, grape colaspis; Lissorhoptrus oryzophilus, rice water weevil; Sitophilus oryzae, rice weevil; Nephotettix nigropictus, rice leafhopper; Blissus leucopterus leucopterus, chinch bug; Acrosternum hilare, green stink bug; Soybean: Pseudoplusia includens, soybean looper; Anticarsia gemmatalis, velvetbean caterpillar; Plathypena scabra, green cloverworm; Ostrinia nubilalis, European corn borer; Agrotis ipsilon, black cutworm; Spodoptera exigua, beet armyworm; Heliothis virescens, cotton budworm; Helicoverpa zea, cotton bollworm; Epilachna varivestis, Mexican bean beetle; Myzus persicae, green peach aphid; Empoascafabae, potato leafhopper; Acrosternum hilare, green stink bug; Melanoplus femurrubrum, redlegged grasshopper; Melanoplus differ entialis, differential grasshopper; Hylemya platura, seedcorn maggot; Sericothrips variabilis, soybean thrips; Thrips tabaci, onion thrips; Tetranychus turkestani, strawberry spider mite; Tetranychus urticae, twospotted spider mite; Barley: Ostrinia nubilalis, European corn borer; Agrotis ipsilon, black cutworm; Schizaphis graminum, greenbug; Blissus leucopterus leucopterus, chinch bug; Acrosternum hilare, green stink bug; Euschistus servus, brown stink bug; Delia platura, seedcorn maggot; Mayetiola destructor, Hessian fly; Petrobia latens, brown wheat mite; Oil Seed Rape: Brevicoryne brassicae, cabbage aphid; Phyllotreta cruciferae, Flea beetle; Mamestra configurata, Bertha armyworm; Plutella xylostella, Diamond-back moth; Delia ssp., Root maggots. Definitions Units, prefixes, and symbols may be denoted in their SI accepted form. Unless otherwise indicated, nucleic acids are written left to right in 5 to 3 orientation, and amino acid sequences are written left to right in amino to carboxy orientation, respectively. Numeric ranges are inclusive ofthe numbers defining the range and include each integer within the defined range. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes. The terms defined below are more fully defined by reference to the specification as a whole. By "amplified" is meant the construction of multiple copies of a nucleic acid sequence or multiple copies complementary to the nucleic acid sequence using at least one ofthe nucleic acid sequences as a template. Amplification systems include the polymerase chain reaction (PCR) system, ligase chain reaction (LCR) system, nucleic acid sequence based amplification (NASBA, Cangene, Mississauga, Ontario), Q-Beta Replicase systems, transcription-based amplification system (TAS), and strand displacement amplification (SDA). See, e.g., Diagnostic Molecular Microbiology: Principles and Applications, DH Persing et al, Ed., American Society for Microbiology, Washington, D.C. (1993). The product of amplification is termed an amplicon. As used herein, "antisense orientation" includes reference to a duplex polynucleotide sequence which is operably linked to a promoter in an orientation where the antisense strand is transcribed. The antisense strand is sufficiently complementary to an endogenous transcription product such that translation ofthe endogenous transcription product is often inhibited. By "encoding" or "encoded," with respect to a specified nucleic acid is intended that the nucleic acid comprises the information for translation into the specified protein. A nucleic acid encoding a protein may comprise non-translated sequences {e.g., introns) within translated regions ofthe nucleic acid, or may lack such intervening non-translated sequences {e.g., as in cDNA). The information by which a protein is encoded is specified by the use of codons. Typically, the amino acid sequence is encoded by the nucleic acid using the "universal" genetic code. However, variants ofthe universal code, such as are present in some plant, animal, and fungal mitochondria, the bacterium Mycoplasma capricolum, or the ciliate Macronucleus, may be used when the nucleic acid is expressed therein. When the nucleic acid is prepared or altered synthetically, advantage can be taken of known codon preferences ofthe intended host where the nucleic acid is to be expressed. For example, although nucleic acid sequences ofthe present invention may be expressed in both monocotyledonous and dicotyledonous plant species, sequences can be modified to account for the specific codon preferences and GC content preferences of monocotyledons or dicotyledons, as these preferences have been shown to differ (Murray et al. (1989) Nucl. Acids Res. 17: 477-498). Thus, the maize preferred codon for a particular amino acid might be derived from known gene sequences from maize. Maize codon usage for 28 genes from maize plants is listed in Table 4 of Murray et al, supra. As used herein, "heterologous" in reference to a nucleic acid means a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention. For example, a promoter operably linked to a heterologous structural gene is from a species different from that species from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form. A heterologous protein may originate from a foreign species, or, if from the same species, is substantially modified from its original form by deliberate human intervention. By "host cell" is meant a cell which contains a vector and supports the replication and/or expression ofthe vector. Host cells may be prokaryotic cells such as E. coli or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells. Preferably, host cells are monocotyledonous or dicotyledonous plant cells. A particularly preferred monocotyledonous host cell is a maize host cell. The term "introduced" in the context of inserting a nucleic acid into a cell means "transfection" or "transformation" or "transduction" and includes reference to the incorporation of a nucleic acid into a eukaryotic or prokaryotic cell where the nucleic acid may be incoφorated into the genome ofthe cell {e.g., chromosome, plasmid, plastid or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed {e.g., transfected mRNA). As used herein, "marker" includes reference to a locus on a chromosome that serves to identify a unique position on the chromosome. A "polymorphic marker" includes reference to a marker which appears in multiple forms (alleles) such that different forms ofthe marker, when they are present in a homologous pair, allow one of skill in the art to follow the transmission of each ofthe chromosomes of that pair. Use of one or a plurality of markers may define a genotype. As used herein, "nucleic acid" includes reference to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited encompasses known analogues having the essential nature of natural nucleotides in that they hybridize to single-stranded nucleic acids in a manner similar to naturally occurring nucleotides {e.g., peptide nucleic acids). By "nucleic acid library" is meant a collection of isolated DNA or RNA molecules which comprise and substantially represent the entire transcribed fraction of a genome of a specified organism. Construction of exemplary nucleic acid libraries, such as genomic and cDNA libraries, is taught in standard molecular biology references such as: Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol. 152, Academic Press, Inc., San Diego, CA (Berger); Sambrook et al. (1989) Molecular Cloning - A Laboratory Manual, 2 n ed., Vol. 1-3; and Current Protocols in Molecular Biology, F.M. Ausubel et al, Eds., Current Protocols, a joint venture between Greene Publishing Associates, h e. and John Wiley & Sons, Inc. (1994). As used herein, "polynucleotide" includes reference to a deoxyribopolynucleotide, ribopolynucleotide, or analogs thereof that have the essential nature of a natural ribonucleotide in that they hybridize, under stringent hybridization conditions, to substantially the same nucleotide sequence as naturally occurring nucleotides and/or allow translation into the same amino acid(s) as the naturally occurring nucleotide(s). A polynucleotide can be full-length or a subsequence of a native or heterologous structural or regulatory gene. Unless otherwise indicated, the term includes reference to the specified sequence as well as the complementary sequence thereof. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term polynucleotide as it is employed herein embraces such chemically, enzymatically, or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including among other things simple and complex cells. The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid. The terms also apply to naturally occurring amino acid polymers. The essential nature of such analogues of naturally occurring amino acids is that when incorporated into a protein, that protein is specifically reactive to antibodies elicited to a protein having the same amino acid sequence but consisting entirely of naturally occurring amino acids. The terms "polypeptide," "peptide," and "protein" are also inclusive of modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation. It will be appreciated, as is well known and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination and they may be circular (with or without branching), generally as a result of post-translation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods as well. Further, this invention contemplates the use of both the methionine-containing and the methionine-less amino terminal variants ofthe protein ofthe invention. The invention encompasses isolated or substantially purified nucleic acid or protein compositions. An "isolated" or "purified" nucleic acid molecule or protein, or biologically active portion thereof, is substantially or essentially free from components that normally accompany or interact with the nucleic acid molecule or protein as found in its naturally occurring environment. Thus, an isolated or purified nucleic acid molecule or protein is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. Preferably, an "isolated" nucleic acid is free of sequences (preferably protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends ofthe nucleic acid) in the genomic DNA ofthe organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0J kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA ofthe cell from which the nucleic acid is derived. A protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of contaminating protein. When the protein ofthe invention or biologically active portion thereof is recombinantly produced, preferably culture medium represents less than about 30%, 20%, 10%, 5%, or 1% (by dry weight) of chemical precursors or non-protein-of-interest chemicals. As used herein, "operably linked" includes reference to a functional linkage between a promoter and a second sequence wherein the promoter sequence initiates and mediates transcription ofthe DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame. As used herein, "promoter" includes reference to a region of DNA upstream from the start of transcription and involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating transcription in plant cells whether or not its origin is a plant cell. Exemplary plant promoters include but are not limited to those that are obtained from plants, plant viruses, and bacteria which comprise genes expressed in plant cells, such as Agrobacterium or Rhizobium. Examples of promoters under developmental control include promoters that preferentially initiate transcription in certain tissues, such as leaves, roots, or seeds. Such promoters are referred to as "tissue preferred." A "cell-type-preferred" promoter preferentially drives expression in certain cell types in one or more organs, for example, vascular cells in roots or leaves. An "inducible" or "repressible" promoter is a promoter which is under environmental control, or affected by environmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions or the presence of light. Tissue-preferred, cell-type-preferred, and inducible promoters constitute the class of "non-constitutive" promoters. A "constitutive" promoter is a promoter which is active under most environmental conditions. As used herein, "recombinant" includes reference to a cell or vector that has been modified by the introduction of a heterologous nucleic acid or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found in identical form within the native (non-recombinant) form ofthe cell or express native genes that are otherwise abnormally expressed, under- expressed, or not expressed at all as a result of deliberate human intervention. The term "recombinant" as used herein does not encompass the alteration ofthe cell or vector by naturally occurring events {e.g., spontaneous mutation and natural transformation, transduction, or transposition), such as those occurring without deliberate human intervention. As used herein, a "recombinant expression cassette" is a nucleic acid construct generated recombinantly or synthetically and having a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a host cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid to be transcribed and a promoter. The term "residue" or "amino acid residue" or "amino acid" are used interchangeably herein to refer to an amino acid that is incorporated into a protein, polypeptide, or peptide (collectively, "protein"). The amino acid may be a naturally occurring amino acid and, unless otherwise limited, may encompass non-natural analogs of natural amino acids that can function in a manner similar to that of naturally occurring amino acids. The term "selectively hybridizes" includes a reference to hybridization, under stringent hybridization conditions, of a nucleic acid sequence to a specified nucleic acid target sequence to a detectably greater degree {e.g., at least 2-fold over background) than its hybridization to non-target nucleic acid sequences and to the substantial exclusion of non-target nucleic acids. Selectively hybridizing sequences typically have about at least 80% sequence identity, preferably 90% sequence identity, and most preferably 100% sequence identity {i.e., complementarity) with each other. The nucleotide sequences ofthe invention can be used to isolate corresponding sequences from other organisms, particularly other plants. In this manner, methods such as PCR, hybridization, and the like can be used to identify such sequences based on their sequence homology to the sequences set forth herein. Sequences isolated based on their sequence identity to the entire KCP-like sequences set forth herein or to fragments thereof are encompassed by the present invention. Such sequences include sequences that are orthologs ofthe disclosed sequences. By "orthologs" is intended genes derived from a common ancestral gene and which are found in different species as a result of speciation. Genes found in different species are considered orthologs when their nucleotide sequences and/or their encoded protein sequences share substantial identity as defined elsewhere herein. Functions of orthologs are often highly conserved among species. Thus, isolated sequences that encode a KCP-like polypeptide and which hybridize under stringent conditions to the sequences disclosed herein, or to fragments thereof, are encompassed by the present invention. In a PCR approach, oligonucleotide primers can be designed for use in PCR reactions to amplify corresponding DNA sequences from cDNA or genomic DNA extracted from any organism of interest. Methods for designing PCR primers and PCR cloning are generally known in the art and are disclosed in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). See also Innis et al, eds. (1990) PCR Protocols: A Guide to Methods and Applications (Academic Press, New York); Innis and Gelfand, eds. (1995) PCR Strategies (Academic Press, New York); and Innis and Gelfand, eds. (1999) PCR Methods Manual (Academic Press, New York). Known methods of PCR include, but are not limited to, methods using paired primers, nested primers, single specific primers, degenerate primers, gene-specific primers, vector- specific primers, partially-mismatched primers, and the like. In hybridization techniques, all or part of a known nucleotide sequence is used as a probe that selectively hybridizes to other corresponding nucleotide sequences present in a population of cloned genomic DNA fragments or cDNA fragments (i.e., genomic or cDNA libraries) from a chosen organism. The hybridization probes may be genomic DNA fragments, cDNA fragments, RNA fragments, or other oligonucleotides, and may be labeled with a detectable group such as 32 P, or any other detectable marker. Thus, for example, probes for hybridization can be made by labeling synthetic oligonucleotides based on the KCP-like sequences ofthe invention. Methods for preparation of probes for hybridization and for construction of cDNA and genomic libraries are generally known in the art and are disclosed in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). For example, the entire KCP-like sequences disclosed herein, or one or more portions thereof, may be used as a probe capable of specifically hybridizing to corresponding KCP-like sequences and messenger RNAs. To achieve specific hybridization under a variety of conditions, such probes include sequences that are unique among KCP-like sequences and are preferably at least about 10 nucleotides in length, and most preferably at least about 20 nucleotides in length. Such probes may be used to amplify corresponding KCP-like sequences from a chosen plant or other organism by PCR. This technique may be used to isolate additional coding sequences from a desired plant or other organism or as a diagnostic assay to determine the presence of coding sequences in a plant or other organism. Hybridization techniques include hybridization screening of plated DNA libraries (either plaques or colonies; see, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). Hybridization of such sequences may be carried out under stringent conditions. By "stringent conditions" or "stringent hybridization conditions" is intended conditions under which a probe will hybridize to its target sequence to a detectably greater degree than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency ofthe hybridization and/or washing conditions, target sequences that are 100% complementary to the probe can be identified (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, preferably less than 500 nucleotides in length. Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37°C, and a wash in IX to 2X SSC (20X SSC = 3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55°C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to IX SSC at 55 to 60°C. Exemplary high stringency conditions include hybridization in 50%> formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in OJX SSC at 60 to 65°C. Optionally, wash buffers may comprise about 0.1% to about 1% SDS. Duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours. Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature ofthe final wash solution. For DNA- DNA hybrids, the T m can be approximated from the equation of Meinkoth and Wahl (1984) Anal. Biochem. 138:267-284: T m = 81.5°C + 16.6 (log M) + 0.41 (%GC) - 0.61 (% form) - 500/L; where M is the molarity of monovalent cations, %>GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length ofthe hybrid in base pairs. The T m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T m is reduced by about 1°C for each 1% of mismatching; thus, T m , hybridization, and/or wash conditions can be adjusted to hybridize to sequences ofthe desired identity. For example, if sequences with >90% identity are sought, the T m can be decreased 10°C. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T m ) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4°C lower than the thermal melting point (T m ); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10°C lower than the thermal melting point (T m ); low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20°C lower than the thermal melting point (T m ). Using the equation, hybridization and wash compositions, and desired T m , those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T m of less than 45°C (aqueous solution) or 32°C (formamide solution), it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology — Hybridization with Nucleic Acid Probes, Part I, Chapter 2 (Elsevier, New York); and Ausubel et al, eds. (1995) Current Protocols in Molecular Biology, Chapter 2 (Greene Publishing and Wiley Jnterscience, New York). See Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). As used herein, the term "plant" includes reference to whole plants, plant organs {e.g., leaves, stems, roots, etc.), seeds, and plant cells and progeny of same. "Plant cell" as used herein includes without limitation seeds, suspension cultures, embryos, meristematic regions, callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen, and microspores. The class of plants which can be used in the methods ofthe invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants. Preferred plants include but are not limited to maize, soybean, sunflower, sorghum, canola, wheat, alfalfa, cotton, rice, barley, and millet. A particularly preferred plant is maize {Zea mays). As used herein, "transgenic plant" refers to a plant which comprises within its genome a heterologous polynucleotide. Generally, the heterologous polynucleotide is stably integrated within the genome such that the polynucleotide is passed on to successive generations. The heterologous polynucleotide may be integrated into the genome alone or as part of a recombinant expression cassette. "Transgenic" is used herein to include any cell, cell line, callus, tissue, plant part or plant, the genotype of which has been altered by the presence of heterologous nucleic acid. The term "transgenic" includes those transgenics initially so altered as well as those created by sexual crosses or asexual propagation from the initial transgenic. The term "transgenic" as used herein does not encompass the alteration ofthe genome (chromosomal or extra-chromosomal) by conventional plant breeding methods or by naturally occurring events such as random cross-fertilization, non-recombinant viral infection, non-recombinant bacterial transformation, non-recombinant transposition, or spontaneous mutation. As used herein, "vector" includes reference to a nucleic acid used in transfection of a host cell and into which can be inserted a polynucleotide. Vectors are often replicons. Expression vectors permit transcription of a nucleic acid inserted therein. The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) "reference sequence", (b) "comparison window", (c) "sequence identity", (d) "percentage of sequence identity", and (e) "substantial identity". (a) As used herein, "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence. (b) As used herein, "comparison window" makes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment ofthe two sequences. Generally, the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced and is subtracted from the number of matches. Methods of alignment of sequences for comparison are well known in the art. Thus, the determination of percent sequence identity between any two sequences can be accomplished using a mathematical algorithm. Non-limiting examples of such mathematical algorithms are the algorithm of Myers and Miller (1988) CABIOS 4:11- 17; the local homology algorithm of Smith et al. (1981)-4c v. Appl Math. 2:482; the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. ¥5:443-453; the search-for-similarity-method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 872264, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Computer implementations of these mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. Such implementations include, but are not limited to: CLUSTAL in the PC/Gene program (available from Intelligenetics, Mountain View, California); the ALIGN program (Version 2.0) and GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Version 8 (available from Genetics Computer Group (GCG), 575 Science Drive, Madison, Wisconsin, USA). Alignments using these programs can be performed using the default parameters. The CLUSTAL program is well described by Higgins et al. (1988) Gene 75:237-244 (1988); Higgins et al. (1989) CABIOS 5:151- 153; Corpet et al. (1988) Nucleic Acids Res. 5:10881-90; Huang et al. (1992) CABIOS 8: 155-65; and Pearson et al. (1994) Meth. Mol. Biol. 24:307-331. The ALIGN program is based on the algorithm of Myers and Miller (1988) supra. A PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used with the ALIGN program when comparing amino acid sequences. The BLAST programs of Altschul et al (1990) J. Mol. Biol. 215:403 are based on the algorithm of Karlin and Altschul (1990) supra. BLAST nucleotide searches can be performed with the BLASTN program, score = 100, wordlength = 12, to obtain nucleotide sequences homologous to a nucleotide sequence encoding a protein ofthe invention. BLAST protein searches can be performed with the BLASTX program, score = 50, wordlength = 3, to obtain amino acid sequences homologous to a protein or polypeptide ofthe invention. To obtain gapped alignments for comparison purposes, Gapped BLAST (in BLAST 2.0) can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389. Alternatively, PSI-BLAST (in BLAST 2.0) can be used to perform an iterated search that detects distant relationships between molecules. See Altschul et al. (1997) supra. When utilizing BLAST, Gapped BLAST, PSI-BLAST, the default parameters ofthe respective programs (e.g., BLASTN for nucleotide sequences, BLASTX for proteins) can be used. See http://www.ncbi.nlm.nih.gov. Alignment may also be performed manually by inspection. Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using GAP version 10 using the following parameters: % identity using GAP Weight of 50 and Length Weight of 3; % similarity using Gap Weight of 12 and Length Weight of 4, or any equivalent program. By "equivalent program" is intended any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by GAP Version 10. GAP uses the algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48: 443-453, to find the alignment of two complete sequences that maximizes the number of matches and minimizes the number of gaps. GAP considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps. It allows for the provision of a gap creation penalty and a gap extension penalty in units of matched bases. GAP must make a profit of gap creation penalty number of matches for each gap it inserts. If a gap extension penalty greater than zero is chosen, GAP must, in addition, make a profit for each gap inserted ofthe length ofthe gap times the gap extension penalty. Default gap creation penalty values and gap extension penalty values in Version 10 ofthe Wisconsin Genetics Software Package for protein sequences are 8 and 2, respectively. For nucleotide sequences the default gap creation penalty is 50 while the default gap extension penalty is 3. The gap creation and gap extension penalties can be expressed as an integer selected from the group of integers consisting of from 0 to 200. Thus, for example, the gap creation and gap extension penalties can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or greater. GAP presents one member ofthe family of best alignments. There may be many members of this family, but no other member has a better quality. GAP displays four figures of merit for alignments: Quality, Ratio, Identity, and Similarity. The Quality is the metric maximized in order to align the sequences. Ratio is the quality divided by the number of bases in the shorter segment. Percent Identity is the percent ofthe symbols that actually match. Percent Similarity is the percent ofthe symbols that are similar. Symbols that are across from gaps are ignored. A similarity is scored when the scoring matrix value for a pair of symbols is greater than or equal to 0.50, the similarity threshold. The scoring matrix used in Version 10 ofthe Wisconsin Genetics Software Package is BLOSUM62 (see Henikoff and Henikoff (1989) Proc. Natl Acad. Sci. USA SP: 10915). (c) As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties ofthe molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature ofthe substitution. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity". Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California). (d) As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion ofthe polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity. (e)(i) The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70%) sequence identity, preferably at least 80%, more preferably at least 90%>, and most preferably at least 95%o, compared to a reference sequence using one ofthe alignment programs described using standard parameters. One of skill in the art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning, and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%, more preferably at least 70%, 80%, 90%, and most preferably at least 95%. Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH. However, stringent conditions encompass temperatures in the range of about 1°C to about 20°C lower than the T m , depending upon the desired degree of stringency as otherwise qualified herein. Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid. (e)(ii) The term "substantial identity" in the context of a peptide indicates that a peptide comprises a sequence with at least 70% sequence identity to a reference sequence, preferably 80%, more preferably 85%>, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window. Preferably, optimal alignment is conducted using the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 45:443-453. An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution. Peptides that are "substantially similar" share sequences as noted above except that residue positions that are not identical may differ by conservative amino acid changes. Nucleic Acids The present invention provides, among other things, isolated nucleic acids of RNA, DNA, and analogs and/or chimeras thereof, comprising a polynucleotide ofthe present invention. A polynucleotide ofthe present invention is inclusive of: (a) a polynucleotide encoding a polypeptide of any of SEQ ID NOS:37-72, including exemplary polynucleotides of SEQ ID NOS: 1-36; (b) a polynucleotide which is the product of amplification from a Zea mays " nucleic acid library using primer pairs which selectively hybridize under stringent conditions to loci within a polynucleotide selected from the group consisting of SEQ ID NOSJ-36; (c) a polynucleotide which selectively hybridizes to a polynucleotide of (a) or (b); (d) a polynucleotide having at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with polynucleotides of (a), (b), or (c); (e) complementary sequences of polynucleotides of (a), (b), (c), or (d); (f) a polynucleotide comprising at least 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, or 70 contiguous nucleotides from a polynucleotide of (a), (b), (c), (d), or (e); and (g) an isolated polynucleotide made by the process of: 1) providing a full- length enriched nucleic acid library, 2) selectively hybridizing the polynucleotide to a polynucleotide of (a), (b), (c), (d), (e), (f), (g), or (h), thereby isolating the polynucleotide from the nucleic acid library. The present invention provides, among other things, isolated nucleic acids of RNA, DNA, and analogs and/or chimeras thereof, comprising a polynucleotide ofthe present invention. A. Polynucleotides Encoding a Polypeptide ofthe Present Invention The present invention provides isolated nucleic acids comprising a polynucleotide ofthe present invention, wherein the polynucleotide encodes a polypeptide ofthe present invention. Every nucleic acid sequence herein that encodes a polypeptide also, by reference to the genetic code, describes every possible silent variation ofthe nucleic acid. One of ordinary skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine; and UGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Thus, each silent variation of a nucleic acid, which encodes a polypeptide ofthe present invention, is implicit in each described polypeptide sequence and is within the scope ofthe present invention. Accordingly, the present invention includes polynucleotides ofthe present invention and polynucleotides encoding a polypeptide ofthe present invention. B. Polynucleotides Amplified fi'om a Plant Nucleic Acid Library The present invention provides an isolated nucleic acid comprising a polynucleotide ofthe present invention, wherein the polynucleotides are amplified under nucleic acid amplification conditions from a plant nucleic acid library. Nucleic acid amplification conditions for each ofthe variety of amplification methods are well known to those of ordinary skill in the art. The plant nucleic acid library can be constructed from a monocot such as a cereal crop. Exemplary cereals include corn, sorghum, alfalfa, canola, wheat, or rice. The plant nucleic acid library can also be constructed from a dicot such as soybean. Zea mays lines B73, PHRE1, A632, BMS- P2#l 0, W23, and Mo 17 are known and publicly available. Other publicly known and available maize lines can be obtained from the Maize Genetics Cooperation (Urbana, IL). Wheat lines are available from the Wheat Genetics Resource Center (Manhattan, KS). The nucleic acid library may be a cDNA library, a genomic library, or a library generally constructed from nuclear transcripts at any stage of intron processing. cDNA libraries can be normalized to increase the representation of relatively rare cDNAs. In optional embodiments, the cDNA library is constructed using an enriched full-length cDNA synthesis method. Examples of such methods include Oligo-Capping (Maruyama and Sugano (1994) Gene 138: 171-174), Biotinylated CAP Trapper (Carninci et al. ( 1996) Genomics 37: 327-336), and CAP Retention Procedure (Edery et al. (1995) Molecular and Cellular Biology 15: 3363- 3371). Rapidly growing tissues or rapidly dividing cells are preferred for use as an mRNA source for construction of a cDNA library. Growth stages of corn is described in "How a Corn Plant Develops," Special Report No. 48, Iowa State University of Science and Technology Cooperative Extension Service, Ames, Iowa, Reprinted February 1993. A polynucleotide of this embodiment (or subsequences thereof) can be obtained, for example, by using amplification primers which are selectively hybridized and primer extended, under nucleic acid amplification conditions, to at least two sites within a polynucleotide ofthe present invention, or to two sites within the nucleic acid which flank and comprise a polynucleotide ofthe present invention, or to a site within a polynucleotide ofthe present invention and a site within the nucleic acid which comprises it. Methods for obtaining 5 and/or 3 ends of a vector insert are well known in the art. See, e.g. , RACE (Rapid Amplification of Complementary Ends) as described in Frohman, M. A., in PCR Protocols: A Guide to Methods and Applications, M. A. Innis, D. H. Gelfand, J. J. Sninsky, T. J. White, eds. (Academic Press, Inc., San Diego), pp. 28-38 (1990)); see also, U.S. Pat. No. 5,470,722, and Current Protocols in Molecular Biology, Unit 15.6, Ausubel, et al., Eds., Greene Publishing and Wiley-Interscience, New York (1995); Frohman and Martin, Techniques 1:165 (1989). Optionally, the primers are complementary to a subsequence ofthe target nucleic acid which they amplify but may have a sequence identity ranging from about 85% to 99% relative to the polynucleotide sequence which they are designed to anneal to. As those skilled in the art will appreciate, the sites to which the primer pairs will selectively hybridize are chosen such that a single contiguous nucleic acid can be formed under the desired nucleic acid amplification conditions. The primer length in nucleotides is selected from the group of integers consisting of from at least 15 to 50. Thus, the primers can be at least 15, 18, 20, 25, 30, 40, or 50 nucleotides in length. Those of skill will recognize that a lengthened primer sequence can be employed to increase specificity of binding {i.e., annealing) to a target sequence. A non-annealing sequence at the 5 end of a primer (a "tail") can be added, for example, to introduce a cloning site at the terminal ends ofthe amplicon. The amplification products can be translated using expression systems well known to those of skill in the art. The resulting translation products can be confirmed as polypeptides ofthe present invention by, for example, assaying for the appropriate catalytic activity (e.g., specific activity and/or substrate specificity), or verifying the presence of one or more linear epitopes, which are specific to a polypeptide ofthe present invention. Methods for protein synthesis from PCR derived templates are known in the art and available commercially. See, e.g., Amersham Life Sciences, Inc, Catalog '97, p.354. C. Polynucleotides that Selectively Hybridize to a Polynucleotide of (A) or (B) The present invention provides isolated nucleic acids comprising polynucleotides ofthe present invention, wherein the polynucleotides selectively hybridize, under selective hybridization conditions, to a polynucleotide of section (A) or (B) as discussed above. Thus, the polynucleotides of this embodiment can be used for isolating, detecting, and/or quantifying nucleic acids comprising the polynucleotides of section (A) or (B). For example, polynucleotides ofthe present invention can be used to identify, isolate, or amplify partial or full-length clones in a deposited library. In some embodiments, the polynucleotides are genomic or cDNA sequences isolated or otherwise complementary to a cDNA from a dicot or monocot nucleic acid library. Exemplary species of monocots and dicots include, but are not limited to: maize, canola, soybean, cotton, wheat, sorghum, sunflower, alfalfa, oats, sugar cane, millet, barley, and rice. The cDNA library comprises at least 50% to 95%) full-length sequences (for example, at least 50%, 60%, 70%, 80%, 90%, or 95% full- length sequences). The cDNA libraries can be normalized to increase the representation of rare sequences. See, e.g., U.S. Patent No. 5,482,845. Low stringency hybridization conditions are typically, but not exclusively, employed with sequences having a reduced sequence identity relative to complementary sequences. Moderate and high stringency conditions can optionally be employed for sequences of greater identity. D. Polynucleotides Having a Specific Sequence Identity with the Polynucleotides of (A), (B) or (C) The present invention provides isolated nucleic acids comprising polynucleotides ofthe present invention, wherein the polynucleotides have a specified identity at the nucleotide level to a polynucleotide as disclosed above in sections (A), (B), or (C), above. Identity can be calculated using, for example, the BLAST or GAP algorithms as described elsewhere herein. The percentage of identity to a reference sequence is at least 60%> and, rounded upwards to the nearest integer, can be expressed as an integer selected from the group of integers consisting of from 60 to 99. Thus, for example, the percentage of identity to a reference sequence can be at least about 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. E. Polynucleotides Encoding a Protein Having a Subsequence from a Prototype Polypeptide and Cross-Reactive to the Prototype Polypeptide The present invention provides isolated nucleic acids comprising polynucleotides ofthe present invention, wherein the polynucleotides encode a protein having a subsequence of contiguous amino acids from a prototype polypeptide ofthe present invention such as are provided in section (A), above. The subsequences of a nucleotide sequence may encode protein fragments that retain the biological activity ofthe native protein and hence KCP-like activity. Alternatively, subsequences of a nucleotide sequence that are useful as hybridization probes generally do not encode fragment proteins retaining biological activity. Thus, subsequences of a nucleotide sequence may range from at least about 20 nucleotides, about 50 nucleotides, about 100 nucleotides, and up to the full-length nucleotide sequence encoding the proteins ofthe invention. The length of contiguous amino acids from the prototype polypeptide is selected from the group of integers consisting of from at least 10 to the number of amino acids within the prototype sequence. Thus, for example, the polynucleotide can encode a polypeptide having a biologically active subsequence having at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 contiguous amino acids from the prototype polypeptide. Further, the number of such subsequences encoded by a polynucleotide ofthe instant embodiment can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5. The subsequences can be separated by any integer of nucleotides from 1 to the number of nucleotides in the sequence such as at least 5, 10, 15, 25, 50, 100, or 200 nucleotides. Thus, a subsequence of a KCP-like nucleotide sequence may encode a biologically active portion of a KCP-like protein, or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed below. A biologically active portion of a KCP-like protein can be prepared by isolating a portion of one ofthe KCP-like nucleotide sequences ofthe invention, expressing the encoded portion ofthe KCP-like protein (e.g., by recombinant expression in vitro), and assessing the activity ofthe encoded portion ofthe KCP-like protein. Nucleic acid molecules that are subsequences of a KCP-like nucleotide sequence comprise at least 16, 20, 50, 75, 100, 150, 200, 250, 300, 350, or 400 nucleotides, or up to the number of nucleotides present in a full-length KCP-like nucleotide sequence disclosed herein (for example, 730 nucleotides for SEQ ID NO: 1 , 549 nucleotides for SEQ ID NO:2, 691 nucleotides for SEQ ID NO:3, 831 nucleotides for SEQ ID NO:4, 621 nucleotides for SEQ ID NO:5, 648 nucleotides for SEQ LO NO:6, 806 nucleotides for SEQ ID NO:7, 720 nucleotides for SEQ ID NO:8, 754 nucleotides for SEQ ID NO:9, 594 nucleotides for SEQ ID NOJ0, 677 nucleotides for SEQ ID NO:l 1, 639 nucleotides for SEQ ID NOJ2, 506 nucleotides for SEQ ID NO:13, 506 nucleotides for SEQ ID NOJ4, 769 nucleotides for SEQ ID NO:15, 692 nucleotides for SEQ ID NOJ6, 685 nucleotides for SEQ ID NOJ7, 660 nucleotides for SEQ ID NOJ8, 677 nucleotides for SEQ ID NO : 19, 756 nucleotides for SEQ ID NO :20, 579 nucleotides for SEQ ID NO:21, 509 nucleotides for SEQ ID NO:22, 439 nucleotides for SEQ ID NO:23, 783 nucleotides for SEQ ID NO:24, 607 nucleotides for SEQ ID NO:25, 788 nucleotides for SEQ ID NO:26, 996 nucleotides for SEQ ID NO:27, 615 nucleotides for SEQ ID NO:28, 628 nucleotides for SEQ ID NO:29, 1066 nucleotides for SEQ ID NO:30, 697 nucleotides for SEQ ID NO:31 , 692 nucleotides for SEQ ID NO:32, 702 nucleotides for SEQ ID NO:33, 783 nucleotides for SEQ ID NO:34, 742 nucleotides for SEQ ID NO:35, 652 nucleotides for SEQ ID NO:36, respectively). In generating subsequences or fragments retaining biological activity, a variety of methods are contemplated for measuring the activity of such subsequences or fragments, including both in vivo and in silico methods. For example, biological activity of a subsequence or fragment may be determined using any ofthe variety of biological assays described elsewhere herein. Alternatively, or in addition, such subsequences or fragments may be generated using the guidance provided by methods known to the skilled artisan to predict protein regions of important functionality. For example, subsequences or fragments may be generated which preserve conserved regions of sequence, as identified using alignment programs or domain-identification programs known to the skilled artisan. Since conserved regions are important for biological activity, such in silico predictions provide guidance for producing subsequences or fragments with the requisite properties. Conserved regions may be identified using, for example, the information provided by the consensus sequences of the present invention. That is, regions which are likely to be important for biological activity are expected to include those identified using either SEQ ID NO: 97 or SEQ ID NO:98, and it is therefore generally advantageous to conserve, or minimally vary, regions identified by methods using these sequences. For example, the Zm-KCPl protein sequence (SEQ ID NO:37) contains the SEQ ID NO:97 consensus sequence at positions 77-93, and the SEQ ID NO:98 consensus sequence at positions 98-112. Thus it is generally advantageous to preserve, or minimally or conservatively vary these two regions in subsequences or fragments. The skilled artisan would know to identify regions corresponding to SEQ ID NO:97 or SEQ ID NO:98 in other protein sequences or corresponding nucleotide sequences ofthe present invention and preserve these regions in the same manner as just described. The proteins encoded by polynucleotides of this embodiment, when presented as an immunogen, elicit the production of polyclonal antibodies which specifically bind to a prototype polypeptide such as (but not limited to) a polypeptide encoded by the polynucleotide of sections (A) or (B) above. Generally, however, a protein encoded by a polynucleotide of this embodiment does not bind to antisera raised against the prototype polypeptide when the antisera has been fully immunosorbed with the prototype polypeptide. Methods of making and assaying for antibody binding specificity/affinity are well known in the art. Exemplary immunoassay formats include ELISA, competitive immunoassays, radioimmunoassays, Western blots, indirect immunofluorescent assays and the like. In a preferred assay method, fully immunosorbed and pooled antisera which is elicited to the prototype polypeptide can be used in a competitive binding assay to test the protein. The concentration ofthe prototype polypeptide required to inhibit 50% of the binding ofthe antisera to the prototype polypeptide is determined. If the amount ofthe protein required to inhibit binding is less than twice the amount ofthe prototype protein, then the protein is said to specifically bind to the antisera elicited to the immunogen. Accordingly, the proteins ofthe present invention embrace allelic variants, conservatively modified variants, and minor recombinant modifications to a prototype polypeptide. A polynucleotide ofthe present invention optionally encodes a protein having a molecular weight as the non-glycosylated protein within 20% ofthe molecular weight ofthe full-length non-glycosylated polypeptides ofthe present invention. Molecular weight can be readily determined by SDS-PAGE under reducing conditions. Optionally, the molecular weight is within 15%) of a full length polypeptide ofthe present invention, more preferably within 10%> or 5%, and most preferably within 3%, 2%, or 1% of a full length polypeptide ofthe present invention. Optionally, the polynucleotides of this embodiment will encode a protein having a specific enzymatic activity at least 50%, 60%>, 70%), 80%>, or 90% of a cellular extract comprising the native, endogenous full-length polypeptide ofthe present invention. Further, the proteins encoded by polynucleotides of this embodiment will optionally have a substantially similar affinity constant (K m ) and/or catalytic activity {i.e., the microscopic rate constant, k ca t) as the native endogenous, full-length protein. Those of skill in the art will recognize that k cat /K m value determines the specificity for competing substrates and is often referred to as the specificity constant. Proteins of this embodiment can have a k cat /K m value at least 10%) of a full-length polypeptide ofthe present invention as determined using the endogenous substrate of that polypeptide. Optionally, the k cat /K m value will be at least 20%, 30%, 40%, 50%, and most preferably at least 60%, 70%, 80%, 90%, or 95% the k cat /K m value ofthe full-length polypeptide ofthe present invention. Determination of k cat , K m , and k ca t/K m can be determined by any number of means well known to those of skill in the art. For example, the initial rates {i.e., the first 5%> or less ofthe reaction) can be determined using rapid mixing and sampling techniques {e.g., continuous-flow, stopped-flow, or rapid quenching techniques), flash photolysis, or relaxation methods {e.g., temperature jumps) in conjunction with such exemplary methods of measuring as spectrophotometry, spectrofluorimetry, nuclear magnetic resonance, or radioactive procedures. Kinetic values are conveniently obtained using a Lineweaver-Burk or Eadie-Hofstee plot. F. Polynucleotides Complementary to the Polynucleotides of(A)-(E) The present invention provides isolated nucleic acids comprising polynucleotides complementary to the polynucleotides of sections A-E, above. As those of skill in the art will recognize, complementary sequences base pair throughout the entirety of their length with the polynucleotides of sections (A)-(E) {i.e., have 100% sequence identity over their entire length). Complementary bases associate through hydrogen bonding in double stranded nucleic acids. For example, the following base pairs are complementary: guanine and cytosine; adenine and thymine; and adenine and uracil. G Polynucleotides that are Subsequences ofthe Polynucleotides of (A) -(F) The present invention provides isolated nucleic acids comprising polynucleotides which comprise at least 15 contiguous bases from the polynucleotides of sections (A) (B), (C), (D), (E), or (F) {i.e., sections (A) - (F), as discussed above). A subsequence of a KCP-like nucleotide sequence may encode a biologically active portion of a KCP-like protein, or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed elsewhere herein. Subsequences of a KCP-like nucleotide sequence that are useful as hybridization probes or PCR primers generally need not encode a biologically active portion of a KCP-like protein. The length ofthe polynucleotide is given as an integer selected from the group consisting of from at least 15 to the length ofthe nucleic acid sequence from which the polynucleotide is a subsequence of. Thus, for example, polynucleotides ofthe present invention are inclusive of polynucleotides comprising at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 contiguous nucleotides in length from the polynucleotides of sections (A) through (F). Optionally, the number of such subsequences encoded by a polynucleotide ofthe instant embodiment can be any integer selected from the group consisting of from 1 to 1000, such as 2, 3, 4, or 5. The subsequences can be separated by any integer of nucleotides from 1 to the number of nucleotides in the sequence such as at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides. Subsequences can be made by in vitro synthetic, in vitro biosynthetic, or in vivo recombinant methods. In optional embodiments, subsequences can be made by nucleic acid amplification. For example, nucleic acid primers will be constructed to selectively hybridize to a sequence (or its complement) within, or co-extensive with, the coding region. The subsequences ofthe present invention can comprise structural characteristics ofthe sequence from which it is derived. Alternatively, the subsequences can lack certain structural characteristics ofthe larger sequence from which it is derived such as a poly (A) tail. Optionally, a subsequence from a polynucleotide encoding a polypeptide having at least one linear epitope in common with a prototype polypeptide sequence as provided in (a), above, may encode an epitope in common with the prototype sequence. Alternatively, the subsequence may not encode an epitope in common with the prototype sequence but can be used to isolate the larger sequence by, for example, nucleic acid hybridization with the sequence from which it is derived. Subsequences can be used to modulate or detect gene expression by introducing into the subsequences compounds which bind, intercalate, cleave and/or crosslink to nucleic acids. Exemplary compounds include acridine, psoralen, phenanthroline, naphthoquinone, daunomycin or chloroethylaminoaryl conjugates. H. Polynucleotides that are Variants ofthe Polynucleotides of(A)-(G). By "variants" is intended substantially similar sequences. For nucleotide sequences, conservative variants include those sequences that, because ofthe degeneracy ofthe genetic code, encode the amino acid sequence of one ofthe KCP- like polypeptides ofthe invention. Naturally occurring allelic variants such as these can be identified with the use of well-known molecular biology techniques, as, for example, with polymerase chain reaction (PCR) and hybridization techniques as outlined below. Variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated, for example, by using site-directed mutagenesis, but which still encode a protein ofthe invention. Generally, variants of a particular nucleotide sequence ofthe invention will have at least about 40%, 50%, 60%, 65%, 70%, generally at least about 75%, 80%, 85%, preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, and more preferably at least about 98%o, 99%) or more sequence identity to that particular nucleotide sequence as determined by sequence alignment programs described elsewhere herein using default parameters. I. Polynucleotides from a Full-length Enriched cDNA Library having the Physico- chemical Property of Selectively Hybridizing to a Polynucleotide of(A)-(H) The present invention provides an isolated polynucleotide from a full-length enriched cDNA library having the physico-chemical property of selectively hybridizing to a polynucleotide of sections (A), (B), (C), (D), (E), (F), (G), or (H) as discussed above. Methods of constructing full-length enriched cDNA libraries are known in the art and discussed briefly below. The cDNA library comprises at least 50% to 95% full-length sequences (for example, at least 50%, 60%, 70%, 80%, 90%, or 95% full-length sequences). The cDNA library can be constructed from a variety of tissues from a monocot or dicot at a variety of developmental stages. Exemplary species include maize, wheat, rice, canola, soybean, cotton, sorghum, sunflower, alfalfa, oats, sugar cane, millet, barley, and rice. Methods of selectively hybridizing, under selective hybridization conditions, a polynucleotide from a full-length enriched library to a polynucleotide ofthe present invention are known to those of ordinary skill in the art. Any number of stringency conditions can be employed to allow for selective hybridization. In optional embodiments, the stringency allows for selective hybridization of sequences having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, up to 100% sequence identity over the length ofthe hybridized region. Full-length enriched cDNA libraries can be normalized to increase the representation of rare sequences. J. Polynucleotide Products Made by a cDNA Isolation Process The present invention provides an isolated polynucleotide made by the process of: 1) providing a full-length enriched nucleic acid library; and 2) selectively hybridizing the polynucleotide to a polynucleotide of sections (A), (B), (C), (D), (E), (F), (G), (H), or (I) as discussed above, and thereby isolating the polynucleotide from the nucleic acid library. Full-length enriched nucleic acid libraries are constructed and selective hybridization conditions are used, as discussed below. Such techniques, as well as nucleic acid purification procedures, are well known in the art. Purification can be conveniently accomplished using solid-phase methods; such methods are well known to those of skill in the art and kits are available from commercial suppliers such as Advanced Biotechnologies (Surrey, UK). For example, a polynucleotide of sections (A)-(H) can be immobilized to a solid support such as a membrane, bead, or particle. See, e.g., U.S. Patent No. 5,667,976. The polynucleotide product ofthe present process is selectively hybridized to an immobilized polynucleotide and the solid support is subsequently isolated from non-hybridized polynucleotides by methods including, but not limited to, centrifugation, magnetic separation, filtration, electrophoresis, and the like. Construction of Nucleic Acids The isolated nucleic acids ofthe present invention can be made using standard recombinant methods, synthetic techniques, or combinations thereof. In some embodiments, the polynucleotides ofthe present invention will be cloned, amplified, or otherwise constructed from a monocot. The nucleic acids may conveniently comprise sequences in addition to a polynucleotide ofthe present invention. For example, a multi-cloning site comprising one or more endonuclease restriction sites may be inserted into the nucleic acid to aid in isolation ofthe polynucleotide. Also, translatable sequences may be inserted to aid in the isolation ofthe translated polynucleotide ofthe present invention. For example, a hexa-histidine marker sequence provides a convenient means to purify the proteins ofthe present invention. A polynucleotide ofthe present invention can be attached to a vector, adapter, or linker for cloning and/or expression of a polynucleotide ofthe present invention. Additional sequences may be added to such cloning and/or expression sequences to optimize their function in cloning and/or expression, to aid in isolation ofthe polynucleotide, or to improve the introduction ofthe polynucleotide into a cell. Typically, the length of a nucleic acid ofthe present invention less the length of its polynucleotide ofthe present invention is less than 20 kilobase pairs, often less than 15 kb, and frequently less than 10 kb. Use of cloning vectors, expression vectors, adapters, and linkers is well known and extensively described in the art. For a description of various nucleic acids see, for example, Stratagene Cloning Systems, Catalogs 1999 (La Jolla, CA); and, Amersham Life Sciences, Inc, Catalog '99 (Arlington Heights, IL). A. Recombinant Methods for Constructing Nucleic Acids The isolated nucleic acid compositions of this invention, such as RNA, cDNA, genomic DNA, or a hybrid thereof, can be obtained from plant biological sources using any number of cloning methodologies known to those of skill in the art. In some embodiments, oligonucleotide probes which selectively hybridize under stringent conditions to the polynucleotides ofthe present invention are used to identify the desired sequence in a cDNA or genomic DNA library. Techniques for the isolation of RNA and construction of cDNA and genomic libraries are well known to those of ordinary skill in the art. See, e.g., Plant Molecular Biology: A Laboratory Manual, Clark, ed., Springer-Nerlag, Berlin (1997), and Current Protocols in Molecular Biology, Ausubel, et al, eds., Greene Publishing and Wiley Jnterscience, New York (1995). Al. Full-length Enriched cDNA Libraries A number of cDNA synthesis protocols have been described which provide enriched full-length cDNA libraries. Enriched full-length cDNA libraries are constructed to comprise at least 60%, and more preferably at least 70%>, 80%), 90%> or 95% full-length inserts amongst clones containing inserts. The length of insert in such libraries can be at least 2,3, 4, 5, 6, 7, 8, 9, 10 or more kilobase pairs. Nectors to accommodate inserts of these sizes are known in the art and available commercially. See, e.g., Stratagene's lambda ZAP Express (cDΝA cloning vector with 0 to 12 kb cloning capacity). An exemplary method of constructing a greater than 95%> pure full-length cDΝA library is described by Carninci et al. (1996) Genomics 37:327-336. Other methods for producing full-length libraries are known in the art. See, e.g. , Edery et al. (1995) Mol. Cell Biol. 15 (6) -.3363-3371 and PCT Application WO 96/34981. A2. Normalized or Subtracted cDNA Libraries A non-normalized cDΝA library represents the mRΝA population ofthe tissue it was made from. Since unique clones are out-numbered by clones derived from highly expressed genes their isolation can be laborious. Normalization of a cDNA library is the process of creating a library in which each clone is more equally represented. Construction of normalized libraries is described in Ko (1990) Nucl. Acids. Res. 18(19) -.57 5-5711; Patanjali et al. (1991) Proc. Natl. Acad. U.S.A. 55:1943-1947; U.S. Patent Nos. 5,482,685, 5,482,845, and 5,637,685. In an exemplary method described by Soares et al. (1994) Proc. Natl. Acad. Sci. USA i :9228-9232, normalization resulted in reduction ofthe abundance of clones from a range of four orders of magnitude to a narrow range of only 1 order of magnitude. Subtracted cDNA libraries are another means to increase the proportion of less abundant cDNA species. In this procedure, cDNA prepared from one pool of mRNA is depleted of sequences present in a second pool of mRNA by hybridization. The cDNA:mRNA hybrids are removed and the remaining un-hybridized cDNA pool is enriched for sequences unique to that pool. See, Foote et al. in Plant Molecular Biology: A Laboratory Manual, Clark, Ed., Springer- Verlag, Berlin (1997); Kho and Zarbl (1991) Technique 3(2):58-63; Sive and St. John (1988) Nucl. Acids Res. 16(22):10937; Current Protocols in Molecular Biology, Ausubel, et al., eds., Greene Publishing and Wiley-Interscience, New York (1995); and, Swaroop et al. (1991) Nucl. Acids Res., 19(17^:4725-4730. cDNA subtraction kits are commercially available. See, e.g., PCR-Select (Clontech, Palo Alto, CA). To construct genomic libraries, large segments of genomic DNA are generated by fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. Methodologies to accomplish these ends, and sequencing methods to verify the sequence of nucleic acids are well known in the art. Examples of appropriate molecular biological techniques and instructions sufficient to direct persons of skill through many construction, cloning, and screening methodologies are found in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Vols. 1-3, Methods in Enzymology, Vol. 152: Guide to Molecular Cloning Techniques, Berger and Kimmel, eds., San Diego: Academic Press, Inc. (1987), Current Protocols in Molecular Biology, Ausubel, et al., eds., Greene Publishing and Wiley-Interscience, New York (1995); Plant Molecular Biology: A Laboratory Manual, Clark, Ed., Springer- Verlag, Berlin (1997). Kits for construction of genomic libraries are also commercially available. The cDNA or genomic library can be screened using a probe based upon the sequence of a polynucleotide ofthe present invention such as those disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different plant species. Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either or both ofthe hybridization and the wash medium can be stringent. The nucleic acids of interest can also be amplified from nucleic acid samples using amplification techniques. For instance, polymerase chain reaction (PCR) technology can be used to amplify the sequences of polynucleotides ofthe present invention and related genes directly from genomic DNA or cDNA libraries. PCR and other in vitro amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence ofthe desired mRNA in samples, for nucleic acid sequencing, or for other purposes. The T4 gene 32 protein (Boehringer Mannheim) can be used to improve yield of long PCR products. PCR-based screening methods have been described. Wilfinger et al. (1997) BioTechniques 22(3) :481-486 describe a PCR-based method in which the longest cDNA is identified in the first step so that incomplete clones can be eliminated from study. Such methods are particularly effective in combination with a full-length cDNA construction methodology, above. B. Synthetic Methods for Constructing Nucleic Acids The isolated nucleic acids ofthe present invention can also be prepared by direct chemical synthesis by methods such as the phosphotriester method of Narang et al. (1979) Meth. Enzymol. 68:90-99; the phosphodiester method of Brown et al. (1979) Meth. Enzymol. (55:109-151; the diethylphosphoramidite method of Beaucage et al. (1981) Tetra. Lett. 22:1859-1862; the solid phase phosphoramidite triester method described by Beaucage and Caruthers (1981) Eetra. Letts. 22:1859-1862, e.g., using an automated synthesizer, e.g., as described in Needham- VanDevanter et al. (1984) Nucleic Acids Res. 12: 6159-6168; and the solid support method of U.S. Patent No. 4,458,066. Chemical synthesis generally produces a single stranded oligonucleotide. This may be converted into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill will recognize that while chemical synthesis of DNA is best employed for sequences of about 100 bases or less, longer sequences may be obtained by the Hgation of shorter sequences. Recombinant Expression Cassettes The KCP-like sequences ofthe invention are provided in expression cassettes for expression in the plant of interest. The cassette will include 5' and 3' regulatory sequences operably linked to a KCP-like sequence ofthe invention. By "operably linked" is intended a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription ofthe DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame. The cassette may additionally contain at least one additional gene to be cotransformed into the organism. Alternatively, the additional gene(s) can be provided on multiple expression cassettes. Such an expression cassette is provided with a plurality of restriction sites for insertion ofthe KCP-like sequence to be under the transcriptional regulation ofthe regulatory regions. The expression cassette may additionally contain selectable marker genes. The expression cassette will include in the 5 '-3' direction of transcription, a transcriptional and translational initiation region, a KCP-like sequence ofthe invention, and a transcriptional and translational termination region functional in plants. The transcriptional initiation region, the promoter, may be native or analogous or foreign or heterologous to the plant host. Additionally, the promoter may be the natural sequence or alternatively a synthetic sequence. By "foreign" is intended that the transcriptional initiation region is not found in the native plant into which the transcriptional initiation region is introduced. As used herein, a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence. While it may be preferable to express the sequences using heterologous promoters, the native promoter sequences may be used. Such constructs would change expression levels of KCP-like polypeptides in the plant or plant cell. Thus, the phenotype ofthe plant or plant cell is altered. The termination region may be native with the transcriptional initiation region, may be native with the operably linked DNA sequence of interest, or may be derived from another source. Convenient termination regions are available from the Ti- plasmid of J. tumefaciens, such as the octopine synthase and nopaline synthase termination regions. See also Guerineau et al. (1991) Mol. Gen. Genet. 262:141-144; Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991) Genes Dev. 5:141-149; Mogen et al. (1990) Plant Cell 2:1261-1272; Munroe et al. (1990) Gene Pi:151-158; Ballas et al. (1989) Nucleic Acids Res. 7:7891-7903; and Joshi et al. (1987) Nucleic Acid Res. 15:9627-9639. Where appropriate, the gene(s) may be optimized for increased expression in the transformed plant. That is, the genes can be synthesized using plant-preferred codons for improved expression. See, for example, Campbell and Gowri (1990) Plant Physiol. 92:1-11 for a discussion of host-preferred codon usage. Methods are available in the art for synthesizing plant-preferred genes. See, for example, U.S. Patent Nos. 5,380,831, and 5,436,391, and Murray et al. (1989) Nucleic Acids Res. 77:477-498, herein incorporated by reference. Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences that may be deleterious to gene expression. The G-C content ofthe sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures. The expression cassettes may additionally contain 5' leader sequences in the expression cassette construct. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include: picornavirus leaders, for example, EMCV leader (Encephalomyocarditis 5' noncoding region) (Elroy-Stein et al. (1989) Proc. Natl. Acad. Sci. USA 5(5:6126-6130); potyvirus leaders, for example, TEV leader (Tobacco Etch Virus) (Gallie et al. (1995) Gene 165 (2) -.233-238), MDMV leader (Maize Dwarf Mosaic Virus) {Virology 154:9-20), and human immunoglobulin heavy-chain binding protein (BiP) (Macejak et al. (1991) Nature 353:90-94); untranslated leader from the coat protein mRNA of alfalfa mosaic virus (AMV RNA 4) (Jobling et al. (1987) Nature 325:622-625); tobacco mosaic virus leader (TMV) (Gallie et al. (1989) in Molecular Biology of RNA, ed. Cech (Liss, New York), pp. 237-256); and maize chlorotic mottle virus leader (MCMV) (Lommel et al. (1991) Virology 57:382-385). See also, Della-Cioppa et al. (1987) Plant Physiol. 54:965-968. Other methods known to enhance translation can also be utilized, for example, introns, and the like. In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Toward this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, in vitro mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g., transitions and transversions, may be involved. Plant expression vectors may include (1) a cloned plant gene under the transcriptional control of 5' and 3' regulatory sequences and (2) a dominant selectable marker. Such plant expression vectors may also contain, if desired, a promoter regulatory region {e.g., one conferring inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-selective/preferred expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal. A number of promoters can be used in the practice ofthe invention. In one embodiment, a plant promoter fragment can be employed which will direct expression of a polynucleotide of the present invention in all tissues of a regenerated plant. Such promoters are referred to herein as "constitutive" promoters and are active under most environmental conditions and stated of development or cell differentiation. Examples of constitutive promoters include the cauliflower mosaic virus (CaMN) 35S transcription initiation region, the 1'- or 2'- promoter derived from T-DΝA of Agrobacterium tumefaciens, the ubiquitin 1 promoter (Christensen et al. (1992) Plant Mol Biol 75:675-689; Bruce et al. (1989) Proc Natl Acad Sci USA 86:9692-9696), the Smas promoter, the cinnamyl alcohol dehydrogenase promoter (U.S. Patent No, 5,683,439), the Nos promoter, the pEmu promoter, the Rubisco promoter, the GRPl-8 promoter, the maize constitutive promoters described in PCT Publication No. WO 99/43797 which include the histone H2B, metallothionein, alpha-tubulin 3, elongation factor efla, ribosomal protein rps8, chlorophyll a/b binding protein, and glyceraldehyde-3 -phosphate dehydrogenase promoters, and other transcription initiation regions from various plant genes known to those of skill. Where low level expression is desired, weak promoters will be used. It is recognized that weak inducible promoters may be used. Additionally, either a weak constitutive or a weak tissue specific promoter may be used. Generally, by "weak promoter" is intended a promoter that drives expression of a coding sequence at a low level. By low level is intended at levels of about 1/1000 transcripts to about 1/100,000 transcripts to about 1/500,000 transcripts. Alternatively, it is recognized that weak promoters also encompass promoters that are expresses in only a few cells and not in others to give a total low level of expression. Such weak constitutive promoters include, for example, the core promoter ofthe Rsyn7 (PCT Publication No. WO 97/44756), the core 35S CaMV promoter, and the like. Where a promoter is expressed at unacceptably high levels, portions ofthe promoter sequence can be deleted or modified to decrease expression levels. Additionally, to obtain a varied series in the level of expression, one can also make a set of transgenic plants containing the polynucleotides ofthe present invention with a strong constitutive promoter, and then rank the transgenic plants according to the observed level of expression. The transgenic plants will show a variety in performance, from high expression to low expression. Factors such as chromosomal position effect, cosuppression, and the like will affect the expression ofthe polynucleotide. Alternatively, the plant promoter can direct expression of a polynucleotide of the present invention under environmental control. Such promoters are referred to here as "inducible" promoters. Environmental conditions that may effect transcription by inducible promoters include pathogen attack, anaerobic conditions, or the presence of light. Examples of inducible promoters are the Adhl promoter, which is inducible by hypoxia or cold stress, the Hsp70 promoter, which is inducible by heat stress, and the PPDK promoter, which is inducible by light. Examples of pathogen-inducible promoters include those from proteins, which are induced following infection by a pathogen; e.g., PR proteins, SAR proteins, beta-l,3-glucanase, chitinase, etc. See, for example, Redolfi et al. (1983) Meth J. Plant Pathol 5P:245-254; Uknes et al. (1992) The Plant Cell 4:645-656; Van Loon (1985) Plant Mol. Virol. 4:111-116; PCT Publication No. WO 99/43819. Of interest are promoters that are expressed locally at or near the site of pathogen infection. See, for example, Marineau et al. (1987) Plant Mol. Biol. P:335- 342; Matton et al. (1987) Molecular Plant-Microbe Interactions 2:325-342; Somssich et al. (1986) Proc. Natl. Acad. Sci. USA 53:2427-2430; Somssich et al. (1988) Mol. Gen. Genetics 2:93-98; Yang (1996) Proc. Natl. Acad. Sci. USA 93: 14972-14977. See also, Chen, et al. (1996) Plant J. 10:955-966; Zhang and Sing (1994) Proc. Natl. Acad. Sci. USA P7:2507-2511; Warner et al. (1993) Plant J. 3:191- 201, and Siebertz et al. (1989) Plant Cell 1 :961-968, all of which are herein incorporated by reference. Of particular interest is the inducible promoter for the maize PRms gene, whose expression is induced by the pathogen Fusarium moniliforme (see, for example, Cordero et al. (1992) Physiol. Mol. Plant Path. 41:189-200, herein incorporated by reference). Additionally, as pathogens find entry into plants through wounds or insect damage, a wound-inducible promoter may be used in the constructs ofthe invention. Such wound-inducible promoter include potato proteinase inhibitor (pin II) gene (Ryan (1990) Annu Rev Phytopath 25:425-449; Duan et al. (1996) Nat Biotech 74:494-498); wunl and wun 2, US Patent No. 5,428,148; winl and win2 (Stanford et al. (1989) Mol. Gen. Genet. 215:200-208); systemin (McGurl et al. (1992) Science 225:1570-1573); WIP1 (Rohmeier et al. (1993) Plant Mol Biol 22:783-792; Eckelkamp et al. (1993) FEB Letters 323:73-76); MPI gene (Cordero et al. (1994) The Plant J. 6(2):141-150); and the like, herein incorporated by reference. Examples of promoters under developmental control include promoters that initiate transcription only or preferentially in certain tissues, such as leaves, roots, fruit, seeds, or flowers. Exemplary promoters include the anther-specific promoter 5126 (U.S. Patent Nos. 5,689,049 and 5,689,051), glob-1 promoter, and gamma-zein promoter. An exemplary promoter for leaf- and stalk-preferred expression is MS8-15 (PCT Publication No. WO 98/00533). Examples of seed-preferred promoters include, but are not limited to, 27 kD gamma zein promoter and waxy promoter (Boronat et αl (1986) Plant Sci. 47:95-102; Reina et α/. (1990) Nucleic Acids Res. 18(21):6426; and Kloesgen et αl (1986) Mol. Gen. Genet. 203:237-244). Promoters that express in the embryo, pericarp, and endosperm are disclosed in U.S. Application Nos. 60/097,233 (filed August 20, 1998) and 60/098,230 (filed August 28, 1998), both hereby incorporated by reference. The operation of a promoter may also vary depending on its location in the genome. Thus, a developmentally-regulated promoter may become fully or partially constitutive in certain locations. A developmentally-regulated promoter can also be modified, if necessary, for weak expression. In one embodiment, the nucleic acids encoding the KCP-like polypeptides of the invention are operably linked to a promoter as part of an expression cassette, and introduced into a crop plant such that a transgenic plant is formed. Where a high level of expression is desired, a strong constitutive promoter, such as the ubiquitin promoter is utilized. In this manner, the gene's expression is constitutively high and disease- or stress-resistance is constitutively enhanced. In another embodiment, the gene may be linked to a tissue-preferred promoter to direct expression to one or more tissues particularly known to be susceptible to a pathogen that is sought to be controlled. Tissue-preferred promoters can also be used to circumvent expression in tissues that are susceptible to food safety concern. The timing of expression can also be manipulated. For example, by judicious choice of promoter, the expression ofthe transgene can be enhanced earlier than that ofthe native gene in response to pathogen attack; thereby resulting in enhanced disease resistance. For pathogens that do not cause induced expression ofthe native gene, again judicious choice of promoter, may result in induced expression of this gene's coding region in response to that pathogen. Both heterologous and non-heterologous {i.e., endogenous) promoters can be employed to direct expression ofthe nucleic acids ofthe present invention. These promoters can also be used, for example, in recombinant expression cassettes to drive expression of antisense nucleic acids to reduce, increase, or alter concentration and/or composition ofthe proteins ofthe present invention in a desired tissue. Thus, in some embodiments, the nucleic acid construct will comprise a promoter functional in a plant cell, such as in Zea mays, operably linked to a polynucleotide ofthe present invention. Promoters useful in these embodiments include the endogenous promoters driving expression of a polypeptide ofthe present invention. In some embodiments, isolated nucleic acids which serve as promoter or enhancer elements can be introduced in the appropriate position (generally upstream) of a non-heterologous form of a polynucleotide ofthe present invention so as to up- or down- regulate expression of a polynucleotide ofthe present invention. For example, endogenous promoters can be altered in vivo by mutation, deletion, and/or substitution (see U.S. Patent No. 5,565,350 and PCT/US93/03868), or isolated promoters can be introduced into a plant cell in the proper orientation and distance from a gene ofthe present invention so as to control the expression ofthe gene. Gene expression can be modulated under conditions suitable for plant growth so as to alter the total concentration and/or alter the composition ofthe polypeptides ofthe present invention in plant cell. Thus, the present invention provides compositions, and methods for making, heterologous promoters and/or enhancers operably linked to a native, endogenous {i.e., non-heterologous) form of a polynucleotide ofthe present invention. If polypeptide expression is desired, it is generally desirable to include a polyadenylation region at the 3' end of a polynucleotide coding region. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA. The 3' end sequence to be added can be derived from, for example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene, or less preferably from any other eukaryotic gene. It may also be synthetically designed and constructed. An intron sequence can be added to the 5' untranslated region or the coding sequence ofthe partial coding sequence to increase the amount ofthe mature message that accumulates in the cytosol. Inclusion of a spliceable intron in the transcription unit in both plant and animal expression constructs has bee shown to increase gene expression at both the mRNA and protein levels up to 1000-fold. See Buchman and Berg (1988) Mol. Cell Biol 5:4395-4405; Callis et α/. (1987) Genes Dev. 7:1183- 1200. Such intron enhancement of gene expression is typically greatest when placed near the 5' end ofthe transcription unit. Use ofthe maize introns Adhl-S intron 1, 2, and 6, and the Bronze- 1 intron are known in the art. See generally, The Maize Handbook, Chapter 116, Freeling and Walbot, Eds., Springer, New York (1994). The vector comprising the sequences of a polynucleotide ofthe present invention will typically comprise a marker gene which confers a selectable phenotype on plant cells. Usually, the selectable marker gene will encode antibiotic resistance, with suitable genes including genes coding for resistance to the antibiotic spectinomycin (e.g., the aada gene), the streptomycin phosphotransferase (SPT) gene coding for streptomycin resistance, the neomycin phosphotransferase (NPTII) gene encoding kanamycin or geneticin resistance, the hygromycin phosphotransferase (HPT) gene coding for hygromycin resistance, genes coding for resistance to herbicides which act to inhibit the action of acetolactate synthase (ALS), in particular the sulfonylurea-type herbicides (e.g., the acetolactate synthase (ALS) gene containing mutations leading to such resistance in particular the S4 and/or Hra mutations), genes coding for resistance to herbicides which act to inhibit action of glutamine synthase, such as phosphinothricin or basta (e.g., the bar gene), or other such genes known in the art. The bar gene encodes resistance to the herbicide basta, the nptll gene encodes resistance to the antibiotics kanamycin and geneticin, and the ALS gene encodes resistance to the herbicide chlorsulfuron. The above list of selectable marker genes is not meant to be limiting. Any selectable marker gene can be used in the present invention. Typical vectors useful for expression of genes in higher plants are well known in the art and include vectors derived from the tumor-induced (Ti) plasmid of Agrobacterium tumefaciens, described by Rogers et al. (1987) Meth. Enzymol. 753:253-277. These vectors are plant integrating vectors; upon transformation, the vectors integrate a portion of vector DNA into the genome ofthe host plant. Exemplary A. tumefaciens vectors useful herein are plasmids pKYLX6 and pKYLX7 of Schardl et al (1987) Gene 61:1-11 and Berger et al. (1989) Proc. Natl Acad. Sci. U S.A. 86: 8402-8406. Another useful vector herein is plasmid pBI 101.2 that is available from Clontech Laboratories, Inc. (Palo Alto, CA). It is recognized that with these nucleotide sequences, antisense constructions, complementary to at least a portion ofthe messenger RNA (mRNA) for the KCP-like sequences can be constructed. Antisense nucleotides are constructed to hybridize with the corresponding mRNA. Modifications ofthe antisense sequences may be made as long as the sequences hybridize to and interfere with expression ofthe corresponding mRNA. In this manner, antisense constructions having 70%, preferably 80%), more preferably 85% sequence identity to the corresponding antisense sequences may be used. Furthermore, portions ofthe antisense nucleotides may be used to disrupt the expression ofthe target gene. Generally, sequences of at least 50 nucleotides, 100 nucleotides, 200 nucleotides, or greater may be used. For an example ofthe use of this method to modulate expression of endogenous genes, see Sheehg et. al. (1988) Proc. Natl. Acad. Sci. 55:8805-8809, and U.S. Patent No. 4,801,340. The nucleotide sequences ofthe present invention may also be used in the sense orientation to suppress the expression of endogenous genes in plants. Methods for suppressing gene expression in plants using nucleotide sequences in the sense orientation are known in the art. The methods generally involve transforming plants with a DNA construct comprising a promoter that drives expression in a plant operably linked to at least a portion of a nucleotide sequence that corresponds to the transcript ofthe endogenous gene. Typically, such a nucleotide sequence has substantial sequence identity to the sequence ofthe transcript ofthe endogenous gene, preferably greater than about 65% sequence identity, more preferably greater than i . - - / v,l 58 about 85%) sequence identity, most preferably greater than about 95% sequence identity. See Napul et al (1990) The Plant Cell 2:279-289, and U.S. Patent Nos. 5,283,184 and 5,034,323; herein incorporated by reference. Catalytic RNA molecules or ribozymes can also be used to inhibit expression of plant genes. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity ofthe constructs. The design and use of target RNA-specific ribozymes is described in Haseloff et al. (1988) Nature 334:585-591. A variety of cross-linking agents, alkylating agents and radical generating species as pendant groups on polynucleotides ofthe present invention can be used to bind, label, detect, and/or cleave nucleic acids. For example, Vlassov et al (1986) Nucleic Acids Res. 74:4065-4076 describe covalent bonding of a single-stranded DNA fragment with alkylating derivatives of nucleotides complementary to target sequences. (A report of similar work by the same group may be found in Knorre et al. (1985) Biochimie 57:785-789). Iverson and Dervan also showed sequence-specific cleavage of single- stranded DNA mediated by incoφoration of a modified nucleotide which was capable of activating cleavage (Iverson and Dervan (1987) J. Am. Chem. Soc. 109:1241-1243). Meyer et al. ((1989) J. Am. Chem. Soc. 777:8517-8519) effect covalent crosslinking to a target nucleotide using an alkylating agent complementary to the single-stranded target nucleotide sequence. A photoactivated crosslinking to single-stranded oligonucleotides meditated by psoralen was disclosed by Lee et al. (1988) Biochemistry 27:3197-3203. Use of crosslinking in triple-helix forming probes was also disclosed by Home et al. ((1990) J. Am. Chem. Soc. 772:435-2437). Use of N4, N4-ethanocytosine as an alkylating agent to crosslink to single-stranded oligonucleotides has also been described by Webb and Matteucci ((1986) J. Am. Chem. Soc. 108:2764-2765); (1986) Nucleic Acids Res. 14:7661-7674; Feteritz et al. (1991) J. Am. Chem. Soc. 773:4000. Various compounds to bind, detect, label, and/or cleave nucleic acids are known in the art. See, for example, U.S. Patent Nos. 5,543,507; 5,672,593; 5,484,908; 5,256,648; and 5,681,941. Proteins The isolated proteins ofthe present invention comprise a polypeptide having at least 10 amino acids encoded by any one ofthe polynucleotides ofthe present invention as discussed more fully, above, or polypeptides which are conservatively modified variants thereof. The proteins ofthe present invention or variants thereof can comprise any number of contiguous amino acid residues from a polypeptide of the present invention, wherein that number is selected from the group of integers consisting of from 10 to the number of residues in a full-length polypeptide ofthe present invention. Optionally, this subsequence of contiguous amino acids is at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 38, 39, or 40 amino acids in length, often at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids in length. By "variant" protein is intended a protein derived from the native protein by deletion (so-called truncation) or addition of one or more amino acids to the N- terminal and/or C-terminal end ofthe native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein. Variant proteins encompassed by the present invention are biologically active, that is they continue to possess the desired biological activity ofthe native protein, that is, KCP-like activity as described herein. Such variants may result from, for example, genetic polymoφhism or from human manipulation. Biologically active variants of a native KCP-like protein ofthe invention will have at least about 40%, 50%, 60%, 65%>, 70%, generally at least about 75%), 80%>, 85%, preferably at least about 90%>, 91%., 92%., 93%, 94%, 95%, 96%, 97%, and more preferably at least about 98%, 99% or more sequence identity to the amino acid sequence for the native protein as determined by sequence alignment programs described elsewhere herein using default parameters. A biologically active variant of a protein ofthe invention may differ from that protein by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue. As contemplated herein, the proteins ofthe present invention are also intended to include KCP-like sequences wherein the signal or transit peptide has been removed. As discussed elsewhere herein, most ofthe KCP-like proteins ofthe present invention are predicted to have such sequences using standard techniques such as, for example, PSORT ("Prediction of Protein Translocation Sites"), or SIGNALP ("Signal Peptide Prediction Analysis") or other known methods. Thus as a group these proteins have signal or transit peptides and are targeted for the extracellular space. It may be advantageous to use matured polypeptides in some instances, that is polypeptides where the signal or transit peptide sequence has been cleaved or otherwise removed. For example, candidate anti-microbial proteins are expected to be targetted to the extracellular space, since this is the most likely area where a pathogen will be encountered. Thus the present invention is intended to encompass such sequences . As those of skill will appreciate, the present invention includes catalytically active polypeptides ofthe present invention (i.e., enzymes). Catalytically active polypeptides have a specific activity of at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% that ofthe native (non-synthetic), endogenous polypeptide. Further, the substrate specificity (k cat /K m ) is optionally substantially similar to the native (non-synthetic), endogenous polypeptide. Typically, the K m will be at least 30%, 40%>, or 50%, that ofthe native (non-synthetic), endogenous polypeptide; and more preferably at least 60%>, 70%, 80%), or 90%.. Methods of assaying and quantifying measures of enzymatic activity and substrate specificity (k cat /K m ), are well known to those of skill in the art. Generally, the proteins ofthe present invention will, when presented as an immunogen, elicit production of an antibody specifically reactive to a polypeptide of the present invention. Further, the proteins ofthe present invention will not bind to antisera raised against a polypeptide ofthe present invention which has been fully immunosorbed with the same polypeptide. Immunoassays for determining binding are well known to those of skill in the art. A preferred immunoassay is a competitive - immunoassay as discussed infra. Thus, the proteins ofthe present invention can be employed as immunogens for constructing antibodies immunoreactive to a protein of the present invention for such exemplary utilities as immunoassays or protein purification techniques. The proteins ofthe invention may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants ofthe KCP-like proteins can be prepared by mutations in the DNA. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel (1985) Proc. Natl. Acad. Sci. USA 52:488-492; Kunkel et al. (1987) Methods in Enzymol. 154:367-382; U.S. Patent No. 4,873,192; Walker and Gaastra, eds. (1983) Techniques in Molecular Biology (MacMillan Publishing Company, New York) and the references cited therein. Guidance as to appropriate amino acid substitutions that do not affect biological activity ofthe protein of interest may be found in the model of Dayhoff et al. (1978) Atlas of Protein Sequence and Structure (Natl. Biomed. Res. Found., Washington, D.C.), herein incoφorated by reference. Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be preferable. Thus, the genes and nucleotide sequences ofthe invention include both the naturally occurring sequences as well as mutant forms. Likewise, the proteins ofthe invention encompass both naturally occurring proteins as well as variations and modified forms thereof. Such variants will continue to possess the desired KCP-like activity. Obviously, the mutations that will be made in the DNA encoding the variant must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. See, EP Patent Application Publication No. 75,444. The deletions, insertions, and substitutions ofthe protein sequences encompassed herein are not expected to produce radical changes in the characteristics ofthe protein. However, when it is difficult to predict the exact effect ofthe substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by routine screening assays. That is, the activity can be evaluated by determining the KCP-like properties ofthe sequence or polypeptide which has been deleted, inserted or substituted as described herein. Such properties include, for example, anti-microbial activity. Assays for measuring antimicrobial or anti-pathogenic activity are described elsewhere herein. As discussed elsewhere herein, variant nucleotide sequences and proteins also encompass sequences and proteins derived from a mutagenic and recombinogenic procedure such as DNA shuffling. With such a procedure, one or more different KCP-like coding sequences can be manipulated to create a new KCP-like possessing the desired properties. In this manner, libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides comprising sequence regions that have substantial sequence identity and can be homologously recombined in vitro or in vivo. Expression of Proteins in Host Cells Using the nucleic acids ofthe present invention, one may express a protein of the present invention in a recombinantly engineered cell such as bacterial, yeast, insect, mammalian, or preferably plant cells. The cells produce the protein in a non- natural condition (e.g., different from the natural condition in quantity, composition, location, and/or time), because they have been genetically altered through human intervention to do so. It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of a nucleic acid encoding a protein ofthe present invention. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes will be made. In brief summary, the expression of isolated nucleic acids encoding a protein ofthe present invention will typically be achieved by operably linking, for example, the DNA or cDNA to a promoter (which is either constitutive or regulatable), followed by incoφoration into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation ofthe expression ofthe DNA encoding a protein of the present invention. To obtain high level expression of a cloned gene, it is desirable to construct expression vectors which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. One of skill will recognize that modifications could be made to a protein ofthe present invention without diminishing its biological activity. Some modifications may be made to facilitate the cloning, expression, or incoφoration ofthe targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located purification sequences. Restriction sites or termination codons can also be introduced. A. Expression in Prokaryotes Prokaryotic cells may be used as hosts for expression. Prokaryotes most frequently are represented by various strains of E. coli; however, other microbial strains may also be used. Commonly used prokaryotic control sequences (which are defined herein to include promoters for transcription initiation, optionally with an operator and ribosome binding sequences) include such commonly used promoters as the beta lactamase (penicillinase) and lactose (lac) promoter systems (Chang et al. (1977) Nαtwre 198:1056), the tryptophan (tφ) promoter system (Goeddel et al. (1980) Nucleic Acids Res. 5:4057) and the lambda-derived P L promoter and Ν-gene ribosome binding site (Shimatake et al. (1981) Nature 292:128). The inclusion of selection markers in DΝA vectors transfected in E coli. is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol . The vector is selected to allow introduction into the appropriate host cell. Bacterial vectors are typically of plasmid or phage origin. Appropriate bacterial cells are infected with phage vector particles or transfected with naked phage vector DΝA. If a plasmid vector is used, the bacterial cells are transfected with the plasmid vector DΝA. Expression systems for expressing a protein ofthe present invention are available using Bacillus spp. and Salmonella (Palva et al. (1983) Gene 22:229-235; Mosbach, et al. (1983) Nature 302:543-545). B. Expression in Eukaryotes A variety of eukaryotic expression systems such as yeast, insect cell lines, plant and mammalian cells, are known to those of skill in the art. As explained briefly below, a polynucleotide ofthe present invention can be expressed in these eukaryotic systems. In some embodiments, transformed/transfected plant cells, as discussed infra, are employed as expression systems for production ofthe proteins ofthe instant invention. Synthesis of heterologous proteins in yeast is well known. Sherman, F., et al (Methods in Yeast Genetics, Cold Spring Harbor Laboratory (1982)) is a well- recognized work describing the various methods available to produce the protein in yeast. Two widely utilized yeasts for production of eukaryotic proteins are Saccharomyces cerevisiae and Pichia pastoris. Nectors, strains, and protocols for expression in Saccharomyces and Pichiα are known in the art and available from commercial suppliers (e.g., Invitrogen). Suitable vectors usually have expression control sequences such as promoters (including 3-phosphoglycerate kinase or alcohol oxidase) and an origin of replication, termination sequences and the like as desired. A protein ofthe present invention, once expressed, can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysate. The monitoring ofthe purification process can be accomplished by using Western blot techniques or radioimmunoassay of other standard immunoassay techniques. The sequences encoding proteins ofthe present invention can also be ligated to various expression vectors for use in transfecting cell cultures of, for instance, mammalian, insect, or plant origin. Illustrative cell cultures useful for the production ofthe peptides are mammalian cells. Mammalian cell systems often will be in the form of monolayers of cells, although mammalian cell suspensions may also be used. A number of suitable host cell lines capable of expressing intact proteins have been developed in the art and include the HEK293, BHK21, and CHO cell lines. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (e.g., the CMN promoter, a HSV tk promoter or pgk (phosphoglycerate kinase) promoter), an enhancer (Queen et αl. (1986) Immunol. Rev. 89:49), and necessary processing information sites, such as ribosome binding sites, RΝA splice sites, polyadenylation sites {e.g., an SV40 large T-ag polyA addition site), and transcriptional terminator sequences. Other animal cells useful for production of proteins ofthe present invention are available from, for instance, the American Type Culture Collection. Appropriate vectors for expressing proteins ofthe present invention in insect cells are usually derived from the SF9 baculovirus. Suitable insect cell lines include mosquito larvae, silkworm, armyworm, moth and Drosophila cell lines such as a Schneider cell line (see Schneider (1987) J. Embryol Exp. Morphol 27:353-365). As with yeast, when higher animal or plant host cells are employed, polyadenylation or transcription terminator sequences are typically incoφorated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing ofthe transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague et al. (1983) J. Virol. 45:773-781). Additionally, gene sequences to control replication in the host cell may be incoφorated into the vector such as those found in bovine papilloma virus type-vectors (see Saveria-Campo, "Bovine Papilloma Virus DNA: A Eukaryotic Cloning Vector," in DNA Cloning Vol. II a Practical Approach, D.M. Glover, ed., IRL Press, Arlington, Virginia, pp. 213- 238 (1985)). Transfection/Transformation of Cells The method of transformation/transfection is not critical to the instant invention; various methods of transformation or transfection are currently available. As newer methods are available to transform crops or other host cells they may be directly applied. Accordingly, a wide variety of methods have been developed to insert a DNA sequence into the genome of a host cell to obtain the transcription and/or translation ofthe sequence to effect phenotypic changes in the organism. Thus, any method which provides for effective transformation and/or transfection may be employed. A. Plant Transformation The genes ofthe present invention can be used to transform any plant. In this manner, genetically modified plants, plant cells, plant tissue, seed, and the like can be obtained. Transformation protocols may vary depending on the type of plant cell targeted for transformation, i.e. monocot or dicot. Suitable methods of transforming plant cells include microinjection (Crossway et al. (1986) BioTechniques 4:320-334), electroporation (Riggs et al. (1986) Proc. Natl. Acad. Sci. USA 53:5602-5606), Agrobacterium mediated transformation (Hinchee et al. (1988) Biotechnology 6: 15- 921; U.S. Patent No. 5,981,840 (maize); U.S. PatentNo. 5,932,782 (sunflower), European Patent No. 0486233 (sunflower); PCT Application No. WO 98/49332 (sorghum)), direct gene transfer (Paszkowski et al. (1984) EMBOJ. 3:2717-2722), and ballistic particle acceleration (see, for example, Sanford et al, U.S. Patent 4,945,050; Tomes et al, "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment" in Gamborg and Phillips (eds.) Plant Cell, Tissue and Organ Culture: Fundamental Methods, Springer- Verlag, Berlin (1995); McCabe et al. (1988) Biotechnology 5:923-926); U.S. Patent No. 5,990,387 (maize), U.S. Patent No. 5,886,244 (maize); U.S. PatentNo. 5,322,783 (sorghum)). Also see, Weissinger et al (1988) Annual Rev. Genet. 22:421-477; Sanford et /. (1987) Paniculate Science and Technology 5:27-37 (onion); Christou et al. (1988) Plant Physiol. 87:671-674 (soybean); McCabe et al. (1988) Bio/Technology 6:923-926 (soybean); Datta et al, (1990) Biotechnology 5:736-740 (rice); Klein et al, (1988) Proc. Natl. Acad. Sci. USA 55:4305-4309 (maize); Klein et al (1988) Biotechnology 6:559-563 (maize); Tomes et al, "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in Gamborg and Phillips (eds.) Plant Cell, Tissue and Organ Culture: Fundamental Methods, Springer-Verlag, Berlin (1995) (maize); Klein et al. (1988) Plant Physiol. 91 :440-444 (maize); Fromm et al. (1990) Biotechnology 5:833-839 (maize); Hooydaas-Van Slogteren & Hooykaas (1984) Nature (London) 377:763-764; Bytebier et al. (1987) Proc. Natl. Acad. Sci. USA 54:5345-5349 (Liliaceae); De Wet et al. (1985) in The Experimental Manipulation of Ovule Tissues, G.P. Chapman et al, eds., pp. 197-209, Longman, NY (pollen); Kaeppler et al (1990) Plant Cell Reports 9:415-418; and Kaeppler et al. (1992) Theor. Appl. Genet. 84:560- 566 (whisker-meditated transformation); D'Halluin et al. (1992) Plant Cell 4:1495- 1505 (electroporation); Li et al. (1993) Plant Cell Reports 72:250-255 and Christou and Ford (1995) Annals of Botany 75:745-750 (maize via Agrobacterium tumefaciens); all of which are hereby incoφorated by reference. The methods ofthe invention do not depend on a particular method for introducing a nucleotide construct to a plant, only that the nucleotide construct gains access to the interior of at least one cell ofthe plant. Methods for introducing nucleotide constructs into plants are known in the art including, but not limited to, stable transformation methods, transient transformation methods, and virus-mediated methods. By "stable transformation" is intended that the nucleotide construct introduced into a plant integrates into the genome ofthe plant and is capable of being inherited by progeny thereof. By "transient transformation" is intended that a nucleotide construct introduced into a plant does not integrate into the genome ofthe plant. The nucleotide constructs ofthe invention may be introduced into plants by contacting plants with a virus or viral nucleic acids. Generally, such methods involve incoφorating a nucleotide construct ofthe invention within a viral DNA or RNA molecule. It is recognized that the a KCP-like protein ofthe invention may be initially synthesized as part of a viral polyprotein, which later may be processed by proteolysis in vivo or in vitro to produce the desired recombinant protein. Further, it is recognized that promoters ofthe invention also encompass promoters utilized for transcription by viral RNA polymerases. Methods for introducing nucleotide constructs into plants and expressing a protein encoded therein, involving viral DNA or RNA molecules, are known in the art. See, for example, U.S. Patent Nos. 5,889,191, 5,889,190, 5,866,785, 5,589,367 and 5,316,931; herein incoφorated by reference. The cells that have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick et al. (1986) Plant Cell Reports 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having constitutive expression ofthe desired phenotypic characteristic identified. Two or more generations may be grown to ensure that expression ofthe desired phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure expression ofthe desired phenotypic characteristic has been achieved. One of skill will recognize that after the recombinant expression cassette is stably incoφorated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed. In vegetatively propagated crops, mature transgenic plants can be propagated by cuttings or by tissue culture techniques to produce multiple identical plants. Selection of desirable transgenics is made and new varieties are obtained and propagated vegetatively for commercial use. In seed-propagated crops, mature transgenic plants can be self-crossed to produce a homozygous inbred plant. The inbred plant produces seed containing the newly introduced heterologous nucleic acid. These seeds can be grown to produce plants having the selected phenotype. Parts obtained from the regenerated plant, such as flowers, seeds, leaves, branches, fruit, and the like are included in the invention, provided that these parts comprise cells comprising the isolated nucleic acid ofthe present invention. Progeny, variants, and mutants ofthe regenerated plants are also included within the scope of the invention, provided that these parts comprise the introduced nucleic acid sequences. A preferred embodiment is a transgenic plant that is homozygous for the added heterologous nucleic acid, i.e., a transgenic plant that contains two added nucleic acid sequences, one gene at the same locus on each chromosome of a chromosome pair. A homozygous transgenic plant can be obtained by sexually mating ("selfing") a heterozygous transgenic plant that contains a single added heterologous nucleic acid, germinating some ofthe seed produced, and analyzing the resulting plants produced for altered expression of a polynucleotide ofthe present invention relative to a control plant (i.e., native, non-transgenic). Backcrossing to a parental plant and out-crossing with a non-transgenic plant are also contemplated. B. Transfection of Prokaryotes, Lower Eukaryotes, and Animal Cells Animal and lower eukaryotic host cells (e.g., yeast) are competent or rendered competent for transfection by various means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion ofthe recipient cells with bacterial protoplasts containing the DNA, treatment ofthe recipient cells with liposomes containing the DNA, DEAE- dextran, electroporation, biolistics, and micro-injection ofthe DNA directly into the cells. The transfected cells are cultured by means well known in the art. See Kuchler, R.J., Biochemical Methods in Cell Culture and Virology, Dowden, Hutchinson and Ross, Inc (1997). Modulating polypeptide Levels and/or Composition The present invention further provides a method for modulating {i.e., increasing or decreasing) the concentration or composition ofthe polypeptides ofthe present invention in a plant or part thereof. Increasing or decreasing the concentration and/or the composition of polypeptides in a plant can effect modulation. For example, increasing the ratio of polypeptides ofthe invention to native polypeptides can affect modulation. The method comprises: introducing a polynucleotide ofthe present invention into a plant cell with a recombinant expression cassette as described above to obtain a transformed plant cell, culturing the transformed plant cell under appropriate growing conditions, and inducing or repressing expression of a polynucleotide ofthe present invention in the plant for a time sufficient to modulate concentration and/or composition of polypeptides in the plant or plant part. In some embodiments, the content and/or composition of polypeptides ofthe present invention in a plant may be modulated by altering, in vivo or in vitro, the promoter of a gene to up- or down- regulate gene expression. In some embodiments, the coding regions of native genes ofthe present invention can be altered via substitution, addition, insertion, or deletion to decrease activity ofthe encoded enzyme. See U.S. Patent No. 5,565,350 and PCT/US93/03868. In some embodiments, an isolated nucleic acid comprising a promoter sequence (e.g., a vector) is transfected into a plant cell. Subsequently, a plant cell comprising the promoter operably linked to a polynucleotide ofthe present invention is identified and selected by means known to those of skill in the art (such as, but not limited to, Southern blot, DNA sequencing, or PCR analysis using primers specific to the promoter and to the gene and detecting amplicons produced therefrom). A plant or plant part altered or modified by the foregoing embodiments is grown under appropriate conditions for a time sufficient to modulate the concentration and/or composition of polypeptides of the present invention in the plant. Appropriate growth conditions for transformed plant cells, plant parts, and plants are well known in the art and are discussed briefly elsewhere herein. In general, concentration or composition is increased or decreased by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%., 85%, 90%, 95%, or 100%. relative to a native control plant, plant part, or cell lacking the aforementioned recombinant expression cassette. Modulation in the present invention may occur during and/or subsequent to growth ofthe plant to the desired stage of development. Modulating nucleic acid expression temporally and/or in particular tissues can be controlled by employing the appropriate promoter operably linked to a polynucleotide ofthe present invention in, for example, sense or antisense orientation as discussed in greater detail elsewhere herein. Induction of expression of a polynucleotide ofthe present invention can also be controlled by exogenous administration of an effective amount of inducing compound. Inducible promoters and inducing compounds which activate expression from these promoters are well known in the art. In preferred embodiments, the polypeptides ofthe present invention are modulated in monocots, particularly maize. Molecular Markers The present invention provides a method of genotyping a plant comprising a polynucleotide ofthe present invention. Optionally, the plant is a monocot, such as maize or sorghum. Genotyping provides a means of distinguishing homologs of a chromosome pair and can be used to differentiate segregants in a plant population. Molecular marker methods can be used for exemplary applications such as phylogenetic studies, characterizing genetic relationships among crop varieties, identifying crosses or somatic hybrids, localizing chromosomal segments affecting monogenic traits, map-based cloning, and the study of quantitative inheritance. See, e.g. , Plant Molecular Biology: A Laboratory Manual, Chapter 7, Clark, Ed., Springer- Verlag, Berlin (1997). For molecular marker methods, see generally, The DNA Revolution, Andrew H. Paterson (1996) (Chapter 2) in: Genome Mapping in Plants (Andrew H. Paterson, ed.) by Academic Press/R.G. Lands Company, Austin, Texas, pp. 7-21. The particular method of genotyping in the present invention may employ any number of molecular marker analytic techniques such as, but not limited to, restriction fragment length polymoφhism's (RFLPs). RFLPs are the product of allelic differences between DNA restriction fragments resulting from nucleotide sequence variability. As is well known to those of skill in the art, RFLPs are typically detected by extraction of genomic DNA and digestion with a restriction enzyme. Generally, the resulting fragments are separated according to size and hybridized with a probe; single-copy probes are preferred. Restriction fragments from homologous chromosomes are thereby revealed. Differences in fragment size among alleles represent an RFLP; thus, the present invention further provides a means to follow segregation of a gene or nucleic acid ofthe present invention as well as chromosomal sequences genetically linked to these genes or nucleic acids using such techniques as RFLP analysis. Linked chromosomal sequences are within 50 centiMorgans (cM), often within 40 or 30 cM, preferably within 20 or 10 cM, more preferably within 5, 4, 3, 2, or 1 cM of a gene ofthe present invention. In the present invention, the nucleic acid probes employed for molecular marker mapping of plant nuclear genomes selectively hybridize (under selective hybridization conditions) to a gene encoding a polynucleotide ofthe present invention. In certain embodiments, the probes are selected from polynucleotides of the present invention. Typically, these probes are cDNA probes or restriction- enzyme-treated genomic clones. The length ofthe probes is discussed in greater detail elsewhere herein, but is typically at least 15 bases in length, more preferably at least 20, 25, 30, 35, 40, or 50 bases in length. Generally, however, the probes are less than about 1 kilobase in length. Preferably, the probes are single-copy probes that hybridize to a unique locus in the haploid chromosome compliment. Some exemplary restriction enzymes employed in RFLP mapping are EcoRI, EcoRV, and Sst . As used herein, the term "restriction enzyme" includes reference to a composition that recognizes and cleaves at a specific nucleotide sequence, either alone or in conjunction with another composition. The method of detecting an RFLP comprises the steps of: (a) digesting genomic DNA of a plant with a restriction enzyme; (b) hybridizing a nucleic acid probe, under selective hybridization conditions, to a sequence of a polynucleotide of the present invention comprised by said genomic DNA; (c) detecting thereby an RFLP. Other methods of differentiating polymoφhic (allelic) variants of polynucleotides ofthe present invention can be performed by utilizing molecular marker techniques well known to those of skill in the art, including such techniques as: 1) single stranded conformation analysis (SSCA); 2) denaturing gradient gel electrophoresis (DGGΕ); 3) RNase protection assays; 4) allele-specific oligonucleotides (ASOs); 5) the use of proteins which recognize nucleotide mismatches, such as the E. coli mutS protein; and 6) allele-specific PCR. Other approaches based on the detection of mismatches between the two complementary DNA strands include clamped denaturing gel electrophoresis (CDGΕ), heteroduplex analysis (HA), and chemical mismatch cleavage (CMC). Thus, the present invention further provides a method of genotyping comprising the steps of contacting, under stringent hybridization conditions, a sample suspected of comprising a polynucleotide ofthe present invention with a nucleic acid probe. Generally, the sample is a plant sample. For example, the plant sample may be a sample suspected of comprising a maize polynucleotide ofthe present invention (e.g., gene or mRNA). The nucleic acid probe selectively hybridizes under stringent conditions to a subsequence of a polynucleotide ofthe present invention comprising a polymoφhic marker. Selective hybridization ofthe nucleic acid probe to the polymoφhic marker nucleic acid sequence yields a hybridization complex. Detection ofthe hybridization complex indicates the presence of that polymoφhic marker in the sample. In certain embodiments, the nucleic acid probe comprises a polynucleotide ofthe present invention. UTRs and Codon Preference In general, translational efficiency has been found to be regulated by specific sequence elements in the 5' non-coding or nontranslated or untranslated region (5' UTR) ofthe RNA. Positive sequence motifs include translational initiation consensus sequences (Kozak (1987) Nucleic Acids Res. 15:8125) and the 7-methylguanosine cap structure (Drummond et al. (1985) Nucleic Acids Res. 13:7375). Negative elements include stable intramolecular 5' UTR stem-loop structures (Muesing et al. (1987) Cell 45:691) and AUG sequences or short open reading frames preceded by an appropriate AUG in the 5' UTR (Kozak, supra, Rao et al. (1988) Mol. Cell. Biol. 5:284). Accordingly, the present invention provides 5' and/or 3' UTR regions for modulation of translation of heterologous coding sequences. Further, the polypeptide-encoding segments ofthe polynucleotides ofthe present invention can be modified to alter codon usage. Altered codon usage can be employed to alter translational efficiency and/or to optimize the coding sequence for expression in a desired host such as to optimize the codon usage in a heterologous sequence for expression in maize. Codon usage in the coding regions ofthe polynucleotides ofthe present invention can be analyzed statistically using commercially available software packages, such as "Codon Preference/' available from the University of Wisconsin Genetics Computer Group (see Devereaux et al. (1984) Nucleic Acids Res. 72:387-395) or MacNector 4.1 (Eastman Kodak Co., New Haven, Conn.). Thus, the present invention provides a codon usage frequency characteristic ofthe coding region of at least one ofthe polynucleotides ofthe present invention. The number of polynucleotides that can be used to determine a codon usage frequency can be any integer from 1 to the number of polynucleotides ofthe present invention as provided herein. Optionally, the polynucleotides will be full- length sequences. An exemplary number of sequences for statistical analysis can be at least 1, 5, 10, 20, 50, or 100. Sequence Shufflin The present invention provides methods for sequence shuffling using polynucleotides ofthe present invention, and compositions resulting therefrom. Sequence shuffling is described in PCT Publication No. WO 96/19256. See also, Zhan et al. (1997) Proc. Natl. Acad. Sci. USA P4:4504-4509. Generally, sequence shuffling provides a means for generating libraries of polynucleotides having a desired characteristic for which one of skill can select or screen. Libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides which comprise sequence regions which have substantial identity and can be homologously recombined in vitro or in vivo. The population of sequence- recombined polynucleotides comprises a subpopulation of polynucleotides which possess desired or advantageous characteristics and which can be selected by a suitable selection or screening method. The characteristics can be any property or attribute capable of being selected for or detected in a screening system, and may include properties of: an encoded protein, a transcriptional element, a sequence controlling transcription, RNA processing, RNA stability, chromatin conformation, translation, or other expression property of a gene or transgene, a replicative element, a protein-binding element, or the like, such as any feature which confers a selectable or detectable property. In some embodiments, the selected characteristic will be a decreased K m and/or increased K cat over the wild-type protein as provided herein. In other embodiments, a protein or polynucleotide generated from sequence shuffling will have a ligand-binding affinity greater than the non-shuffled wild-type polynucleotide. The increase in such properties can be at least 110%, 120%, 130%, 140%), or at least 150% ofthe wild-type value. Chimeraplasty The use ofthe term "nucleotide constructs" herein is not intended to limit the present invention to nucleotide constructs comprising DNA. Those of ordinary skill in the art will recognize that nucleotide constructs, particularly polynucleotides and oligonucleotides, comprised of ribonucleotides and combinations of ribonucleotides and deoxyribonucleotides may also be employed in the methods disclosed herein. Thus, the nucleotide constructs ofthe present invention encompass all nucleotide constructs that can be employed in the methods ofthe present invention for transforming plants including, but not limited to, those comprised of deoxyribonucleotides, ribonucleotides, and combinations thereof. Such deoxyribonucleotides and ribonucleotides include both naturally occurring molecules and synthetic analogues. The nucleotide constructs ofthe invention also encompass all forms of nucleotide constructs including, but not limited to, single-stranded forms, double-stranded forms, haiφins, stem-and-loop structures, and the like. Furthermore, it is recognized that the methods ofthe invention may employ a nucleotide construct that is capable of directing, in a transformed plant, the expression of at least one protein, or at least one RNA, such as, for example, an antisense RNA that is complementary to at least a portion of an mRNA. Typically such a nucleotide construct is comprised of a coding sequence for a protein or an RNA operably linked to 5' and 3' transcriptional regulatory regions. Alternatively, it is also recognized that the methods ofthe invention may employ a nucleotide construct that is not capable of directing, in a transformed plant, the expression of a protein or an RNA. In addition, it is recognized that methods ofthe present invention do not depend on the incoφoration ofthe entire nucleotide construct into the genome, only that the plant or cell thereof is altered as a result ofthe introduction ofthe nucleotide construct into a cell. In one embodiment ofthe invention, the genome may be altered following the introduction ofthe nucleotide construct into a cell. For example, the nucleotide construct, or any part thereof, may incoφorate into the genome ofthe plant. Alterations to the genome ofthe present invention include, but are not limited to, additions, deletions, and substitutions of nucleotides in the genome. While the methods ofthe present invention do not depend on additions, deletions, or substitutions of any particular number of nucleotides, it is recognized that such additions, deletions, or substitutions comprise at least one nucleotide. The nucleotide constructs ofthe invention also encompass nucleotide constructs that may be employed in methods for altering or mutating a genomic nucleotide sequence in an organism, including, but not limited to, chimeric vectors, chimeric mutational vectors, chimeric repair vectors, mixed-duplex oligonucleotides, self-complementary chimeric oligonucleotides, and recombinogenic oligonucleobases. Such nucleotide constructs and methods of use, such as, for example, chimeraplasty, are known in the art. Chimeraplasty involves the use of such nucleotide constructs to introduce site-specific changes into the sequence of genomic DNA within an organism. See, U.S. Patent Nos. 5,565,350; 5,731,181; 5,756,325; 5,760,012; 5,795,972; and 5,871,984; all of which are herein incoφorated by reference. See also, WO 98/49350, WO 99/07865, WO 99/25821, and Beetham et al. (1999) Proc. Natl. Acad. Sci. USA 96: 8774-8778; herein incoφorated by reference. Generic and Consensus Sequences Polynucleotides and polypeptides ofthe present invention further include those having: (a) a generic sequence of at least two homologous polynucleotides or polypeptides, respectively, ofthe present invention; and (b) a consensus sequence of at least three homologous polynucleotides or polypeptides, respectively, ofthe present invention. The generic sequence ofthe present invention comprises each species of polypeptide or polynucleotide embraced by the generic polypeptide or polynucleotide - sequence, respectively. The individual species encompassed by a polynucleotide having an amino acid or nucleic acid consensus sequence can be used to generate antibodies or produce nucleic acid probes or primers to screen for homologs in other species, genera, families, orders, classes, phyla, or kingdoms. For example, a polynucleotide having a consensus sequence from a gene family of Zea mays can be used to generate antibody or nucleic acid probes or primers to other Grαmineαe species such as wheat, rice, or sorghum. Alternatively, a polynucleotide having a consensus sequence generated from orthologous genes can be used to identify or isolate orthologs of other taxa. Typically, a polynucleotide having a consensus sequence will be at least 9, 10, 15, 20, 25, 30, or 40 amino acids in length, or about at least 20, 30, 40, 50, 100, or 150 nucleotides in length. As those of skill in the art will recognize, a conservative amino acid substitution can be used to derive a consensus or generic amino acid sequence. Optionally, no more than 1 or 2 conservative amino acids are substituted for each 10 amino acid length of consensus sequence. Similar sequences used for generation of a consensus or generic sequence include any number and combination of allelic variants ofthe same gene, including orthologous or paralogous sequences as provided herein. Optionally, similar sequences used in generating a consensus or generic sequence are identified using the BLAST algorithm's smallest sum probability (P(N)). Various suppliers of sequence- analysis software are listed in Current Protocols in Molecular Biology, (F.M. Ausubel et al, eds., Current Protocols, Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (Supplement 30)). A polynucleotide sequence is considered similar to a reference sequence if the smallest sum probability in a comparison ofthe test nucleic acid to the reference nucleic acid is less then about OJ, preferably less than about 0.01, or 0.001, and more preferably less than about 0.0001, or 0.00001. Similar polynucleotides can be aligned and a consensus or generic sequence generated using multiple sequence alignment software available from a number of commercial suppliers such as the Genetics Computer Group's (Madison, WI) PILEUP software, Vector NTI's (North Bethesda, MD) ALIGNX, or Genecode's (Ann Arbor, MI) SEQUENCER. Conveniently, default parameters of such software can be used to generate consensus or generic sequences. Methods for Identifying KCP-like Proteins Methods are presented for identifying KCP-like proteins. Such methods entail, generally, searching a protein database with a pattern, selecting among the protein sequences identified or retrieved and, optionally, further characterizing the selected protein or proteins as KCP-like using other sequence analysis methods, or using biological assays such as have been described previously herein. As used herein, "searching" refers to comparing an amino acid sequence pattern with a database of amino acid sequences. Such searches may be performed with a variety of well-known techniques, such as those presented in Example 7 ofthe Experimental section. For example, searching may be performed utilizing PHI- BLAST or PHI-PSI-BLAST under parameters comprising a default Expectation value (E) of 10, a gap opening cost with a default value of 11, and a gap extension cost with a default value of 1, or, additionally, with BLOSUM62 substitution matrix. "Pattern" refers to an amino acid consensus sequence pattern, as exemplified by SEQ ID NO:97 and SEQ ID NO:98. "Database" refers to a protein database such as would be well-known to one of ordinary skill, and includes a database of amino acid sequences obtained from protein sequencing as well as presumptive protein sequences obtained by in silico translation of nucleotide sequences. "Selecting," as used herein refers to choosing one or more ofthe proteins obtained in the search which contain the pattern of interest. As used herein, "further characterizing" refers to further analysis of a selected sequence, which the skilled artisan would know would include a variety of methods, including both computer methods to look for other sequence characteristics indicative of a KCP-like protein, or biological methods, such as assaying the protein corresponding to the identified sequence for KCP-like activity. Such assays have been described elsewhere herein. An exemplar of a method for identifying a KCP-like protein is a method for identifying KCP-like proteins, said method comprising: (a) searching at least one protein database with a pattern selected from the group consisting of: i) a pattern representing a compound having the formula (SEQ ID NO:97) C-X(2)-C-C-X(2)- [CS]-X(1,2)-C-V-P-[PSATK]-[GR]-X(2)-[GAQR], wherein: C is cysteine; X(2) is any two amino acids selected independently from one another; [CS] is one amino acid selected from the group consisting of cysteine and serine; X(l ,2) is X(l) or X(2) wherein X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; V is valine; P is proline; [PSATK] is one amino acid selected from the group consisting of proline, serine, alanine, threonine, and lysine; [GR] is one amino acid selected from the group consisting of glycine and arginine; and [GAQR] is one amino acid selected from the group consisting of glycine, alanine, glutamine and arginine; and ii) a pattern for a compound having the formula (SEQ ID NO:98) [CS]-[PSQAG]-X(0,2)-C-Y-X(4)-[TNSM]-X(5,8)-K, wherein [CS] is one amino acid selected from the group consisting of cysteine and serine; [PSQAG] is one amino acid selected from the group consisting of proline, serine, glutamine, alanine, and glycine; X(0,2) is X(0) or X(l) or X(2) wherein X(0) is no amino acid, X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; C is cysteine; Y is tyrosine; X(4) is any four amino acids selected independently from one another; [TNSM] is one amino acid selected from the group consisting of threonine, asparagine, serine, and methionine; X(5,8) is X(5) or X(6) or X(7) or X(8) wherein X(5) is any five amino acids selected independently from one another, X(6) is any six amino acids selected independently from one another, X(7) is any seven amino acids selected independently from one another, and X(8) is any eight amino acids selected independently from one another; and K is lysine; and (b) selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by at least one formula selected from said group. The invention also contemplates a computer device capable of implementing the aforementioned methods, and a system for implementing the methods. Specifically the invention contemplates a computer device comprising a processing portion capable of searching at least one protein database with a pattern, and a processing portion capable of selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by at least one formula selected from said group. Optionally, this computer device may also include a processing portion for further characterizing the selected protein. The skilled artisan would be familiar with the meaning ofthe terms "computer device" and processing portion" as used in the preceding description. As a specific example ofthe preceding discussion, the present invention is directed to a computer device capable of implementing a method for identifying KCP- like proteins, said computer device comprising: (a) a processing portion capable of searching at least one protein database with a pattern selected from the group consisting of: i) a pattern representing a compound having the formula (SEQ ID NO:97) C-X(2)-C-C-X(2)-[CS]-X(l,2)-C-V-P-[PSATK]-[GR]-X(2)-[GAQR], wherein: C is cysteine; X(2) is any two amino acids selected independently from one another; [CS] is one amino acid selected from the group consisting of cysteine and serine; X(l,2) is X(l) or X(2) wherein X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; V is valine; P is proline; [PSATK] is one amino acid selected from the group consisting of proline, serine, alanine, threonine, and lysine; [GR] is one amino acid selected from the group consisting of glycine and arginine; and [GAQR] is one amino acid selected from the group consisting of glycine, alanine, glutamine and arginine; and ii) a pattern for a compound having the formula (SEQ ID NO:98) [CS]-[PSQAG]-X(0,2)-C-Y-X(4)- [TNSM]-X(5,8)-K, wherein [CS] is one amino acid selected from the group consisting of cysteine and serine; [PSQAG] is one amino acid selected from the group consisting of proline, serine, glutamine, alanine, and glycine; X(0,2) is X(0) or X(l) or X(2) wherein X(0) is no amino acid, X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; C is cysteine; Y is tyrosine; X(4) is any four amino acids selected independently from one another; [TNSM] is one amino acid selected from the group consisting of threonine, asparagine, serine, and methionine; X(5,8) is X(5) or X(6) or X(7) or X(8) wherein X(5) is any five amino acids selected independently from one another, X(6) is any six amino acids selected independently from one another, X(7) is any seven amino acids selected independently from one another, and X(8) is any eight amino acids selected independently from one another; and K is lysine; and (b) a processing portion capable of selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by at least one formula selected from said group. The present invention is also directed to a system for implementing the preceding methods, said system comprising: a reference protein database; and a computer device in communication with the reference protein database and comprising a processing portion capable of searching at least one protein database with a pattern, and a processing portion capable of selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by at least one formula selected from said group. Optionally, the computer device in this system may also include a processing portion for further characterizing the selected protein. The skilled artisan would be familiar with the meaning ofthe term "reference protein database," examples of which are presented elsewhere herein. An example of such a system is one for implementing a method for identifying KCP-like proteins, said system comprising: a reference protein database; and a computer device in communication with the reference protein database and comprising: (a) a processing portion capable of searching at least one protein database with a pattern selected from the group consisting of: i) a pattern representing a compound having the formula (SEQ ID NO:97) C-X(2)-C-C-X(2)-[CS]-X(1,2)-C-V-P-[PSATK]-[GR]-X(2)- [GAQR], wherein: C is cysteine; X(2) is any two amino acids selected independently from one another; [CS] is one amino acid selected from the group consisting of cysteine and serine; X(l,2) is X(l) or X(2) wherein X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; V is valine; P is proline; [PSATK] is one amino acid selected from the group consisting of proline, serine, alanine, threonine, and lysine; [GR] is one amino acid selected from the group consisting of glycine and arginine; and [GAQR] is one amino acid selected from the group consisting of glycine, alanine, glutamine and arginine; and ii) a pattern for a compound having the formula (SEQ ID NO:98) [CS]-[PSQAG]-X(0,2)-C-Y-X(4)- [TNSM]-X(5,8)-K, wherein [CS] is one amino acid selected from the group consisting of cysteine and serine; [PSQAG] is one amino acid selected from the group consisting of proline, serine, glutamine, alanine, and glycine; X(0,2) is X(0) or X(l) or X(2) wherein X(0) is no amino acid, X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; C is cysteine; Y is tyrosine; X(4) is any four amino acids selected independently from one another; [TNSM] is one amino acid selected from the group consisting of threonine, asparagine, serine, and methionine; X(5,8) is X(5) or X(6) or X(7) or X(8) wherein X(5) is any five amino acids selected independently from one another, X(6) is any six ' amino acids selected independently from one another, X(7) is any seven amino acids selected independently from one another, and X(8) is any eight amino acids selected independently from one another; and K is lysine; and (b) a processing portion capable of selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by at least one formula selected from said group. Further, the present invention is directed to a method for identifying a member of a family of polypeptides, said method comprising: (a) aligning a reference dataset consisting of preselected members of said family; (b) determining a consensus sequence pattern that identifies all said preselected members; (c) searching at least one protein database with said consensus sequence pattern; (d) selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by said pattern; and (e) identifying the selected protein as a member of said family. Other methods contemplated by the present invention include a computer device capable of implementing a method for identifying a member of a family of polypeptides, said computer device comprising: (a) a processing portion capable of aligning a reference dataset consisting of preselected members of said family; (b) a processing portion capable of determining a consensus sequence pattern that identifies all said preselected members; (c) a processing portion capable of searching at least one protein database with said consensus sequence pattern; (d) a processing portion capable of selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by said pattern; and (e) a processing portion capable of identifying the selected protein as a member of said family. Another contemplated method ofthe present invention is directed to a system for implementing a method for identifying a member of a family of polypeptides, said system comprising: a reference dataset; and a computer device in communcation with the reference dataset and comprising: (a) a processing portion capable of aligning said reference dataset consisting of preselected members of said family; (b) a processing portion capable of determining a consensus sequence pattern that identifies all said preselected members; (c) a processing portion capable of searching at least one protein database with said consensus sequence pattern; (d) a processing portion capable of selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by said pattern; and (e) a processing portion capable of identifying the selected protein as a member of said family. Although the present invention has been described in some detail by way of illustration and example for puφoses of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope ofthe appended claims. * The following examples are offered by way of illustration and not by way of limitation. EXPERIMENTAL Example 1 : Transformation and Regeneration of Transgenic Plants Immature maize embryos from greenhouse donor plants are bombarded with a plasmid containing a KCP-like nucleotide sequence operably linked to a ubiquitin promoter and the selectable marker gene PAT (Wohlleben et al. (1988) Gene 70:25- 37), which confers resistance to the herbicide Bialaphos. Alternatively, the selectable marker gene is provided on a separate plasmid. Transformation is performed as follows. Media recipes follow below. Preparation of Target Tissue The ears are husked and surface sterilized in 30%> Clorox bleach plus 0.5% Micro detergent for 20 minutes and rinsed two times with sterile water. The immature embryos are excised and placed embryo axis side down (scutellum side up), 25 embryos per plate, on 560Y medium for 4 hours and then aligned within the 2.5- cm target zone in preparation for bombardment. Preparation of DNA A plasmid vector comprising the KCP-like gene operably linked to an ubiquitin promoter is made. This plasmid DNA plus plasmid DNA containing a PAT selectable marker is precipitated onto 1.1 μm (average diameter) tungsten pellets using a CaCl precipitation procedure as follows: 100 μl prepared tungsten particles in water 10 μl (1 μg) DNA in Tris EDTA buffer (1 μg total DNA) 100 μl 2.5 M CaCl 2 10 μl 0J M spermidine Each reagent is added sequentially to the tungsten particle suspension while vortexing is maintained on the multitube vortexer. The final mixture is sonicated briefly and allowed to incubate under constant vortexing for 10 minutes. After the precipitation period, the tubes are centrifuged briefly, liquid is removed, and the pellet is washed with 500 ml 100%) ethanol and centrifuged for 30 seconds. Again the liquid is removed, and 105 μl 100% ethanol is added to the final tungsten particle pellet. For particle gun bombardment, the tungsten/DNA particles are briefly sonicated and 10 μl spotted onto the center of each macrocarrier and allowed to dry about 2 minutes before bombardment. Particle Gun Treatment The sample plates are bombarded at level #4 in particle gun #HE34-1 or #HE34-2. All samples receive a single shot at 650 psi, with a total often aliquots taken from each tube of prepared particles/DNA. Subsequent Treatment Following bombardment, the embryos are kept on 560Y medium for 2 days, then transferred to 560R selection medium containing 3 mg/liter Bialaphos and subcultured every 2 weeks. After approximately 10 weeks of selection, selection- resistant callus clones are transferred to 288J medium to initiate plant regeneration. Following somatic embryo maturation (2-4 weeks), well-developed somatic embryos are transferred to medium for germination and transferred to the lighted culture room. Approximately 7-10 days later, developing plantlets are transferred to 272V hormone- free medium in tubes for 7-10 days until plantlets are well established. Plants are then transferred to inserts in flats (equivalent to 2.5" pot) containing potting soil and grown for 1 week in a growth chamber, subsequently grown an additional 1-2 weeks in the greenhouse, then transferred to classic 600 pots (1.6 gallon) and grown to maturity. Plants are monitored and scored for expression of KCP-like protein. Assays to monitor expression of KCP-like sequences include, for example, Northern and Western analysis and phenotypic assays including enhanced disease resistance. Bombardment and Culture Media Bombardment medium (560 Y) comprises 4.0 g/1 N6 basal salts (SIGMA C- 1416), 1.0 ml/1 Eriksson's Vitamin Mix (1000X SIGMA-1511), 0.5 mg/1 thiamine HC1, 120.0 g/1 sucrose, 1.0 mg/12,4-D, and 2.88 g/1 L-proline (brought to volume with D-I H 0 following adjustment to pH 5.8 with KOH); 2.0 g/1 Gelrite (added after bringing to volume with D-I H 2 0); and 8.5 mg/1 silver nitrate (added after sterilizing the medium and cooling to room temperature). Selection medium (560R) comprises 4.0 g/1 N6 basal salts (SIGMA C-1416), 1.0 ml/1 Eriksson's Vitamin Mix (1000X SIGMA-1511), 0.5 mg/1 thiamine HC1, 30.0 g/1 sucrose, and 2.0 mg/12,4-D (brought to volume with D-I H 2 0 following adjustment to pH 5.8 with KOH); 3.0 g/1 Gelrite (added after bringing to volume with D-I H 2 0); and 0.85 mg/1 silver nitrate and 3.0 mg/1 bialaphos(both added after sterilizing the medium and cooling to room temperature). Plant regeneration medium (288J) comprises 4.3 g/1 MS salts (GIBCO 11117- 074), 5.0 ml/1 MS vitamins stock solution (0.100 g nicotinic acid, 0.02 g/1 thiamine HCL, 0.10 g/1 pyridoxine HCL, and 0.40 g/1 glycine brought to volume with polished D-I H 2 0) (Murashige and Skoog (1962) Physiol Plant. 75:473), 100 mg/1 myo- inositol, 0.5 mg/1 zeatin, 60 g/1 sucrose, and 1.0 ml/1 of 0.1 mM abscisic acid (brought to volume with polished D-I H 2 0 after adjusting to pH 5.6); 3.0 g/1 Gelrite (added after bringing to volume with D-I H 2 0); and 1.0 mg/1 indoleacetic acid and 3.0 mg/1 bialaphos (added after sterilizing the medium and cooling to 60°C). Hormone-free medium (272V) comprises 4.3 g/1 MS salts (GIBCO l l l l 7-074), 5.0 ml/1 MS vitamins stock solution (0.100 g/1 nicotinic acid, 0.02 g/1 thiamine HCL, 0.10 g/1 pyridoxine HCL, and 0.40 g/1 glycine brought to volume with polished D-I H 2 0), 0.1 g/1 myo-inositol, and 40.0 g/1 sucrose (brought to volume with polished D-I H 2 0 after adjusting pH to 5.6); and 6 g/1 bacto-agar (added after bringing to volume with polished D-I H 2 0), sterilized and cooled to 60° C. Example 2: Soybean Embryo Transformation Soybean embryos are bombarded with a plasmid containing a KCP-like nucleic acid operably linked to an ubiquitin promoter as follows. To induce somatic embryos, cotyledons 3 - 5 mm in length are dissected from surface-sterilized, immature seeds of the soybean cultivar A2872 and cultured in the light or dark at 26°C on an appropriate agar medium for six to ten weeks. Somatic embryos producing secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos that multiplied as early, globular-staged embryos, the suspensions are maintained as described below. Soybean embryogenic suspension cultures can be maintained in 35 ml of liquid media on a rotary shaker at 150 φm and 26°C with fiorescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 ml of liquid medium. Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) Nature 327:70-73); U.S. Patent No. 4,945,050). A DuPont Biolistic PDS1000/HE instrument (helium retrofit) can be used for these transformations. A selectable marker gene that can be used to facilitate soybean transformation is a transgene composed ofthe 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) Nature 373:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from E. coli; Gritz et al. (1983) Gene 25:179-188), and the 3' region ofthe nopaline synthase gene from the T-DNA ofthe Agrobacterium tumefaciens Ti plasmid. The expression cassette comprising the KCP-like sequence operably linked to the promoter can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site ofthe vector carrying the marker gene. To 50 μl of a 60 mg/ml 1 μm gold particle suspension is added (in order): 5 μl DNA (1 μg/μl), 20 μl spermidine (0.1 M), and 50 μl CaCl2 (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 μl 70% ethanol and resuspended in 40 μl of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five microliters ofthe DNA-coated gold particles are then loaded on each macrocarrier disk. Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm Petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally bombarded. Membrane rupture pressure is set at 1100 psi, and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above. Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post-bombardment with fresh media containing 50 mg/ml hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post-bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos. Example 3: Agrobacterium-mediated Transformation For_4grøbtfcter/«m-mediated transformation of maize with KCP-like genes or nucleotide sequences ofthe invention, preferably the method of Zhao is employed (U.S. Patent No. 5,981,840, and PCT patent publication WO98/32326; the contents of which are hereby incoφorated by reference). Briefly, immature embryos are isolated from maize and the embryos contacted with a suspension of Agrobacterium, where the bacteria are capable of transferring the KCP-like genes or nucleotide sequences of interest to at least one cell of at least one ofthe immature embryos (step 1 : the infection step). In this step the immature embryos are preferably immersed in an Agrobacterium suspension for the initiation of inoculation. The embryos are co- cultured for a time with the Agrobacterium (step 2: the co-cultivation step). Preferably the immature embryos are cultured on solid medium following the infection step. Following this co-cultivation period an optional "resting" step is contemplated. In this resting step, the embryos are incubated in the presence of at least one antibiotic known to inhibit the growth of Agrobacterium without the addition of a selective agent for plant transformants (step 3: resting step). Preferably the immature embryos are cultured on solid medium with antibiotic, but without a selecting agent, for elimination of Agrobacterium and for a resting phase for the infected cells. Next, inoculated embryos are cultured on medium containing a selective agent and growing transformed callus is recovered (step 4: the selection step). Preferably, the immature embryos are cultured on solid medium with a selective agent resulting in the selective growth of transformed cells. The callus is then regenerated into plants (step 5: the regeneration step), and preferably calli grown on selective medium are cultured on solid medium to regenerate the plants. Example 4: Construction ofthe cDNA Libraries. Total RNA was isolated from corn tissues with TRIzol Reagent (Life Technology Inc. Gaithersburg, MD) using a modification ofthe guanidine isothiocyanate/acid-phenol procedure described by Chomczynski and Sacchi (1987) Anal- Biochem. 162:156. In brief, plant tissue samples were pulverized in liquid nitrogen before the addition of the TRIzol Reagent, and then were further homogenized with a mortar and pestle. Addition of chloroform followed by centrifugation was conducted for separation of an aqueous phase and an organic phase. Total RNA was recovered by precipitation with isopropyl alcohol from the aqueous phase. The selection of poly(A)+ RNA from total RNA was performed using PolyATact system (Promega Coφoration, Madison WI). In brief, biotinylated oligo(dT) primers were used to hybridize to the 3' poly(A) tails on mRNA. The hybrids were captured using streptavidin coupled to paramagnetic particles and a magnetic separation stand. The mRNA was washed in highly stringent conditions and eluted with RNase-free deionized water. cDNA synthesis was performed and unidirectional cDNA libraries were constructed using the Superscript Plasmid System (Life Technology, Inc., Gaithersburg, MD). The first strand of cDNA was synthesized by priming an oligo(dT) primer containing a Not I site. The reaction was catalyzed by Superscript Reverse Transcriptase II at 45 °C. The second strand of cDNA was labeled with alpha- 32 P-dCTP and a portion ofthe reaction was analyzed by agarose gel electrophoresis to determine cDNA sizes. cDNA molecules smaller than 500 base pairs and unligated adaptors were removed by Sephacryl-S400 chromatography. The selected cDNA molecules were ligated into a pSPORTl vector between the Not/ and Sail sites. Example 5: cDΝA Sequencing and Library Subtraction. Individual colonies were picked and DΝA was prepared either by PCR with Ml 3 forward primers and Ml 3 reverse primers, or by plasmid isolation. All the cDΝA clones were sequenced using Ml 3 reverse primers. cDΝA libraries subjected to the subtraction procedure were plated out on 22 x 22 cm 2 agar plate at density of about 3,000 colonies per plate. The plates were incubated in a 37°C incubator for 12-24 hours. Colonies were picked into 384-well plates by a robot colony picker, Q-bot (GEΝETIX Limited). These plates were incubated overnight at 37°C. Once sufficient colonies were picked, they were pinned onto 22 x 22 cm 2 nylon membranes using Q-bot. Each membrane contained 9,216 colonies or 36,864 colonies. These membranes were placed onto agar plate with appropriate antibiotic. The plates were incubated at 37°C overnight. After colonies were recovered on the second day, these filters were placed on filter paper prewetted with denaturing solution for four minutes, then were incubated on top of a boiling water bath for additional four minutes. The filters were then placed on filter paper prewetted with neutralizing solution for four minutes. After excess solution was removed by placing the filters on dry filter papers for one minute, the colony side of each filter was placed into Proteinase K solution and incubated at 37°C for 40-50 minutes. The filters were placed on dry filter papers to dry overnight. DΝA was then cross-linked to the nylon membrane by UN light treatment. Colony hybridization was conducted as described by Sambrook, Fritsch, and Maniatis (in Molecular Cloning: A Laboratory Manual, 2 nd Edition). The following probes were used in colony hybridization: 1. First strand cDNA from the same tissue as that from which the library was made in order to identify and remove the most redundant clones. 2. 48-192 most redundant cDNA clones from the same library based on previous sequencing data. 5 3. 192 most redundant cDNA clones in the entire corn sequence database. 4. A Sal-A20 oligo nucleotide TCG ACC CAC GCG TCC GAA AAA AAA AAA AAA AAA AAA (set forth in SEQ ID NO:99), which can be used to identify and remove clones containing a poly A tail but no cDNA. 10 5. cDN A clones derived from rRNA. The image ofthe autoradiography was scanned into an analysis computer and the signal intensity and "cold colony" addresses of each colony was analyzed. Re- arraying of cold colonies from 384 well plates to 96 well plates was conducted using Q-bot. 15 Example 6: Identification ofthe Gene from a Computer Homology Search Gene identities can be determined by conducting BLAST searches (Basic Local Alignment Search Tool; Altschul etal. (1993) J. Mol Biol. 275:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) under default parameters for similarity to 20 sequences contained in the BLAST "nr" database. The publicly-available NCBI nr database comprises all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release ofthe SWISS-PROT protein sequence database, and the EMBL and DDBJ databases. The . cDNA sequences are analyzed for similarity to all publicly available 25. DNA sequences contained in the "nr" database using the BLASTN algorithm. The DNA sequences ' are translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) Nature Genetics 3:266-272). In some cases, the sequencing data from two or more clones containing overlapping segments 30 of DNA are used to construct contiguous DNA sequences. Sequence alignments and percent identity calculations can be performed using the Megalign program ofthe LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment ofthe sequences can be performed using the CLUSTAL method of alignment (Higgins and Shaφ (1989) CABIOS 5:151-153) with default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the CLUSTAL method are KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. A search of publicly available databases revealed that a petunia sequence (Q43615) shares 54% identity and 63% similarity with the Zm-KCPl predicted peptide, and a cotton sequence (W15751) shares 44% identity and 52% similarity with the Zm-KCPl predicted peptide. Example 7: Computer-Implemented Methods, and Consensus Patterns (Regular Expressions) that Specifically Identify KCP Gene Family Members As set forth above, the invention encompasses the discovery and analysis of 36 crop plant genes in the KCP family, which are related to the potato antimicrobial peptide snakin. The invention additionally provides computer-implemented methods, and two amino acid consensus sequence patterns (regular expressions 1 and 2) that specifically identify KCP-like gene family members. Thus, these regular expressions are useful for identifying a subset of KCP related proteins that are within the family of the KCP-like proteins of the invention. Regular expression 1 has the amino acid sequence consensus pattern: C-x(2)-C-C-x(2)-[CS]-x(l,2)-C-V-P-[PSATK]-[GR]-x(2)-[GAQR] (SEQ ID NO:97). The notation of this expression follows a standard protocol (Bairoch (1991) Nucleic Acids Research. 19:22 1-2245) and designates the following sequence pattern: cysteine— two amino acids of any type—cysteine— cysteine— two amino acids of any type-cysteine or serine— one or two amino acids of any type— cysteine— valine— proline—pfόline or serine or alanine or threonine or lysine— glycine or arginine— two amino acids of any type—glycine or alanine or glutamine or arginine. Regular expression 2 has the amino acid sequence consensus pattern: [CS]-[PSQAG]-x(0,2)-C-Y-x(4)-[TNSM]-x(5,8)-K (SEQ ID NO:98). This notation of this expression also follows the protocol referred to above, and designates the following sequence pattern: cysteine or serine— proline or serine or glutamine or alanine or glycine— zero or one or two amino acids of any type— cysteine—tyrosine— four amino acids of any type— threonine or asparagine or serine or methionine— five or six or seven or eight amino acids of any type— lysine. KCP-like reference dataset: A reference dataset of KCP-like polypeptide sequences was constructed to test the effectiveness of various candidate regular expressions in identifying KCP-like proteins. This reference dataset consisted ofthe KCP-like polypeptides ofthe invention set forth in SEQ ID NO:37-72, a KCP polypeptide set forth in SEQ ID NO: 73 a novel KCP-like polypeptide (sequence not shown), as well as a set of KCP- like polypeptides identified from public databases by a combination of BLAST and PSI-BLAST. The set of KCP-like polypeptides identified from public databases correspond to those identified in TABLE 1 and set forth in SEQ ID NOS:74-96 respectively. TABLE 1 -AF014396, Potato snakin-1. -gi_5102600 _emb_CAB45241J_ (AJ005206) GEG protein [Gerbera hybrida]. -gi_6539267 _gb_AAF15937.1_AC011765_33 (AC011765) GASTl-hke protein [Arabidopsis thaliana]. -gi_405585 gb_AAA20129.1_ RSI-l protein [Solanum lycopersicum]gi_405587_gb_AAA20130.1_ RSI-l protein [Solanum lycopersicum]pir_S43910_S43910 gibberellm-regulated protein RSI-1 precursor - tomatosp_P47926_RSIl_LYCES RSI-1 PROTEIN PRECURSOR (TR132). -gi_2764941 emb_C AA66909.1_ transcriptionally stimulated by gibberellins expressed in meristematic region, and style [Arabidopsis thaliana]sp_O49593_O49593 GASA4 GENE. -gi_950099 gb_AAA74480.1_ gibberellin-regulated [Arabidopsis thaliana]sp_P46690_GAS4_ARATH GIBBERELLIN-REGULATED PROTEIN 4 PRECURSOR. -gi_1289320 gb_AAA98520.1_ GASA5 [Arabidopsis thaliana]pir_S71371_S71371 gibberellin-regulated protein GASA5 precursor - Arabidopsis thalianasp_Q38939_Q38939 GASA5. -gi_l 9247 emb_CAA44807.1_ gastl [Lycopersicon esculentum]pir_S22151_S22151 gibberellin-regulated protein GASTl - tomatosp_P27057_GSTl_LYCES GASTl PROTEIN PRECURSOR. -gi_887935 gb_AAB 06308 J_ GASTl protein homolog [Arabidopsis thaliana]pir_S60231_S60231 gibberellin-regulated protein GASA3 precursor - Arabidopsis thalianasp_P46687_GAS3_ARATH GIBBERELLIN-REGULATED PROTEIN 3 PRECURSOR. -gi_887937 gb_AAB06309.1_ GASTl protein homolog [Arabidopsis thaliana]pir_S60230_S60230 gibberellin-regulated protein GASA2 precursor - Arabidopsis thalianasp_P46688_GAS2_ARATH GIBBERELLIN-REGULATED PROTEIN 2 PRECURSOR. -gi_887939 gb_AAB06310J_ GASTl protein homolog [Arabidopsis thaliana]sp_P46689_GASl_ARATH GIBBERELLIN-REGULATED PROTEIN 1 PRECURSOR. -gi_825524 emb_CAA60677.1_ gipl [Petunia x hybrida]pir_S54832_S54832 gipl protein - garden petuniasp_Q43615_Q43615 GIP1 PROTEIN. -gi_2253442 gb_AAB62947.1_ (AF007784) LTCOR11 [Lavatera thuringiaca]sp_O24040_O24040 LTCOR11. -gi_2792297 gb_AAB97006.1_ (AF039183) GAST-like gene product [Fragaria x ananassa]sp_O49134_O49134 GAST-LIKE GENE PRODUCT. -gi_3094012 gb_AAC15460.1_ (AF060569) cold-regulated LTCOR12 [Lavatera thuringiaca]sp_O65313_O65313 COLD-REGULATED LTCOR12. -gi_3201610 gb_AAC20716J_ (AC004669) unknown protein [Arabidopsis thaliana]sp_O80848_O80848 F7F1.2 PROTEIN. -gi_3355483 gb_AAC27845.1_ (AC004218) gibberellin-regulated protein (GASA5)- like [Arabidopsis thaliana]pir_T00564_T00564 gibberellin-regulated protein (GASA5)-like protein - Arabidopsis thalianasp_O80641_O80641 GIBBERELLIN- REGULATED PROTEIN (GASA5)-LIKE. -gi_2982285 gb_AAC32128.1_ (AF051227) GAS A5-like protein [Picea mariana]sp_ O65066_O65066 GASA5-LIKE PROTEIN. -gi_3650032 gb_AAC61287.1_ (AC005396) gibberellin-regulated protein GAST1- like [Arabidopsis thaliana]sp_O82328_O82328 GIBBERELLIN-REGULATED PROTEIN GAST1-LIKE. -gi_4309725 gb_AAD 15495.1_ (AC006439) putative gibberellin-regulated protein [Arabidopsis thaliana]sp_AAD15495_AAD 15495 Putative gibberellin-regulated protein. -pir_S60229 S60229 gibberellin-regulated protein GASA1 precursor - Arabidopsis thaliana. -pir JEO 159 JEO 159 gibberellin-stimulated transcript 1 like protein - rice. -pir_S60232 S60232 gibberellin-regulated protein GASA4 precursor - Arabidopsis thaliana. Alignments and generation of regular expressions: All available KCP related predicted amino acid sequences were multiply aligned using AlignX (Vector NTI Suite 5.5, Informax Inc.) which is based on the GhisxalW algorithm (Thompson etal. (1994) Nucleic Acids Research 22: 4673-4680). The conserved amino acids revealed by the alignment describe regular expressions shared by the entire gene family. Twelve conserved cysteines which are prominent conserved features of KCP related proteins were included in many of these regular expressions that were designed and tested. Testing regular expressions for effectiveness using PHI-BLAST and PSI-BLAST: The method employed for identifying all the KCP sequences was either PHI- BLAST (Pattern Hit Initiated BLAST) or a combination of PHI-BLAST and PSI- BLAST (Position Specific Iteration Blast). See Zhang et al (1998) Nucleic Acids Research 26: 3986-3990. When both PHI-BLAST and PSI-BLAST were used in combination, the search was done in two rounds, with the first round using PHI- BLAST, and the second round using PSI-BLAST (PHI-PSI-BLAST). The BLOSUM62 substitution matrix was used, as was the default Expectation value (E) of 10. Cost for opening gaps was used with the default value of 11, and the cost to extend a gap was also used with the default value of 1. In order to run the PHI-BLAST, PSI-BLAST, or the PHI-PSI-BLAST tandem routine, a designated query sequence was required. The initial default query sequence used to test various candidate regular expressions was Zm-KCPl . For those regular expressions showing promise, the routine was repeated with at least three other query sequences, namely Os-KCP 1 , Ta-KCP 1 and Gm-KCP 1 , that represent breadth and diversity in the KCP-like protein family. Repeating the routine with the additional sequences indicated that the result for a regular expression was independent ofthe KCP-like query sequence used. For testing the effectiveness ofthe regular expressions, the reference dataset stated above was used. The goal was to find a regular expression that could identify all the sequences in this reference dataset, given the parameters of PHI-BLAST or the PHI-PSI-BLAST tandem routine defined above. In this manner, multiple regular expressions were designed and considered. Two regular expressions were found to identify all the sequences in the reference dataset using either PHI-BLAST or PHI-PSI-BLAST. These were regular "expressions 1 and 2 given elsewhere herein and set forth in SEQ ID NO:97 and SEQ ID NO:98, respectively. One embodiment of regular expression 1 corresponds to amino acid positions 77 to 93 of default query sequence Zm-KCPl (SEQ ID NO:37). One embodiment of regular expression 2 corresponds to amino acid positions 98 to 112 of default query sequence Zm-KCPl (SEQ ID NO:37). In order to test the consistancy ofthe KCP regular expressions 1 and 2 and identify all members ofthe KCP-like protein family in the reference dataset, three additional "query" sequences were used in addition to Zm-KCPl (SEQ ID NO:37); namely Gm-KCPl, accession NO. JE 0159, and Ta-KCPl (SEQ ID NOS:55, 95, and 46). Using each of these query sequences by the same methods stated above, regular expressions 1 and 2 were both able to identify all ofthe KCP-like proteins in the reference dataset. Subsequently, regular expressions 1 and 2 were tested against an open field dataset, namely the public NR (nonredundant) database. Using either PHI-BLAST or PHI-PSI-BLAST, regular expression 1 was able to identify 22 ofthe 23 ofthe above publicly known KCP-like sequences set forth in TABLE 1, when used with the four different query KCP-like sequences (SEQ ID NOS:37, 46, 55 and 95). It is noted that, when using PHI-BLAST, this regular expression did not identify non-KCP sequences; and identified only the 22 KCP sequences (See appendix I for the output). However, when PHI-PSI-BLAST was used, the entire 23/23 publicly known KCP-like sequences (TABLE 1) were identified. In this manner, tandem PHI-PSI-BLAST is more effective that PHI-BLAST alone for utilizing regular expression 1. Using tandem PHI-PSI-BLAST, additional sequences were also identified with E values below the threshold of 10. These other sequences included distintigrins, mucins, and metallothioproteinases, but not the hemolytic protein kistrin. It should be noted however that their E value scores were markedly less significant than any ofthe 23 core public KCP-like sequences of TABLE 1. The least significant E value score from the PSI-BLAST portion was le-17, and the most significant non-KCP E value score was 0.014 (see appendix II for output). This wide range in the output E value scores indicates that by using PHI-PSI-BLAST as described and in conjunction with regular expression 1, all or nearly all members ofthe KCP-like family can be identified to the exclusion of non-members of this family. For KCP regular expression 2, both PHI-BLAST and tandem PHI-PSI-BLAST identifies all 23 ofthe public KCP-like genes. Initially, a regular expression was designed which was identical to that set forth above, and in SEQ ID NO:98, for regular expression 2, with the exception that a -[TNS]- position was used in place of a -[TNSM]- position. This initial version of regular expression 2 identified all 23 ofthe public KCP-like genes in the reference dataset. For tandem PHI-PSI-BLAST, the gulf in E value scores between the output E value scores was also large. The least significant KCP E value score from the PSI-BLAST portion was le-18, and the most significant non-KCP E value score was 0.003. See appendices III and IV for outputs. However, Ta-KCP 1 sequence ofthe invention (SEQ ID NO:46) did not exactly match this initial KCP regular expression 2. This Ta-KCP 1 sequence had a methionine at the corresponding -[TNS]- position. Inclusion of methionine as an option at this position does allow for identification of Ta-KCP 1 by regular expression 2 set forth above, and in SEQ ID NO:98. Thus, both KCP regular expressions 1 and 2 employed with the methods described here are specific identifiers of members of the KCP gene family. Numerous other regular expressions; including those designed based on twelve conserved cysteines and those including terminal lysine, cysteine, and proline residues. These other regular expressions failed to identify all ofthe KCP-like sequences in the reference dataset. Therefore, it was concluded that KCP regular expressions 1 and 2 are useful for identifying KCP-like protein family members using tandem PHI-PSI-BLAST. These regular expressions can be used alone or in combination to effect a complete or near complete identification of members of KCP-like family of proteins. The methods ofthe present invention could be used to identify members of any family of proteins. That is, the methods ofthe invention can be used to align a reference dataset consisting of known or preselected members of a family, determining a consensus sequence pattern that identifies all ofthe known or preselected members, searching at least one protein database with this consensus sequence pattern, selecting among the retrieved proteins at least one protein comprising at least one amino acid sequence represented by the pattern; and identifying the selected protein as a member of this family. Furthermore, in this manner, the methods ofthe present invention can be used to identify one or more subsets of a known family, wherein the subset consists of members the family that are identified by a consensus sequence that identifies all members ofthe subset and excludes other members ofthe family. Appendix I. Output of PHI-BLAST search versus NR database using KCP Regular Expression 1. BLASTP 2 . 0. 9 Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997) , "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402. Query= Zm-KCPl, p0118.chsbd73r, FL, Zea mays, proofed (114 letters) Database: nr 485,275 sequences; 152,116,570 total letters Searching 1 occurrence (s) of pattern in query Pattern for KCP identification pattern C-x (2) -C-C-x (2) - [CS] -x (1, 2) -C-V-P- [PSATK] - [GR] -x (2) - [GAQR] at position 77 of query sequence effective database length=l.4e+08 pattern probability=3.8e-13 lengthXprobability=5.5e-05 Number of occurrences of pattern in the database is 22 done Score E (bits) Value Significant matches for pattern occurrence 1 at position 77 pir| IS54832 gipl protein - garden petunia >gi I 825524 | emb | CAA606.. 4e-24 sp | P27057 | GST1_LYCES GASTl PROTEIN PRECURSOR >gi | 100217 | pir | | S2 . . 3e-23 pir||S71371 gibberellin-regulated protein GASA5 - Arabidopsis t.. 6e-22 emb I CAA66909.il (X98255) transcriptionally stimulated by gibber.. 2e-21 pir||S60232 GASTl protein homolog (clone GASA4) - Arabidopsis t.. 2e-21 sp|P46690|GAS4_ARATH GIBBERELLIN-REGULATED PROTEIN 4 PRECURSOR .. 2e-21 gb I AAC32128. i l (AF051227 ) GASA5-like protein [Picea mariana] 5e-21 gb|AAF15937.1|AC011765_33 (AC011765) GASTl-like protein [Arabid.. le-20 gb |AAC20716.1 | (AC004669) putative gibberellin-regulated protei . . 2e-20 sp|P47926|RSIl_LYCES RSI-1 PROTEIN PRECURSOR (TR132) >gi|107659.. 4e-20 gb I AAC32170. i l (AF051753) GASA5-like protein [Picea mariana] >g. . 3e-19 gb |AAC61287.1 I (AC005396) similar to gibberellin-regulated prot. . 2e-13 gb I AC27845.il (AC004218) similar to gibberellin-regulated prot.. le-12 sp|P46688 |GAS2_ARATH GIBBERELLIN-REGULATED PROTEIN 2 PRECURSOR .. 9e-ll sp|P46687 |GAS3_ARATH GIBBERELLIN-REGULATED PROTEIN 3 PRECURSOR .. 2e-10 emb I CAB45241. i l (AJ005206) GEG protein [Gerbera ybrida] 8e-09 gb | AAB62947. 1 | (AF007784 ) LTCOR11 [Lavatera thuringiaca] 2e-08 gb|AAC15460.1| (AF060569) cold-regulated LTCOR12 [Lavatera thur... 30 2e-08 gb|AAB97006.1| (AF039183) GAST-like gene product [Fragaria x an... 28 6e-08 gb|AAD01518.1| (AF014396) Snakin-1 [Solanum tuberosum] 28 6e-08 pir||S60229 GASTl protein homolog (clone GASA1) - Arabidopsis t... 27 2e-07 sp|P46689|GASl_ARATH GIBBERELLIN-REGULATED PROTEIN 1 PRECURSOR ... 27 2e-07 Significant alignments for pattern occurrence 1 at position 77 Appendix II. Output of tandem PHI-PSI-BLAST search versus NR database. PHI-Blast Round Output BLASTP 2.0.9 Reference: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402. Query= Zm-KCPl, p0118.chsbd73r, FL, Zea mays, proofed (114 letters) Database: nr 485,275 sequences; 152,116,570 total letters Searching 1 occurrence (s) of pattern in query Pattern for KCP identification pattern C-x (2) -C-C-x (2) - [CS] -x (1, 2) -C-V-P- [PSATK] - [GR] -x (2) - [GAQR] at position 77 of query sequence effective database length=l.4e+08 pattern probability=3.8e-13 lengthXprobability=5.5e-05 Number of occurrences of pattern in the database is 22 Done Results from round 1 Score E (bits) Value Significant matches for pattern occurrence 1 at position 77 pir||S54832 gipl protein - garden petunia >gi | 82552 | emb|CAA606... 82 4e-24 sp|P27057|GSTl_LYCES GASTl PROTEIN PRECURSOR >gi 1100217 |pir | | S2... 79 3e-23 pir| IS71371 gibberellin-regulated protein GASA5 - Arabidopsis t... 75 6e-22 emb I CAA66909.il (X98255) transcriptionally stimulated by gibber... 74 2e-21 pir||S60232 GASTl protein homolog (clone GASA4) - Arabidopsis t... 74 2e-21 sp|P46690|GAS4_ARATH GIBBERELLIN-REGULATED PROTEIN 4 PRECURSOR ... 74 2e-21 gb|AAC32128.1| (AF051227) GASA5-like protein [Picea mariana] 72 5e-21 gb|AAF15937.1|AC011765_33 (AC011765) GASTl-like protein [Arabid... 70 le-20 gbl AAC20716.il (AC004669) putative gibberellin-regulated protei... 70 2e-20 sp | P47926 | RSIl_LYCES RSI-1 PROTEIN PRECURSOR (TR132 ) >gi 1 107659. . . 69 4e-20 gb|AAC32170.1| (AF051753) GASA5-like protein [Picea mariana] >g... 66 3e-19 gb IAAC61287.il (AC005396) similar to gibberellin-regulated prot... 46 2e-13 gb|AAC27845.1| (AC004218) similar to gibberellin-regulated prot... 44 le-12 sp|P46688|GAS2_ARATH GIBBERELLIN-REGULATED PROTEIN 2 PRECURSOR ... 38 9e-ll sp|P46687|GAS3_ARATH GIBBERELLIN-REGULATED PROTEIN 3 PRECURSOR ... 37 2e-10 emb I CAB45241.il (AJ005206) GEG protein [Gerbera hybrida] 31 8e-09 gb IAAB62947.il (AF007784) LTCOR11 [Lavatera thuringiaca] 30 2e-08 gb IAAC15460.il (AF060569) cold-regulated LTCOR12 [Lavatera thur... 30 2e-08 gb IAAB97006.il (AF039183) GAST-like gene product [Fragaria x an... 28 6e-08 gb I AAD01518.il (AF014396) Snakin-1 [Solanum tuberosum] 28 6e-08 pir||S60229 GASTl protein homolog (clone GASA1) - Arabidopsis t... 27 2e-07 sp|P46689|GASl_ARATH GIBBERELLIN-REGULATED PROTEIN 1 PRECURSOR ... 27 2e-07 Significant alignments for pattern occurrence 1 at position 77 PSI-Blast Round Output Searching done Results from round 2 - Using PSI-BLAST based on the PHI-Blast output Score E Sequences producing significant alignments: (bits; Value Sequences used in model and found again: pir||S54832 gipl protein - garden petunia >gi I 825524 I emb I CAA606... 156 5e-38 gb I AAC61287.il (AC005396) similar to gibberellin-regulated prot... 145 le-34 sp|P27057|GSTl_LYCES GASTl PROTEIN PRECURSOR >gi 1100217 |pir| | S2... 139 le-32 gb IAAC32128.il (AF051227) GASA5-like protein [Picea mariana] 132 le-30 gb|AAF15937.1|AC011765_33 (AC011765) GASTl-like protein [Arabid... 131 3e-30 gb|AAC20716.1| (AC004669) putative gibberellin-regulated protei... 130 5e-30 pir||S71371 gibberellin-regulated protein GASA5 - Arabidopsis t... 130 7e-30 gb I AAC32170.il (AF051753) GASA5-like protein [Picea mariana] >g... 126 7e-29 sp|P47926|RSIl_LYCES RSI-1 PROTEIN PRECURSOR (TR132) >gi 1107659... 124 3e-28 pir||S60232 GASTl protein homolog (clone GASA4) - Arabidopsis t... 121 3e-27 sp|P46690|GAS4_ARATH GIBBERELLIN-REGULATED PROTEIN 4 PRECURSOR ... 12-0 4e-27 emb I CAA66909.il (X98255) transcriptionally stimulated by gibber... 120 4e-27 gb |AAB62947.11 (AF007784 ) LTCOR11 [Lavatera thuringiaca] 115 2e-25 gb|AAB97006.1| (AF039183) GAST-like gene product [Fragaria x an: 114 4e-25 sp|P 6687|GAS3_ARATH GIBBERELLIN-REGULATED PROTEIN 3 PRECURSOR . 113 7e-25 gb I AC15460.il (AF060569) cold-regulated LTCOR12 [Lavatera thur. 112 9e-25 sp|P46688|GAS2_ARATH GIBBERELLIN-REGULATED PROTEIN 2 PRECURSOR . 112 9e-25 sp|P46689|GASl_ARATH GIBBERELLIN-REGULATED PROTEIN 1 PRECURSOR . 112 le-24 pir||S60229 GASTl protein homolog (clone GASA1) - Arabidopsis t. 112 le-24 emb I CAB45241.il (AJ005206) GEG protein [Gerbera hybrida] 110 6e-24 gb|AAC27845.1| (AC004218) similar to gibberellin-regulated prot.. 109 le-23 gb I AD01518.il (AF014396) Snakin-1 [Solanum tuberosum] 90 le-17 Sequences not found previously or not previously below threshold: gb|AAD15495.1| (AC006439) similar to gibberellin-regulated prot.. 89 le-17 gb IAAC67545.il (AF086604) mucin [Homo sapiens] 39 0.014 emb I CAA06167.il (AJ004862) mucin [Homo sapiens] 37 0.090 gb IAAB93766.il (U66246) von Willebrand factor [Canis familiaris] 36 0.15 sp|Q28295|VWF_CANFA VON WILLEBRAND FACTOR PRECURSOR >gi | 1478046.. 36 0.15 gb IAAD04919.il (AF099154) von Willebrand factor [Canis familiaris 36 0.15 emb|CAA70525.1| (Y09353) von Willebrand factor [Bos taurus] 35 0.20 gb|AAC06229.1| (AF052036) von Willebrand factor precursor [Sus .. 35 0.20 gb|AAD39266.1|AC007842_l (AC007842) Human Fc gamma BP [AA 1-284.. 35 0.27 ref |NP_003881.1| I IgG Fc binding protein >gi | 1944352 |dbj IBAA195.. 35 0.27 ref | NP_031426.1 1 I a disintegrin and metalloproteinase domain 12. . 35 0.27 gb IAAB71835. i l (AF008583 ) metallothionein [Ambystoma mexicanum] 35 0.27 pir | | S38539 gene MDC protein - human >gi | 455835 | gb |AAB29191.1 | 35 0.35 ref |NP_002381.2 1 I metalloproteinase-like, disintegrin-like, cys 35 0.35 pir | | I52965 disintegrin-like metalloproteinase (EC 3. 4.24. -) - 35 0.35 dbj I BAA06670. i l (D31872 ) metalloprotease/disintegrin-like prote 35 0.35 ref | NP_033743. 1 1 | a disintegrin and metalloprotease domain (ADA 35 0.35 prf I I1101271B metallothionein MT Ipg [Homo sapiens] 34 0.46 pir||S60258 meltrin beta - mouse (fragment) >gi | 1584289 Iprf | | 21.. 34 0.46 ref | NP_002441.1 | I metallothionein 1L >gi I 462637 I sp I P80297 |MT1L_. . 34 0.46 ref |NP_033746.11 I a disintegrin and metalloproteinase domain 19.. 34 0.46 sp|P17816|GRP_H0RVU GLYCINE-RICH CELL WALL STRUCTURAL PROTEIN P... 34 0.46 emb|CAA07188.1| (AJ006692) ultra high sulfer keratin [Homo sapi... 34 0.46 dbj IBAA18923.il (D50410) meltrin beta [Mus musculus] 34 0.46 emb I CAA09979.il (AJ012287) alpha tectorin [Gallus gallus] 34 0.60 emb I CAB04626.il (Z81573) M02G9.3 [Caenorhabditis elegans] 34 0.60 ref |NP_003465.1| I Meltrin-alpha, mouse, homolog of >gi | 2677839 | ... 34 0.60 pir||S43534 integrin beta3 - chicken >gi | 474039 | emb | CAA51069.11... 34 0. 60 Note: There were additional hits of even less significance not shown here. Appendix III. Output of PHI-BLAST search versus NR database using KCP Regular Expression 2. BLASTP 2.0.9 Reference: Altschul, Stephen F. , Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402. Query= Zm-KCPl, p0118.chsbd73r, FL, Zea mays, proofed (114 letters) Database: nr 485,275 sequences; 152,116,570 total letters Searching 1 occurrence (s) of pattern in query Pattern for KCP identification pattern [CS] - [PSQAG] -x (0, 2) -C-Y-x (4) - [TNS] -x (5, 8) -K at position 98 of query sequence effective database length=l .4e+08 pattern probability=l.0e-061engthXprobability=l .5e+02 Number of occurrences of pattern in the database is 291 done Score E (bits) Value Significant matches for pattern occurrence 1 at position 98 em I CAA66909.il (X98255) transcriptionally stimulated by gibber... 80 2e-22 pir||S60232 GASTl protein homolog (clone GASA4) - Arabidopsis t... 80 2e-22 sp|P46690|GAS4_ARATH GIBBERELLIN-REGULATED PROTEIN 4 PRECURSOR ... 80 2e-22 pir||S54832 gipl protein - garden petunia >gi | 825524 | emb ICAA606... 79 5e-22 sp|P27057|GSTl_LYCES GASTl PROTEIN PRECURSOR >gi 1100217 |pir | | S2... 78 le-21 pir||S71371 gibberellin-regulated protein GASA5 - Arabidopsis t... 73 3e-20 gb|AAC32128.1| (AF051227) GASA5-like protein [Picea mariana] 73 4e-20 gb|AAF15937.1|AC011765_33 (AC011765) GASTl-like protein [Arabid... 73 4e-20 gb|AAC32170.1| (AF051753) GASA5-like protein [Picea mariana] >g... 69 7e-19 gb|AAC20716.1| (AC004669) putative gibberellin-regulated protei... 69 7e-19 sp|P47926|RSIl_LYCES RSI-1 PROTEIN PRECURSOR (TR132) >gi 1107659.. - 68 9e-19 gb IAAC61287.il (AC005396) similar to gibberellin-regulated prot... 57 2e-15 sp|P46688|GAS2_ARATH GIBBERELLIN-REGULATED PROTEIN 2 PRECURSOR ... 54 2e-14 gb I AC27845.il (AC004218) similar to gibberellin-regulated prot... 51 le-13 sp|P46687|GAS3_ARATH GIBBERELLIN-REGULATED PROTEIN 3 PRECURSOR ... 50 2e-13 gb|AAB62947.1| (AF007784) LTC0R11 [Lavatera thuringiaca] 49 5e-13 pir||S60229 GASTl protein homolog (clone GASA1) - Arabidopsis t... 44 le-11 sp|P46689|GASl_ARATH GIBBERELLIN-REGULATED PROTEIN 1 PRECURSOR ... 44 le-11 emb|CAB45241.1| (AJ005206) GEG protein [Gerbera hybrida] 43 3e-ll gb|AAB97006.1| (AF039183) GAST-like gene product [Fragaria x an... 41 2e-10 gb IAAC15460.il (AF060569) cold-regulated LTCOR12 [Lavatera thur ... 40 2e-10 gb|AAD01518.1 I (AF014396) Snakin-1 [Solanum tuberosum] 37 2e-09 gb|AAD15495.1| (AC006439) similar to gibberellin-regulated prot... 29 6e-07 ref|NP 037530.11 | zinc finger protein 224 >gi | 6715532 | gb IAAF041... 6 ~ 3.3 emb|CAA84663.1| (Z35600) cDNA EST yk222a6.3 comes from this gen... 6 4.2 gb|AAC97073.1| (AF042838) MEK kinase 1 [Homo sapiens] 5 6.6 gb|AAF53381.1| (AE003643) CG15288 gene product [Drosophila mela... 5 8.3 gb|AAD31714.1|AF135118_l (AF135118) laminin alphal, 2 [Drosophil... 5 8.3 Significant alignments for pattern occurrence 1 at position 98 Appendix IV. Output of PHI-PSI-BLAST search versus NR database using KCP Regular Expression 2. First PHI-BLAST Round Output BLASTP 2.0.9 Reference: Altschul, Stephen F. , Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402. Query= Zm-KCPl, p0118.chsbd73r,FL, Zea mays, proofed (114 letters) Database: nr 485,275 sequences; 152,116,570 total letters Searching 1 occurrence (s) of pattern in query Pattern for KCP identification pattern [CS] - [PSQAG] -x(0, 2) -C-Y-x (4) - [TNS] -x (5, 8) -K at position 98 of query sequence effective database length=l. e+08 pattern probability=l .0e-061engthXprobability=l .5e+02 Number of occurrences of pattern in the database is 291doneResults from round 1 Score (bits) Value Significant matches for pattern occurrence 1 at position 98 emb|CAA66909.1| (X98255) transcriptionally stimulated by gibber. 80 2e-22 pir||S60232 GASTl protein homolog (clone GASA4) - Arabidopsis t. 80 2e-22 sp|P46690|GAS4_ARATH GIBBERELLIN-REGULATED PROTEIN 4 PRECURSOR . 80 2e-22 pir||S54832 gipl protein - garden petunia >gi | 825524 | emb | CAA606. 79 5e-22 sp|P27057|GSTl_LYCES GASTl PROTEIN PRECURSOR >gi | 100217 Ipir | | S2. 78 le-21 pir||S71371 gibberellin-regulated protein GASA5 - Arabidopsis t. 73 3e-20 gb I AAC32128. i l (AF051227 ) GASA5-like protein [Picea mariana] 73 4e-20 gb|AAF15937.1|AC011765_33 (AC011765) GASTl-like protein [Arabid. 73 4e-20 gb|AAC32170.1| (AF051753) GASA5-like protein [Picea mariana] >g. 69 7e-19 gb IAAC20716.il (AC004669) putative gibberellin-regulated protei. 69 7e-19 sp|P47926|RSIl_LYCES RSI-1 PROTEIN PRECURSOR (TR132) >gi|107659. 68 9e-19 gb |AAC61287.1| (AC005396) similar to gibberellin-regulated prot. 57 2e-15 sp|P46688 |GAS2_ARATH GIBBERELLIN-REGULATED PROTEIN 2 PRECURSOR . 54 2e-14 gb IAAC27845.il (AC004218) similar to gibberellm-regulated prot. 51 le-13 sp|P46687 |GAS3_ARATH GIBBERELLIN-REGULATED PROTEIN 3 PRECURSOR . 50 2e-13 gb I AAB62947.il (AF007784) LTCOR11 [Lavatera thuringiaca] 49 5e-13 pir||S60229 GASTl protein homolog (clone GASA1) - Arabidopsis t... 44 le-11 sp|P46689|GASl_ARATH GIBBERELLIN-REGULATED PROTEIN 1 PRECURSOR ... 44 le-11 emb|CAB45241.1| (AJ005206) GEG protein [Gerbera hybrida] 43 3e-ll gb|AAB97006.1| (AF039183) GAST-like gene product [Fragaria x an... 41 2e-10 g I AC15 60.1| (AF060569) cold-regulated LTCOR12 [Lavatera thur... 40 2e-10 gb I AAD01518. i l (AF014396) Snakin-1 [Solanum tuberosum] 37 2e-09 gb|AAD15495.1| (AC006439) similar to gibberellin-regulated prot... 29 6e-07 ref |NP_037530.1| I zinc finger protein 224 >gi | 6715532 |gb IAAF041... 6 3.3 emb|CAA8 663.1| (Z35600) cDNA EST yk222a6.3 comes from this gen... 6 4.2 gb|AAC97073.1| (AF042838) MEK kinase 1 [Homo sapiens] 5 6.6 gb IAAF53381. i l (AE003643 ) CG15288 gene product [Drosophila ela . . . 5 8 . 3 gb|AAD31714.1|AF135118_l (AF135118) laminin alphal, 2 [Drosophil... 5 8.3 Significant alignments for pattern occurrence 1 at position 98 Second, PSI-Blast Round. Searching .done Results from round 2 Score E Sequences producing significant alignments: (bits) Value Sequences used in model and found again: pir||S54832 gipl protein - garden petunia >gi | 825524 | emb I CAA606... 160 4e-39 gb|AAC61287.1| (AC005396) similar to gibberellin-regulated prot... 148 2e-35 sp I P27057 I GST1_LYCES GASTl PROTEIN PRECURSOR >gi 1100217 | pir | j S2... 142 9e-34 gb I AC32128.il (AF051227) GASA5-like protein [Picea mariana] 135 le-31 gb|AAF15937.1|AC011765_33 (AC011765) GASTl-like protein [Arabid... 134 3e-31 gb | AAC20716. 1 | (AC004669) putative gibberellin-regulated protei . . . 133 6e-31 pir | | S71371 gibberellin-regulated protein GASA5 - Arabidopsis t . . . 133 7e-31 gb|AAC32170.1 I (AF051753) GASA5-like protein [Picea mariana] >g... 130 6e-30 sp|P47926|RSIl_LYCES RSI-1 PROTEIN PRECURSOR (TR132) >gi | 107659... 128 2e-29 pir | | S60232 GASTl protein homolog (clone GASA4 ) - Arabidopsis t . . . 124 4e-28 emb I CAA66909.il (X98255) transcriptionally stimulated by gibber... 123 5e-28 sp|P46690|GAS4_ARATH GIBBERELLIN-REGULATED PROTEIN 4 PRECURSOR ... 123 5e-28 gb I AAB62947. i l (AF007784 ) LTCOR11 [Lavatera thuringiaca] 118 2e-26 gb | AAB97006. 1 | (AF039183 ) GAST-like gene product [Fragaria x an. . . 117 4e-26 sp|P46687|GAS3_ARATH GIBBERELLIN-REGULATED PROTEIN 3 PRECURSOR ... 116 8e-26 sp|P46688|GAS2_ARATH GIBBERELLIN-REGULATED PROTEIN 2 PRECURSOR ... 116 8e-26 sp|P46689|GASl_ARATH GIBBERELLIN-REGULATED PROTEIN 1 PRECURSOR ... 116 le-25 gb|AAC15460.1| (AF060569) cold-regulated LTC0R12 [Lavatera thur... 116 le-25 pir||S60229 GASTl protein homolog (clone GASA1) - Arabidopsis t... 116 le-25 emb | CAB45241. 1 | (AJ005206) GEG protein [Gerbera hybrida] 114 4e-25 gb|AAC27845.1| (AC004218) similar to gibberellin-regulated prot... 112 le-24 gb IAAD15495.il (AC006439) similar to gibberellin-regulated prot... 95 3e-19 gb I AD01518. i l (AF014396) Snakin-1 [Solanum tuberosum] 93 le-18 Sequences not found previously or not previously below threshold: gb|AAC67545.1| (AF086604) mucin [Homo sapiens] 42 0.003 emb | CAA06167. 1 | (AJ004862) mucin [Homo sapiens] 39 0.018 ref |NP_002441.1| I metallothionein 1L >gi I 462637 | sp| P80297 |MT1L_... 37 0.052 gb IAAB71835.il (AF008583) metallothionein [Ambystoma mexicanum] 37 0.052 gb |AAD04919.1 | (AF099154 ) von Willebrand factor [Canis familiaris ] 37 0. 068 sp | Q28295 | VWF_CANFA VON WILLEBRAND FACTOR PRECURSOR >gi | 1478046. . . 37 0.068 prf I I 1101271B metallothionein MT Ipg [Homo sapiens] 37 0.068 gb I AB93766. i l (U66246) von Willebrand factor [Canis familiaris] 37 0.068 gb |AAC06229. 1 | (AF052036) von Willebrand factor precursor [Sus . . . 37 0.090 ref |NP_003881.1| I IgG Fc binding protein >gi 11944352 |dbj IBAA195... 37 0.090 emb|CAA70525.1| (Y09353) von Willebrand factor [Bos taurus] 37 0.090 gb|AAC39446.1| (AF060485) MEDEA [Arabidopsis thaliana] >gi|4185 37 0.090 gb|AAD39266.1|AC007842_l (AC007842) Human Fc gamma BP [AA 1-284 37 0.090 sp|P04732|MTlE_HUMAN METALLOTHIONEIN-IE (MT-1E) >gi i 625332 | pi I 36 0.12 pir||S43534 integrin beta3 - chicken >gi | 474039 | emb | CAA51069.11 36 0.12 sp|P09579| T2_BOVIN METALLOTHIONEIN-II (MT-II) >gi | 8965 |pir | | B 36 0.12 ref |NP_033746.1 M a disintegrin and metalloproteinase domain 19 36 0.15 pir||S38539 gene MDC protein - human >gi I 455835 | gb| AAB29191.11 36 0.15 pir||I52965 disintegrin-like metalloproteinase (EC 3.4.24.-) - 36 0.15 dbj IBAA06670.11 (D31872) metalloprotease/disintegrm-like prote 36 0.15 sp|P14425|MT2_STECO METALLOTHIONEIN-II (MT-II) >gi | 225981 Iprf II 36 0.15 pir||S60258 meltrin beta - mouse (fragment) >gi 11584289 Iprf | | 21 36 0.15 ref |NP_031426.11 I a disintegrin and metalloproteinase domain 12 36 0.15 dbj |BAA18923.1| (D50410) meltrin beta [Mus musculus] 36 0.15 emb | CAA07188. 1 | (AJ006692) ultra high sulfer keratin [Homo sapi 36 0.15 emb I CAA09979.il (AJ012287) alpha tectorin [Gallus gallus] 36 0.15 ref |NP_033743.11 I a disintegrin and metalloprotease domain (ADA. 36 0.15 ref | NP_002381.2 I I metalloproteinase-like, disintegrin-like, cys . 36 0. 15 sp | P02801 | MTlB_HORSE METALLOTHIONEIN-IB (MT-IB) 36 0. 15 ref |NP_005944.1| I metallothionein 2A; MT-II >gi 1127397 | sp| P0279. 35 0.20 ref |NP_038631.1| I metallothionein 3 >gi | 127405 | sp| P28184 |MT3_MO. 35 o.2o pirllSMHOlA metallothionein IA - horse 35 0.20 sp|P17816|GRP_HORVU GLYCINE-RICH CELL WALL STRUCTURAL PROTEIN P. 35 0.20 sp|P42124 |EZ_DROME ENHANCER OF ZESTE PROTEIN >gi | 404864 | gb |AAC4. 35 0.20 sp|P02800|MTlA_HORSE METALLOTHIONEIN-IA (MT-1A) 35 0.20 dbj IBAA19183.1I (AB000794) metallothionein isoform [Sus scrofa] 35 0.20 sp|O19000|MTl_CANFA METALLOTHIONEIN-I (MT-I) >gi | 2564070 | dbj |BA... 35 0.20 prf I |1201189A metallothionein [Canis familiaris] 35 0.20 prf I 11101271A metallothionein MT Ilpg [Homo sapiens] 35 0.20 gb|AAF50149.1| (AE003547) E(z) gene product [Drosophila melanog... 35 0.20 sp|P04733|MTlF_HUMAN METALLOTHIONEIN-IF (MT-1F) >gi | 72161 |pir I | ... 35 0.26 sp|P80294|MTlH_HUMAN METALLOTHIONEIN-IH (MT-1H) (METALLOTHIONEI ... 35 0.26 gb|AAF44843.1|AE003406_48 (AE003416) symbol=BG:DS00180.10; cDNA... 35 0.26 sp|P07438|MTlB HUMAN METALLOTHIONEIN-IB (MT-1B) >gi I 625334 | pi | ... 35 0.26 pir I 1146414 etallothionein-Ia - sheep 35 0.26 gb I AAB51591.il (U93207) metallothionein [Liza aurata] 35 0.26 ref |NP_003465.1| I Meltrin-alpha, mouse, homolog of >gi 12677839 | ... 35 0.26 gb I AC08703.il (AF023477) meltrin-S [Homo sapiens] 35 0.26 sp|P52727|MTA_SPAAU METALLOTHIONEIN A (MT A) >gi | 1289282 | emb | CA... 35 0.26 emb I CAB46832.1 | (AJ388530) metallothionein isoform 2 [Canis fam... 35 0.26 gb|AAF23355.1|AF078844_l (AF078844) hqp0376 protein [Homo sapiens] 35 0.26 sp|Q93083|MTlR_HUMAN METALLOTHIONEIN-IR (MT-1R) >gi | 1495464 | emb... 35 0.26 emb|CAB63401.1| (Z98877) cDNA EST yk385a5.3 comes from this gen... 35 0.26 emb I CAB04626. 1 | (Z81573 ) M02G9. 3 [Caenorhabditis elegans ] 35 0.26 gb | AAF53364 . 1 | (AE003642 ) BG : DS00180. 10 gene product [ Drosophil . . . 35 0 .26 sp|P80295|MTH_HUMAN METALLOTHIONEIN-II (MT-II) 35 0.26 ref |NP_033606.1| I zona pellucida glycoprotein 1 >gi I 2137874 Ipir... 35 0.35 sp|Q92145|MT_TREBE METALLOTHIONEIN (MT) >gi 11322388 I emb | CAA9656... 35 0.35 Note: other sequences were left off for sake of brevity that had even less significant scores. All publications and patent applications mentioned in the specification are indicative ofthe level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications maybe practiced within the scope ofthe appended claims.

Claims: WHAT IS CLAIMED IS: 1. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of: a. a polynucleotide that encodes a polypeptide of SEQ ID NOS:37-72; b. a polynucleotide comprising at least 20 contiguous bases of SEQ ID OS.1-36; c. a polynucleotide having at least 70% sequence identity to any of SEQ ID NOS: 1-36, wherein said polynucleotide encodes a polypeptide having KCP-like activity; d. a polynucleotide at least 25 nucleotides in length that hybridizes to a polynucleotide having the sequence set forth in SEQ ID NOS: 1-36, wherein said polynucleotide encodes a polypeptide having KCP-like activity; e. a polynucleotide comprising the sequence set forth in any of SEQ ID NOSJ-36; and, f. a polynucleotide complementary to a polynucleotide of (a) through (e). 2. A vector comprising at least one nucleic acid of claim 1. 3. A recombinant expression cassette comprising a nucleic acid molecule having the polynucleotide sequence of a nucleic acid of claim 1 operably linked to a promoter, wherein the nucleic acid is in the sense or antisense orientation. 4. A host cell comprising the recombinant expression cassette of claim 3. 5. A transgenic plant cell comprising the recombinant expression cassette of claim 3. 6. A transgenic plant comprising the recombinant expression cassette of claim 3. 7. The transgenic plant of claim 6, wherein the plant is maize, soybean, sunflower, sorghum, canola, wheat, alfalfa, cotton, rice, barley, or millet. 8. A transgenic seed from the transgenic plant of claim 7. 9. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: a. an amino acid sequence comprising at least 25 contiguous amino acids ofthe sequence set forth in SEQ ID NOS :37-72; b. an amino acid sequence having at least 75% sequence identity to the sequence set forth in SEQ ID NOS:37-72, wherein said polypeptide retains KCP-like activity; and, c. an amino acid sequence comprising the sequences set forth in SEQ ID NOS:37-72. 10. A method of modulating the level of a KCP-like protein in a plant cell, comprising: a. introducing into a plant cell a nucleic acid of claim 1 operably linked to a promoter; b. culturing said plant cell under appropriate conditions to produce a regenerated plant; and, c. inducing expression of said nucleic acid for a time sufficient to modulate expression of a KCP-like protein in said plant. 11. The method of claim 10, wherein said plant is maize, soybean, sunflower, sorghum, canola, wheat, alfalfa, cotton, rice, barley, or millet. 12. The method of claim 10, wherein the level of KCP-like protein is increased. 13. A method for identifying KCP-like proteins, said method comprising: a. searching at least one protein database with a pattern selected from the group consisting of: i) a pattern representing a compound having the formula (SEQ ID NO:97) C-X(2)-C-C-X(2)-[CS]-X(1,2)-C-V-P-[PSATK]-[GR]-X(2)- [GAQR], wherein: 5 C is cysteine; X(2) is any two amino acids selected independently from one another; [CS] is one amino acid selected from the group consisting of cysteine and serine; 10 X(l,2) is X(l) or X(2) wherein X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; V is valine; P is proline; 15 [PSATK] is one amino acid selected from the group consisting of proline, serine, alanine, threonine, and lysine; [GR] is one amino acid selected from the group consisting of glycine and arginine; and [GAQR] is one amino acid selected from the group consisting 20 of glycine, alanine, glutamine and arginine; and ii) a pattern for a compound having the formula (SEQ ID NO:98) [CS]-[PSQAG]-X(0,2)-C-Y-X(4)-[TNSM]-X(5,8)-K, wherein [CS] is one amino acid selected from the group consisting of cysteine and serine; 25 [PSQAG] is one amino acid selected from the group consisting of proline, serine, glutamine, alanine, and glycine; X(0,2) is X(0) or X(l) or X(2) wherein X(0) is no amino acid, X(l) is any one amino acid, and X(2) is any two amino acids selected independently from one another; 30 C is cysteine; Y is tyrosine; X(4) is any four amino acids selected independently from one another; [TNSM] is one amino acid selected from the group consisting of threonine, asparagine, serine, and methionine; X(5,8) is X(5) or X(6) or X(7) or X(8) wherein X(5) is any five amino acids selected independently from one another, X(6) is any six amino acids selected independently from one another, X(7) is any seven amino acids selected independently from one another, and X(8) is any eight amino acids selected independently from one another; and K is lysine; and b. selecting among retrieved proteins at least one protein comprising at least one amino acid sequence represented by at least one formula selected from said group. 14. The method of claim 13, wherein said searching is performed utilizing PHI-BLAST or PHI-PSI-BLAST under parameters comprising a default Expectation value (E) of 10, a gap opening cost with a default value of 11, and a gap extension cost with a default value of 1. 15. The method of claim 14 wherein said PHI-BLAST or PHI-PSI-BLAST is used with BLOSUM62 substitution matrix. 16. The method of claim 13, wherein said selecting is performed utilizing an alignment program. ABSTRACT OF THE DISCLOSURE The invention provides isolated KCP-like nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering KCP-like nucleic acid and/or protein concentration and/or composition of plants. The invention further provides recombinant expression cassettes, host cells, and transgenic plants. I l l SEQUENCE LISTING <110> Simmons, Carl R. Navarro, Pedro <120> Antimicrobial Peptides and Methods of Use <130> 35718/238419 <150> 60/232,569 <151> 2000-09-13 <160> 99 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 730 <212> DNA <213> Zea mays <220> <221> CDS <222> (97) ... (441) <400> 1 accggacgtc cctcgctccc aaatatctct ccccacctcc cctgagcttc tcccgacctt 60 tggtcaggca aaggaggcgg ccaacaagga cgagcg atg gtg ace aag gtc ate 114 Met Val Thr Lys Val lie 1 5 tgc ttc ctg gtg etc gca tec gtg etc etc gcc gtc get ttt ccc gtg 162 Cys Phe Leu Val Leu Ala Ser Val Leu Leu Ala Val Ala Phe Pro Val 10 15 20 tct get ctg egg cag cag gtg aag aag ggc ggc ggc ggt gaa ggc gga 210 Ser Ala Leu Arg Gin Gin Val Lys Lys Gly Gly Gly Gly Glu Gly Gly 25 30 35 ggc gga ggc agt gtt age gga age gga ggc ggc aac ctg aat ccc tgg 258 Gly Gly Gly Ser Val Ser Gly Ser Gly Gly Gly Asn Leu Asn Pro Trp 40 45 50 gag tgc teg ccc aag tgc ggg teg egg tgc tec aag acg cag tac agg 306 Glu Cys Ser Pro Lys Cys Gly Ser Arg Cys Ser Lys Thr Gin Tyr Arg 55 60 65 70 aag gcc tgc etc ace tta tgc aac aag tgc tgc gcc aag tgc etc tgc 354 Lys Ala Cys Leu Thr Leu Cys Asn Lys Cys Cys Ala Lys Cys Leu Cys 75 80 85 gtg cca ccg ggg ttc tac ggc aac aag ggc gcc tgc ccc tgc tac aac 402 Val Pro Pro Gly Phe Tyr Gly Asn Lys Gly Ala Cys Pro Cys Tyr Asn 90 95 100 aac tgg aaa ace aag gaa gga ggg ccc aag tgc ccc tag aagatccacc 451 Asn Trp Lys Thr Lys Glu Gly Gly Pro Lys Cys Pro * 105 110 gcagctcccg tccgccattg tccccccttc tccgaatctg gaacgtgttg ttcatcttcg 511 accaccccct aaggcttggc attttattac tagtataatg ctagtgtccg cccgttgctt 571 aatctggaat gctaccagcc agatctccat gctctcctgt gagccactcg gcagagtgag 631 gattactagg tagggtggca tgtcatgtgc tccaccctcc actggtacga gtcaatcaac 691 taaagctgaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 730 <210> 2 <211> 549 <212> DNA < 13> Zea mays <220> <221> CDS <222> (242) (529) <400> 2 tacacccaga gaggccagag cgagctagtg atgactgatg actgacgagt ctctatagca 60 tacagacacc gcgcgcggcg gagccaaagc caaggacggt ccggtggtat aaataagtat 120 cacccccacc agaaccccaa gccacaccag gcacgccagc ctcactcact ccccagacca 180 cctcacacgc acgaagcagc agagcagtgg actggactag ctaggtgcct aggtgggcaa 240 c atg aag ctt cag gcc ace gcc aga gtt get ggc etc etc ttc etc gtc 289 Met Lys Leu Gin Ala Thr Ala Arg Val Ala Gly Leu Leu Phe Leu Val 1 5 10 15 etc etc ctg gcg ctg ect tec etc cgc gtc tec atg get gga tea ggg 337 Leu Leu Leu Ala Leu Pro Ser Leu Arg Val Ser Met Ala Gly Ser Gly 20 25 30 ttc tgc gac ggc aag tgc gcg gtg agg tgc tec aag gcg age egg cac 385 Phe Cys Asp Gly Lys Cys Ala Val Arg Cys Ser Lys Ala Ser Arg His 35 40 45 gac gac tgc etc aag tac tgc ggg ate tgc tgc gcc ace tgc aac tgc 433 Asp Asp Cys Leu Lys Tyr Cys Gly lie Cys Cys Ala Thr Cys Asn Cys 50 55 60 gtg ccg tec ggg aca gcg ggc aac aag gac gag tgc cca tgc tac cgc 481 Val Pro Ser Gly Thr Ala Gly Asn Lys Asp Glu Cys Pro Cys Tyr Arg 65 70 75 80 gac atg ace ace gga cac ggc aac cgc ace agg ccc aag tgc ccc tga 529 Asp Met Thr Thr Gly His Gly Asn Arg Thr Arg Pro Lys Cys Pro * 85 90 95 tgatattcat tccttcgctc 549 <210> 3 <211> 691 <212> DNA <213> Zea mays <220> <221> CDS <222> (157) ... (504) <400> 3 aggcgcgtta atacgactca ctatagggcg aattgggtac cgggcccccc ctcgtgccca 60 agaagaggcc cccagtcccc agccagtcca cagctctcca ctcgagaaac ctccagtcca 120 gctccaccct tcgtccagag gcacaacaca cacacc atg get ccc age aag ctt 174 Met Ala Pro Ser Lys Leu 1 5 gcg gtg gtc gtc gcc ttg gta gcg teg etc etc ctg etc ace ace age 222 Ala Val Val Val Ala Leu Val Ala Ser Leu Leu Leu Leu Thr Thr Ser 10 15 20 aac ace aag ctt ggc ctg ttc gtg etc ggc cag get get ccg ggc gcc 270 2 Asn Thr Lys Leu Gly Leu Phe Val Leu Gly Gin Ala Ala Pro Gly Ala 25 30 35 tac cca cca egg get ect ccg ccg cac cag ate gtc gac etc gcc aaa 318 Tyr Pro Pro Arg Ala Pro Pro Pro His Gin lie Val Asp Leu Ala Lys 40 45 50 gac tgc ggg ggc gcg tgc gac gtg egg tgc ggc gcg cac teg cgc aag 366 Asp Cys Gly Gly Ala Cys Asp Val Arg Cys Gly Ala His Ser Arg Lys 55 60 65 70 aac ate tgc ace egg gcg tgc etc aag tgc tgc ggc gtc tgc cgc tgc 414 Asn lie Cys Thr Arg Ala Cys Leu Lys Cys Cys Gly Val Cys Arg Cys 75 80 85 gtg ccg gcg ggc act gcc ggc aac cag cag acg tgc ggc aag tgc tac 462 Val Pro Ala Gly Thr Ala Gly Asn Gin Gin Thr Cys Gly Lys Cys Tyr 90 95 100 ace gac tgg ace acg cac ggc aac aag ace aag tgc ccg tga 504 Thr Asp Trp Thr Thr His Gly Asn Lys Thr Lys Cys Pro * 105 110 115 ctccttgtcc ttgacgagag cagcatgagt ccatgggccc actggcgcca cgttttgtat 564 gatcegaeec cgtcggcgta gatgtccgag cetgtageta tetagcttag atgtacgagg 624 ttgatgtgct ctgctgtttg ttttttgcta gtacttctag tgtgtatctt tgtgttgaaa 684 aaaaaaa 691 <210> 4 <211> 831 <212> DNA <213> Zea mays <220> <221> CDS <222> (144) ... (446) <400> 4 ggtegaecag gttcaegccg aegtccaggt getcgtcgcg gegegcaetg accttgteaa 60 ccggctccag ggcctacggg agaagctcgc ctcactaagc caaagctgac agcagcatac 120 aageaecagc agagctcttg ccg atg gcg gtg gcc aag ccc ccg ctt cag acg 173 Met Ala Val Ala Lys Pro Pro Leu Gin Thr 1 5 10 gcc gcg gtc etc etc etc etc etc ctg gtc gtc geg gcc gcg teg tgg 221 Ala Ala Val Leu Leu Leu Leu Leu Leu Val Val Ala Ala Ala Ser Trp 15 20 25 etc cag ace gtc gac gcc get tea ggg ttc tgc teg age aag tgc age 269 Leu Gin Thr Val Asp Ala Ala Ser Gly Phe Cys Ser Ser Lys Cys Ser 30 35 40 gtc egg tgc ggg egg gcg gcg age gcg egg gcg egg ggc gcg tgc atg 317 Val Arg Cys Gly Arg Ala Ala Ser Ala Arg Ala Arg Gly Ala Cys Met 45 50 55 agg tec tgc ggc etc tgc tgc gag gag tgc aac tgc gtg ccc acg egg 365 Arg Ser Cys Gly Leu Cys Cys Glu Glu Cys Asn Cys Val Pro Thr Arg 60 65 70 ccg ccg cgc gac gtc aac gag tgc ccc tgc tac cgc gac atg etc ace 413 Pro Pro Arg Asp Val Asn Glu Cys Pro Cys Tyr Arg Asp Met Leu Thr 75 80 85 90 gcc ggc ccc agg aag agg ccc aag tgc ccc tga ggccggctca cacacggcgc 466 Ala Gly Pro Arg Lys Arg Pro Lys Cys Pro * 95 100 aacccaagac acgtgctcca tgggactgcc actgctttgc ctgcaactgc gattcgatcc 526 atgctgatgg gceaaggcac cetgttatge tateectaae ettaetacta cgtatttgtg 586 tacgtacgta tctttgtatg catcgcgcgc ccgtgtgatc tataatatat aatctgctac 646 caggtcccgt cagatgtact gttagtgata agctgagcga ctagagaggt actgaatcct 706 cagtagttgg tagaacgggc tgttcctcgg gacagtgtgt gtcatggtta ggctgcctgt 766 actaattaat gtaeatgaac tattgtgcta tatatatata ttgteataaa aaaaaaaaaa 826 aaaaa 831 <210> 5 <211> 621 <212> DNA <213> Zea mays <220> <221> CDS <222> (137) ... (523) <400> 5 attacgccaa gctctaatac gactcactat agggaaagct ggtacgcctg caggtaccgg 60 tccggaattc ccgggtcgac ccacgcgtcc gcttcactca cgaaggcacc ctcccttgcc 120 aetectttte ettgag atg atg acg acg atg aag aag aag aag cag cag cag 172 Met Met Thr Thr Met Lys Lys Lys Lys Gin Gin Gin 1 5 10 cag etc etc etc ctt tct etc atg ttt ctt gtt get gtg aca gca gcc 220 Gin Leu Leu Leu Leu Ser Leu Met Phe Leu Val Ala Val Thr Ala Ala 15 20 25 get gtt get gcc gat cca cat cca cag cag gtg cag gtg cag cag cag 268 Ala Val Ala Ala Asp Pro His Pro Gin Gin Val Gin Val Gin Gin Gin 30 35 40 cag caa gca cag atg agg att aac agg gcc ace aga tec ctt ctt ect 316 Gin Gin Ala Gin Met Arg lie Asn Arg Ala Thr Arg Ser Leu Leu Pro 45 50 55 60 cag ccg ccg ccg aaa eta gac tgc ccg tec ace tgc tec gtg cgc tgc 364 Gin Pro Pro Pro Lys Leu Asp Cys Pro Ser Thr Cys Ser Val Arg Cys 65 70 75 ggc aac aac tgg aag aac cag atg tgc aac aag atg tgc aac gtc tgc 412 Gly Asn Asn Trp Lys Asn Gin Met Cys Asn Lys Met Cys Asn Val Cys 80 85 90 tgc aac aag tgc age tgc gtg ccg ccg ggg ace ggc cag gac ace cgc 460 Cys Asn Lys Cys Ser Cys Val Pro Pro Gly Thr Gly Gin Asp Thr Arg 95 100 105 cac etc tgc ccc tgc tac gac ace atg etc aat cca cac ace ggc aag 508 His Leu Cys Pro Cys Tyr Asp Thr Met Leu Asn Pro His Thr Gly Lys 110 115 120 ctt aag tgc ccc tag gccgtcgcca ctcatgttat gtacaatgta ctatcatcac 563 Leu Lys Cys Pro * 125 ttcaataata ataaaaacaa cttctggttc caaaaaaaaa aaaaaaaaaa aaaaaaaa 621 <210> 6 <211> 64? <212> DNA <213> Zea mays <220> <221> CDS <222> (142) ... (432) <400> 6 ctcacaccga aagcgcctca actctgaagg cgctacagca acgtcgccac ttcactcacg 60 attggagttt cacetcggea geccageeag ccagtggtte eteggctegg aggaaeaggc 120 gaacagcaag agcttctgaa g atg aag gcg ate ccc gtg get etc ctg etc 171 Met Lys Ala lie Pro Val Ala Leu Leu Leu 1 5 10 etc gtc ctg gtt get gcc gcc tec teg ttc aag cat etc gcc gag gca 219 Leu Val Leu Val Ala Ala Ala Ser Ser Phe Lys His Leu Ala Glu Ala 15 20 25 gca gac ggc ggc gcg gtg ccg gac ggc gtg tgc gac ggc aag tgc cgc 267 Ala Asp Gly Gly Ala Val Pro Asp Gly Val Cys Asp Gly Lys Cys Arg 30 35 40 age egg tgc teg ctg aag aag gcc ggg egg tgc atg ggc ctg tgc atg 315 Ser Arg Cys Ser Leu Lys Lys Ala Gly Arg Cys Met Gly Leu Cys Met 45 50 55 atg tgc tgc ggc aag tgc cag ggc tgc gtg ccg teg ggg ccg tac gcc 363 Met Cys Cys Gly Lys Cys Gin Gly Cys Val Pro Ser Gly Pro Tyr Ala 60 65 70 age aag gac gag tgc ccc tgc tac agg gac atg aag tec ccc aag aac 411 Ser Lys Asp Glu Cys Pro Cys Tyr Arg Asp Met Lys Ser Pro Lys Asn 75 80 85 90 cag cgc ccc aag tgc ccc tag gccctaccgc tctaagggag ggaggatgac 462 Gin Arg Pro Lys Cys Pro * 95 ccaggatttc gctcgcgatc ctgcacagct tctagtcttg tactgetagt ttagcgcgcc 522 gagcgtegga atgtcgegac ggttccttec gtgettgtgt getgtgttte tectcggacg 582 tgctttaacc tagaataata accaatgcac tgtatctgtg tgcttgtcaa aaaaaaaaaa 642 aaaaaa 648 <210> 7 <211> 806 <212> DNA <213> Zea mays <220> <221> CDS <222> (136) ... (525) <400> 7 ctcegacctc tctecattat tecatcccgg cggeggegge ggcgcgeggc gtgcgtgtca 60 cactcactga tcagtatccc cgcgggccgt actccttccc ttgtccgttc cgctgcgcag 120 cagacggcgc acggc atg gcc age agg aac aag gcg gcg gcg ctg etc etc 171 Met Ala Ser Arg Asn Lys Ala Ala Ala Leu Leu Leu 1 5 10 tgc ttc ctg ttc ctg gcc gcg gtc gcc gcc tec gcc gcc gag atg ate 219 Cys Phe Leu Phe Leu Ala Ala Val Ala Ala Ser Ala Ala Glu Met lie 15 20 25 gcc ggc agt ggg ate ggc gac ggc gaa ggt gaa gag ctg gac aag ggc 267 5 Ala Gly Ser Gly lie Gly Asp Gly Glu Gly Glu Glu Leu Asp Lys Gly 30 35 40 ggc ggc ggc ggc ggc ggc cac cac aag cac gag ggc tac aag aac aag 315 Gly Gly Gly Gly Gly Gly His His Lys His Glu Gly Tyr Lys Asn Lys 45 50 55 60 gat ggc aag gga aac ctg aag ccc tct cag tgc ggc ggg gag tgc egg 363 Asp Gly Lys Gly Asn Leu Lys Pro Ser Gin Cys Gly Gly Glu Cys Arg 65 70 75 egg egg tgc tec aag acg cac cac aag aag ccg tgc etc ttc ttc tgc 411 Arg Arg Cys Ser Lys Thr His His Lys Lys Pro Cys Leu Phe Phe Cys 80 85 90 aac aag tgc tgc gcc aag tgc ctg tgc gtg ccg ect ggc ace tac ggc 459 Asn Lys Cys Cys Ala Lys Cys Leu Cys Val Pro Pro Gly Thr Tyr Gly 95 100 105 aac aag gag ace tgc ccc tgc tac aac aac tgg aag ace aag aaa gga 507 Asn Lys Glu Thr Cys Pro Cys Tyr Asn Asn Trp Lys Thr Lys Lys Gly 110 115 120 ggg ccc aag tgc ccg tga gtcgtgagaa gatggcggcc caatacgcgg 555 Gly Pro Lys Cys Pro * 125 ttttcccggc ggctacgcgg gcgggccgcc ggcccatcgt aacctaccac cgtagttgga 615 agcgtegtag gataggttag gaataaataa tagectctct tttttttttt gccttgtttc 675 ggtgtttgtt tgggccgggc cggctgecgc ttctctggtc tctggtctaa aaagttcceg 735 aaaaatatta tatatttaat aagaagaaga aggaggggaa aaaaaaaaaa aaaaaaaaaa 795 aaaaaaaaaa a 806 <210> 8 <211> 720 <212> DNA <213> Zea mays <220> <221> CDS <222> (119) (403) <400> 8 ctcgectctc tctcgcgeaa gceacagtag ageaaccaae cataceaeeg gceegtgteg 60 atctctggcc tctctcgtgc aaggaattaa gcaggcaaga ggccaacctt cttccagc 118 atg gcc aag gcg age age agg ctg etc ttc teg etc teg etc gtc gtc 166 Met Ala Lys Ala Ser Ser Arg Leu Leu Phe Ser Leu Ser Leu Val Val 1 5 10 15 ctg ctg etc etc gtg gag ace act act tct ccc cat gga cag get gac 214 Leu Leu Leu Leu Val Glu Thr Thr Thr Ser Pro His Gly Gin Ala Asp 20 25 30 gcc ate gac tgc ggc gcg age tgc teg tac egg tgc age aag teg gga 262 Ala lie Asp Cys Gly Ala Ser Cys Ser Tyr Arg Cys Ser Lys Ser Gly 35 40 45 egg ccc aag atg tgc ctg agg gcg tgc ggc ace tgc tgc cag cgc tgc 310 Arg Pro Lys Met Cys Leu Arg Ala Cys Gly Thr Cys Cys Gin Arg Cys 50 55 60 ggc tgc gtc ccg ccg ggc ace tec ggc aac gag gac gtc tgc ccc tgc 358 Gly Cys Val Pro Pro Gly Thr Ser Gly Asn Glu Asp Val Cys Pro Cys 65 70 75 80 tac gcc aac atg aag ace cac gac ggc cag cac aag tgc ccg tga 403 Tyr Ala Asn Met Lys Thr His Asp Gly Gin His Lys Cys Pro * 85 90 tecatceacc gtggttccca gcatcageag etttgceaaa aagacatgat aeetacatat 463 atataagagt acctagctgc tgctgetcta ctaccttgtt ggttcattat attgtgcgcg 523 tgcatgcatg aataaataaa tgaaeatatt agggeatgta caacccagat aeggctgeac 583 ggtactccaa gtaeaagata caaetaaaac acaacaeaat aeagtggtea tgtctaaaac 643 atgtgtctta cgatatteat tgtaecaate agagtattca ataaattaaa gtgaccaaaa 703 aaaaaaaaaa aaaaaaa 720 <210> 9 <211> 754 <212> DNA <213> Zea mays <220> <221> CDS <222> (102) ... (539) <400> 9 gaattgtaat acgacteact atagggegaa ttgggtaccg ggccceecet cgaggagtcg 60 aggttcaggt tccacggtgc ggcgagagct agctcgcagc c atg gag age aag age 116 Met Glu Ser Lys Ser 1 5 cca tgg teg ctg egg ctg eta att tgc tgc gcg gca atg gtg gcc ate 164 Pro Trp Ser Leu Arg Leu Leu lie Cys Cys Ala Ala Met Val Ala lie 10 15 20 gcg ctt etc ccc caa caa gga ggc cag gcc get tgt ttc gtg ccg acg 212 Ala Leu Leu Pro Gin Gin Gly Gly Gin Ala Ala Cys Phe Val Pro Thr 25 30 35 ccg ggt cca get ccg gca ccg ccc ggc tec tec gcg acg aac acg aac 260 Pro Gly Pro Ala Pro Ala Pro Pro Gly Ser Ser Ala Thr Asn Thr Asn 40 45 50 gcc tec tec get get ect egg cca gcc aag ccc age gca ttc ccg ccc 308 Ala Ser Ser Ala Ala Pro Arg Pro Ala Lys Pro Ser Ala Phe Pro Pro 55 60 65 cca atg tac ggt ggt gtc ace ccc ggc ace ggc age etc cag ccc cac 356 Pro Met Tyr Gly Gly Val Thr Pro Gly Thr Gly Ser Leu Gin Pro His 70 75 80 85 gag tgc ggc ggc egg tgc gcg gag egg tgc teg gcg acg gcg tac cag 404 Glu Cys Gly Gly Arg Cys Ala Glu Arg Cys Ser Ala Thr Ala Tyr Gin 90 95 100 aag ccg tgc etc ttc ttc tgc cgc aag tgc tgc gcg gcg tgc ctg tgc 452 Lys Pro Cys Leu Phe Phe Cys Arg Lys Cys Cys Ala Ala Cys Leu Cys 105 110 115 gtg ccg ccg ggc ace tac ggc aac aag aac ace tgc ccc tgc tac aac 500 Val Pro Pro Gly Thr Tyr Gly Asn Lys Asn Thr Cys Pro Cys Tyr Asn 120 125 130 aac tgg aag ace aag egg gga ggc ccc aag tgc ccc tag tagccctccc 549 Asn Trp Lys Thr Lys Arg Gly Gly Pro Lys Cys Pro * 135 140 145 tctcggtcta cttgatgaga tcttctgttc aaaaaatcaa aaggaataag aatctgttta 609 7 actatcttta gatttcacct cgtgccgaat tcctgcagcc cgggggatcc acttagtttc 669 ttagagcggc ccgcccaccg cggttggagt tcccagcttt tgtttccctt tagtgagggt 729 taatttcgag cttggcgtaa tcctg 754 <210> 10 <211> 594 <212> DNA <213> Triticum aestivum <220> <221> CDS <222> (111) ... (344) <400> 10 getettaecc ageeacaegc ggagaagaga cgcageaage gceatggcca agatctcctt 60 cctcctcgtg gcgctcctcg tcctcgccgt gccgtgccgt gcaggaggtg atg gga 116 Met Gly 1 ggc ggc aac ggc ggc gcc ggc ggc ggc ggc aag etc aag cca tgg gag 164 Gly Gly Asn Gly Gly Ala Gly Gly Gly Gly Lys Leu Lys Pro Trp Glu 5 10 15 tgc teg tec aag tgc teg teg egg tgc teg ggg acg cag tac aag aag 212 Cys Ser Ser Lys Cys Ser Ser Arg Cys Ser Gly Thr Gin Tyr Lys Lys 20 25 30 gcg tgc ctg ace tac tgc aac aag tgc tgc gcc act tgc etc tgc gtg 260 Ala Cys Leu Thr Tyr Cys Asn Lys Cys Cys Ala Thr Cys Leu Cys Val 35 40 45 50 ccg ccg ggc ace tac ggc aac aag ggc gcc tgc ccc tgc tac aac aac 308 Pro Pro Gly Thr Tyr Gly Asn Lys Gly Ala Cys Pro Cys Tyr Asn Asn 55 60 65 tgg aag ace aag gag gga ggc ccc aag tgc ccc tag attcttgatt 354 Trp Lys Thr Lys Glu Gly Gly Pro Lys Cys Pro * 70 75 ttctttcttc ttcttctggg gtgccagctt gcggttgatg gttattcact gctcggccat 414 caaaatgtac tacagtagat ctgaattatg tgatgggcat ttaatcagtg gcatgtgaat 474 tgccctccca gttacctgta tttctatcag taagatgtgg aaaactggag gcactccgcc 534 actcceaeat gattatagtg ggecctaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 594 <210> 11 <211> 677 <212> DNA <213> Triticum aestivum <220> <221> CDS <222> (80) . (364) <400> 11 etecagcctc etcetatcgt caagetcaca ecaaeeagca ggagggctct gceagagcga 60 agcaaccaag aacaccacg atg aag aag ctt cgc ace ace act ctg get etc 112 Met Lys Lys Leu Arg Thr Thr Thr Leu Ala Leu 1 5 10 ctt etc etc etc gtc ttc eta gca gcc teg tec etc cgt gcc gcc atg 160 Leu Leu Leu Leu Val Phe Leu Ala Ala Ser Ser Leu Arg Ala Ala Met 15 20 25 get ggg tea gcg ttc tgc gac ggc aag tgc ggg gtg agg tgc tec aag 208 8 Ala Gly Ser Ala Phe Cys Asp Gly Lys Cys Gly Val Arg Cys Ser Lys 30 35 40. gcg age egg cac gac gac tgc etc aag tac tgc ggg ata tgc tgc gcc 256 Ala Ser Arg His Asp Asp Cys Leu Lys Tyr Cys Gly lie Cys Cys Ala 45 50 55 gag tgc aac tgc gtg ccg teg ggg ace gcc ggc aac aag gac gag tgc 304 Glu Cys Asn Cys Val Pro Ser Gly Thr Ala Gly Asn Lys Asp Glu Cys 60 65 70 75 ccc tgc tac cgc gac aag ace ace ggc cac ggc gcg cgc aag agg ccc 352 Pro Cys Tyr Arg Asp Lys Thr Thr Gly His Gly Ala Arg Lys Arg Pro 80 85 90 aag tgc cca tga tccgccacca ctctccaggc atcgatcctc caccgcccat 404 Lys Cys Pro * ggcgtetaca caceatatge ctgagcttca tgeatcceta tctateatgt cgtaccatgt 464 cgcggatcac tactagtata tcttataagc gtgtaaacca tgatctgtag cgtctggtgc 524 atgatecgat tccgactata tgttgatgtg eataatgctg gcctagetae tggtatgeeg 584 gceggtaaaa atgtcgetgt gctgtaataa tgaaecatga egcateagta aagtttgtce 644 agtaatttcc ttgttaaaaa aaaaaaaaaa aaa 677 <210> 12 <211> 639 <212> DNA <213> Triticum aestivum <220> <221> CDS <222> (81) ... (377) <400> 12 tcaagctcac acggtcacac caaccagcag ggctctgcca ctgccagagc caagcaactc 60 aagaacagta gaacaccacg atg aag aag ctt cgc ace ace ace gcc ace ace 113 Met Lys Lys Leu Arg Thr Thr Thr Ala Thr Thr 1 5 10 act ctg get etc att etc etc etc gtc etc ata gca gcc acg tec etc 161 Thr Leu Ala Leu lie Leu Leu Leu Val Leu lie Ala Ala Thr Ser Leu 15 20 25 cgt gtc gcc atg get gga tea gcg ttc tgc gac age aag tgc ggg gtg 209 Arg Val Ala Met Ala Gly Ser Ala Phe Cys Asp Ser Lys Cys Gly Val 30 35 40 agg tgc tec aag gcg ggc egg cac gac gac tgc etc aag tac tgc ggg 257 Arg Cys Ser Lys Ala Gly Arg His Asp Asp Cys Leu Lys Tyr Cys Gly 45 50 55 ata tgc tgc gcc gag tgc aac tgc gtg ccg teg ggg aca gcc ggc aac 305 lie Cys Cys Ala Glu Cys Asn Cys Val Pro Ser Gly Thr Ala Gly Asn 60 65 70 75 aag gac gag tgc ccc tgc tac cgc gac aaa ace ace ggc cac ggc gcg 353 Lys Asp Glu Cys Pro Cys Tyr Arg Asp Lys Thr Thr Gly His Gly Ala 80 85 90 cgc acg agg ccc aag tgc cca tga tccgccaccg cccatggcgc ctgcatagca 407 Arg Thr Arg Pro Lys Cys Pro * 95 tgtacctgaa cttcatgcat ctttatcatg tcgtactatg tcgcgggtca ctactattat 467 attatactat atgtgtgtaa atcatgatct gaagcgtccg gtgcatgatc cgactgtatg 527 ttgataatgc gtaatgctgg cctactggta tgccggtaaa aatgtcgttg ttctgtaata 587 ataaactaca tgcattatta gagtcaaaaa aaaaaaaaaa aaaaaaaaaa aa 639 <210> 13 <211> 506 <212> DNA <213> Triticum aestivum <220> <221> CDS <222> (2) . (325) <400> 13 g atg aag ect etc ccg gtg ace ctg get etc ctg gcc etc ttc etc gtc 49 Met Lys Pro Leu Pro Val Thr Leu Ala Leu Leu Ala Leu Phe Leu Val 10 15 gcc teg tac cag gac etc ace gtg gcc gca gat gca gat gca gat gca 97 Ala Ser Tyr Gin Asp Leu Thr Val Ala Ala Asp Ala Asp Ala Asp Ala 20 25 30 get gga get gga gat gtt ggc gcc gtt ccg gtt ccg gac age gtg tgc 145 Ala Gly Ala Gly Asp Val Gly Ala Val Pro Val Pro Asp Ser Val Cys 35 40 45 gag ggc aag tgc aag aac egg tgc teg cag aag gtg gcc ggg egg tgc 193 Glu Gly Lys Cys Lys Asn Arg Cys Ser Gin Lys Val Ala Gly Arg Cys 50 55 60 atg ggg ctg tgc atg atg tgc tgc ggc aag tgc gcc ggc tgc gtg ccg 241 Met Gly Leu Cys Met Met Cys Cys Gly Lys Cys Ala Gly Cys Val Pro 65 70 75 80 teg ggg ccg ttg gcc ccc aag gac gag tgc ccc tgc tac cgc gac atg 289 Ser Gly Pro Leu Ala Pro Lys Asp Glu Cys Pro Cys Tyr Arg Asp Met 85 90 95 aaa tec ccc aag age ggc cgc ccc aaa tgc ccc tag gactagggcg 335 Lys Ser Pro Lys Ser Gly Arg Pro Lys Cys Pro * 100 105 ettetttttc tttcttgggt ggaatgggat cttgacgagc cgggtgegtg ggatttaggg 395 gttccecttg tttgtaaget tgatttgtte gggataaaca aegeagatce eggtttgagg 455 gggggcccgg tacccaattc gccctatagt gagtcgtatt acgcgcgctc c 506 <210> 14 <211> 506 <212> DNA <213> Triticum aestivum <220> <221> CDS <222> (79) (372) <221> misc_feature <222> 55 <223> n = a, t, c, or g <221> misc_feature <222> 270 <223> n = a, t, c, or g 10 <221> misc_feature <222> 303 <223> n = a, t, c, or g <221> misc_feature <222> 425 <223> n = a, t, c, or g <221> misc_feature <222> 432 <223> n = a, t, c, or g <221> misc_feature <222> (442) ... (442) <223> n = a, t, c, or g <221> misc_feature <222> (457) ... (457) <223> n = a, t, c, or g <221> misc_feature <222> (465) ... (465) <223> n = a, t, c, or g <221> misc_feature <222> (502) ... (502) <223> n = a, t, c, or g <400> 14 ccaetctgcg accaeettat ctagetcctt etgeaagete etgcatccat ctcanctgca 60 gctcgaagct cgaccagg atg age aag cca teg agg tgc agg gca gtg cag 111 Met Ser Lys Pro Ser Arg Cys Arg Ala Val Gin 1 5 10 acg cag gtc gcc ctg etc etc etc ttg etc gtc get gcc tec ctg etc 159 Thr Gin Val Ala Leu Leu Leu Leu Leu Leu Val Ala Ala Ser Leu Leu 15 20 25 cag gcc ggc gac get get tea ggg ttc tgc gcg ggc aag tgc gcg gtc 207 Gin Ala Gly Asp Ala Ala Ser Gly Phe Cys Ala Gly Lys Cys Ala Val 30 35 40 egg tgc ggg egg teg cgc gca aag egg ggg gcg tgc atg aag tac tgc 255 Arg Cys Gly Arg Ser Arg Ala Lys Arg Gly Ala Cys Met Lys Tyr Cys 45 50 55 ggg ctg tgt tgc gan gag tgc gcc tgc gtg ccg acg ggg agg age ggn 303 Gly Leu Cys Cys Xaa Glu Cys Ala Cys Val Pro Thr Gly Arg Ser Xaa 60 65 70 75 age cgc gac gag tgc ccc tgc tac cgc gac atg etc ace gcc ggg ccc 351 Ser Arg Asp Glu Cys Pro Cys Tyr Arg Asp Met Leu Thr Ala Gly Pro 80 85 90 agg aag agg cca aag tgc ccg tgatctcgtc ggtcgaacgt ctgaacggac 402 Arg Lys Arg Pro Lys Cys Pro 95 aaccggetta acecccaacc tancgagtan cgacaaagan ttatggetgt ttganattgg 462 acncccgtct taagtaactt cctgtgccgt ttcccgtgcn aaat 506 <210> 15 <211> 769 <212> DNA 11 <213> Triticum aestivum <220> <221> CDS <222> (56) ... (400) <400> 15 ctgagcttct cccgaccttt ggtcaggcaa aggaggcggc caacaaggac gagcg atg Met 1 gtg ace aag gtc ate tgc ttc ctg gtg etc gca tec gtg etc etc gcc 106 Val Thr Lys Val He Cys Phe Leu Val Leu Ala Ser Val Leu Leu Ala 5 10 15 gtc get ttt ccc gtg tct get ctg egg cag cag gtg aag aag ggc ggc 154 Val Ala Phe Pro Val Ser Ala Leu Arg Gin Gin Val Lys Lys Gly Gly 20 25 30 ggc ggt gaa ggc gga ggc gga ggc agt gtt age gga age gga ggc ggc 202 Gly Gly Glu Gly Gly Gly Gly Gly Ser Val Ser Gly Ser Gly Gly Gly 35 40 45 aac ctg aat ccc tgg gag tgc teg ccc aag tgc ggg teg egg tgc tec 250 Asn Leu Asn Pro Trp Glu Cys Ser Pro Lys Cys Gly Ser Arg Cys Ser 50 55 60 65 aag acg cag tac agg aag gcc tgc etc ace tta tgc aac aag tgc tgc 298 Lys Thr Gin Tyr Arg Lys Ala Cys Leu Thr Leu Cys Asn Lys Cys Cys 70 75 80 gcc aag tgc etc tgc gtg oca ccg ggg ttc tac ggc aac aag ggc gcc 346 Ala Lys Cys Leu Cys Val Pro Pro Gly Phe Tyr Gly Asn Lys Gly Ala 85 90 95 tgc ccc tgc tac aac aac tgg aaa ace egg gaa gga ggg ccc aag tgc 394 Cys Pro Cys Tyr Asn Asn Trp Lys Thr Arg Glu Gly Gly Pro Lys Cys 100 105 110 ccc tag aagatccacc gcagctcccg tccgccattg tccccccttc tccgaatctg 450 Pro * gaacgtgttg ttcatcttcg accaccccct aggettggca ttttattaet agtataatge 510 tagtgtccgc ccgttgctta atctggaatg ctaccagcca gatctccatg ctetcctgtg 570 ageeactegg cagagtgagg attactaggt agggtggcat gtcatgtget ccacectcca 630 ctggtacgag tcaatcaact aaagctaccc ccggattgat gaggaacatc ccgcgcgatt 690 agtggggcat gteattacat tcatcagctt etatatataa aetagataaa etttttatea 750 aaaaaaaaaa aaaaaaaaa 769 <210> 16 <211> 692 <212> DNA <213> Triticum aestivum <220> <221> CDS <222> (137) ... (448) <400> 16 tcgcaaacca agcccctgcc acttgcaacg cacacttaca ccgcttgcag agctccagct 60 cgacctctag ctagcatcca tggcgcagcc tctcactcgc cgccgtctcc tccttcctcc 120 gcctctgctt ctgctg atg etc etc etc get etc gcc gcc cac cat cag gcc 172 Met Leu Leu Leu Ala Leu Ala Ala His His Gin Ala 12 10 get tec gac cca ccg gcg ace cac ggc ggc atg cga gcc age ggc ace 220 Ala Ser Asp Pro Pro Ala Thr His Gly Gly Met Arg Ala Ser Gly Thr 15 20 25 agg tec ctg etc cag cag cag ccg ect ect ccc agg eta gac tgc ccc 268 Arg Ser Leu Leu Gin Gin Gin Pro Pro Pro Pro Arg Leu Asp Cys Pro 30 35 40 aag gtg tgc gcg ggc egg tgc gcc aac aac tgg agg aag gag atg tgc 316 Lys Val Cys Ala Gly Arg Cys Ala Asn Asn Trp Arg Lys Glu Met Cys 45 50 55 60 aac gac aag tgc aac gtc tgc tgc cag cgc tgc aac tgc gtg ccc ccc 364 Asn Asp Lys Cys Asn Val Cys Cys Gin Arg Cys Asn Cys Val Pro Pro 65 70 75 ggc ace ggc cag gac ace egc cac ate tgc ccc tgc tac gcc ace atg 412 Gly Thr Gly Gin Asp Thr Arg His He Cys Pro Cys Tyr Ala Thr Met 80 85 90 ace aac ccg cac aac ggc aag etc aag tgc ccc tag gcatcacatc 458 Thr Asn Pro His Asn Gly Lys Leu Lys Cys Pro * 95 100 atetteagag geatatgctc cgcetcatgc gtetcccetg ccatgttcta etagctaget 518 ctagtactct agcatgtact atttgatgtg atcttcagct acattccata agctcacagt 578 gteaeactea eacatgtagt gttgagttge attgeagcct eetcattctc aeteaaccat 638 gatgatgatg atttcctgat aattaatttc ctgcatactt gttgatcaaa aaaa 692 <210> 17 <211> 685 <212> DNA <213> Oryza sativa <220> <221> CDS <222> (88) ... (405) <400> 17 ateaatcaet caaggcccet cetectctet ccateaagag aagctctaec tcggeeegtc 60 ctcgcccgcc ggccggccgc cgtcgcc atg get ccc ggc aag etc gcg gtg ttc 114 Met Ala Pro Gly Lys Leu Ala Val Phe 1 5 gcc etc ctg gcg tct etc etc etc etc aac ace ate aag gcc gca gac 162 Ala Leu Leu Ala Ser Leu Leu Leu Leu Asn Thr He Lys Ala Ala Asp 10 15 20 25 tac ect ccg get ect ccc ctt ggg ccg ect ccc cac aag ate gta gac 210 Tyr Pro Pro Ala Pro Pro Leu Gly Pro Pro Pro His Lys He Val Asp 30 35 40 ccc ggc aaa gac tgc gtg ggg gcg tgc gac gcg egg tgc age gag cac 258 Pro Gly Lys Asp Cys Val Gly Ala Cys Asp Ala Arg Cys Ser Glu His 45 50 55 teg cac aag aag egg tgc age cgc tec tgc etc acg tgc tgc age gcg 306 Ser His Lys Lys Arg Cys Ser Arg Ser Cys Leu Thr Cys Cys Ser Ala 60 65 70 tgc cgc tgc gtc ccg gcg ggc acg gcc ggc aac egg gag ace tgc ggc 354 Cys Arg Cys Val Pro Ala Gly Thr Ala Gly Asn Arg Glu Thr Cys Gly 13 75 80 85 agg tgc tac ace gac tgg gtc teg cac aac aac atg ace aag tgc ccg 402 Arg Cys Tyr Thr Asp Trp Val Ser His Asn Asn Met Thr Lys Cys Pro 90 95 100 105 tga gctaagcgcg cacgaatacg atccgtctgc ctgcctagat ctagcttaat 455 ttagctttgc attgctccta gttgagtagt tggtgttgtc cgttgggttt ctgtctttcc 515 agagttatcc ttttttcttt ttcttttttt ttcttcctga gagaagagag ggtgttgacg 575 agctgttact gttagtattc tggacctcta gtatgttttg ttgtgtaaaa aaggactagt 635 gaaatccatc tcggcttgaa tcacgcttga taaaaaaaaa aaaaaaaaaa 685 <210> 18 <211> 660 <212> DNA <213> Oryza sativa <220> <221> CDS <222> (76) ... (330) <400> 18 gegteetcca ceaagatecc cttcctcctc ctegeegtcc tcctectect ttceatcgcc 60 ttcccatcgg aggtg atg gca gga ggg cgc ggg cgc ggc ggc ggc ggc ggc 111 Met Ala Gly Gly Arg Gly Arg Gly Gly Gly Gly Gly 1 5 10 gga ggg gtg gcc ggc ggc ggg aac ctg agg ccg tgg gag tgc teg ccc 159 Gly Gly Val Ala Gly Gly Gly Asn Leu Arg Pro Trp Glu Cys Ser Pro 15 20 25 aag tgc gcg ggg agg tgc tec aac acg cag tac aag aag geg tgc ctg 207 Lys Cys Ala Gly Arg Cys Ser Asn Thr Gin Tyr Lys Lys Ala Cys Leu 30 35 40 acg ttc tgc aac aag tgc tgc gcc aag tgc ctg tgc gtg ccg ccc ggc 255 Thr Phe Cys Asn Lys Cys Cys Ala Lys Cys Leu Cys Val Pro Pro Gly 45 50 55 60 acg tac ggc aac aag ggc gcc tgc ccc tgc tac aac aac tgg aag ace 303 Thr Tyr Gly Asn Lys Gly Ala Cys Pro Cys Tyr Asn Asn Trp Lys Thr 65 70 75 aag gaa ggc ggc ccc aag tgc ccc taa gatgcatgcc tttttttctt 350 Lys Glu Gly Gly Pro Lys Cys Pro * 80 tcttcttttt tttttgtttt tttaccgtat gattaatacc tcctactagt tctactacat 410 tggtgtgtca ctgcctcact gacactggtt tagctcatgg atccggttga ttagttaatt 470 ggtggtgggt tttattgeta gatctgggct tataagtatt agtttatcct gttctagtaa 530 ggttgttggt tgggggaatg tgtgegagag aggagagtga ggattcgtca aagetggtea 590 aaaacttgga tcccctctcc ctgtagtgat tgattgattt gctactactg gagtgtgctt 650 tgccggaaaa 660 <210> 19 <211> 677 <212> DNA <213> Glycine max <220> <221> CDS 14 <222> (145) (411) <400> 19 cctaaataag catcataaat tcatagtctt tcggtccttc cttccttcct ccgctctagt 60 gtatgccact ctggttaatt atcatacccc cttctaggca tagttcttct ccctetgttc 120 tctattctac actgtgaaac caag atg aag gta gca ttt gta get gtt eta 171 Met Lys Val Ala Phe Val Ala Val Leu 1 5 ctt att tgc ctt gtc eta age tec tec ttg ttc gag gtg tea atg gcc 219 Leu He Cys Leu Val Leu Ser Ser Ser Leu Phe Glu Val Ser Met Ala 10 15 20 25 ggt tct get ttc tgc tec tec aag tgc gcg aag agg tgt tct agg get 267 Gly Ser Ala Phe Cys Ser Ser Lys Cys Ala Lys Arg Cys Ser Arg Ala 30 35 40 ggg atg aag gac agg tgc acg agg ttc tgc ggg att tgc tgc age aag 315 Gly Met Lys Asp Arg Cys Thr Arg Phe Cys Gly He Cys Cys Ser Lys 45 50 55 tgt agg tgt gtg cca tct ggg act tat ggg aac aag cac gag tgc ect 363 Cys Arg Cys Val Pro Ser Gly Thr Tyr Gly Asn Lys His Glu Cys Pro 60 65 70 tgc tac aga gac atg aag aac tec aag ggc aag ccc aaa tgc ect tga 411 Cys Tyr Arg Asp Met Lys Asn Ser Lys Gly Lys Pro Lys Cys Pro * 75 80 85 ttgttaattt caccatgcat caacttcaat ctcaaacctt tgaatccttc actcttgcta 471 getgattaag ttttetacet ttattattat tgtgtttgtg tatttatata aagagaaaaa 531 tttggtcact ttagttgaat cgggtatgca tgatatacat gagtgggaat aaatcgtggt 591 cttctttgtc cacctgtgaa tttggtctgt cttaataaaa gtgaattctc ctggttaaaa 651 aaaaaaaaaa aaaaaaaaaa aaaaaa 677 <210> 20 <211> 756 <212> DNA <213> Glycine max <220> <221> CDS <222> (147) ... (413) <400> 20 cctaaataag eatcttaatt eatagtetet tggtcettee ttecttettc tgctcaataa 60 gtgtgtgcca ctctaattaa ttaecacccc cttetagaca tagttcttct ccctetgttc 120 tctattctct acactgtgaa accaag atg aag gta gca ttt gca get gtt eta 173 Met Lys Val Ala Phe Ala Ala Val Leu 1 5 ctt ata tgc ctt gtc etc age tec tec ttg ttc gag gtg tea atg get 221 Leu He Cys Leu Val Leu Ser Ser Ser Leu Phe Glu Val Ser Met Ala 10 15 20 25 ggt tct get ttc tgt tec tec aag tgc teg aag agg tgt tct aga get 269 Gly Ser Ala Phe Cys Ser Ser Lys Cys Ser Lys Arg Cys Ser Arg Ala 30 35 40 ggg atg aag gac agg tgc atg aag ttc tgc ggg att tgc tgc age aag 317 Gly Met Lys Asp Arg Cys Met Lys Phe Cys Gly He Cys Cys Ser Lys 45 50 55 tgc aac tgt gtg cca tct ggg act tat ggg aac aag cat gag tgc ect 365 15 Cys Asn Cys Val Pro Ser Gly Thr Tyr Gly Asn Lys His Glu Cys Pro 60 65 70 tgc tac aga gac atg aag aac tec aag ggc aag gcc aaa tgc ect tga 413 Cys Tyr Arg Asp Met Lys Asn Ser Lys Gly Lys Ala Lys Cys Pro * 75 80 85 ttattttttt ttttcaccat ccacacatca acttcaagcc tttgattcag tcactaccgt 473 gcatgtatat ctccacctta gagatattcc accatggacc cttgctagct gattatgttt 533 actaccttta ttgttgtgtt tgtgtattac ataaagagaa aaatttggtc actttagttg 593 gatcggatat gcatgataca tgagagtgag aataaatcgg ggtcttcttt gtcctcgtgt 653 gaatttggtc tgtcttaatt aggctctatg gatagttaat aaaaatgaat tctccttttg 713 taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 756 <210> 21 <211> 579 <212> DNA <213> Glycine max <220> <221> CDS <222> (83) . ... (349) <400> 21 tagtaagctc ttttaaagtt ctggcccgaa ccctttcttt cgtcacaatc acaacttggt 60 aaaggtactc cgtgcaagaa ag atg aag etc gag ttc gca aat gtg eta ctt 112 Met Lys Leu Glu Phe Ala Asn Val Leu Leu 1 5 10 ctg tgc ctt gtc ctt age tct tct ttc ttg gaa ate tea atg get ggt 160 Leu Cys Leu Val Leu Ser Ser Ser Phe Leu Glu He Ser Met Ala Gly 15 20 25 tct ect ttc tgt gac tea aag tgc gcg cag agg tgt gcc aaa get ggg 208 Ser Pro Phe Cys Asp Ser Lys Cys Ala Gin Arg Cys Ala Lys Ala Gly 30 35 40 gtt cag gac aga tgc ttg agg ttt tgc ggg ate tgc tgc gag aag tgc 256 Val Gin Asp Arg Cys Leu Arg Phe Cys Gly He Cys Cys Glu Lys Cys 45 50 55 aac tgt gtc cca tct ggg act tac gga aac aag gac gag tgc ect tgc 304 Asn Cys Val Pro Ser Gly Thr Tyr Gly Asn Lys Asp Glu Cys Pro Cys 60 65 70 tac agg gac atg aag aac tec aag ggc aag gac aaa tgc ect tga 349 Tyr Arg Asp Met Lys Asn Ser Lys Gly Lys Asp Lys Cys Pro * 75 80 85 agaatatcta atttcatcat cacactccat tccaataaac taccttgtat tgtatcttca 409 gcctteettt teagagtatt geattatgee acggatetat gtacetacce ttcaaettaa 469 gtattccgte tagttaatta gcatagetac ectteaaett atgtgttecg acetagttaa 529 ttagcttatt aattatttac gagagtaaaa aaaaaaaaaa aaaaaaaaaa 579 <210> 22 <211> 509 <212> DNA <213> Glycine max <220> <221> CDS <222> (52) . (324) <400> 22 16 gttgaaacac acctactaca attgctaaag tcctttcttg tcatagcaaa a atg aag 57 Met Lys 1 ctt gtc ttt gcc ace eta ctg tta tgt tct ctt ctt eta age tec tct 105 Leu Val Phe Ala Thr Leu Leu Leu Cys Ser Leu Leu Leu Ser Ser Ser 5 10 15 ttc ttg gag cca gtc ate gcc tat gaa gac teg tct tat tgc age aac 153 Phe Leu Glu Pro Val He Ala Tyr Glu Asp Ser Ser Tyr Cys Ser Asn 20 25 30 aag tgt teg gac aga tgc tea teg gca ggg gtt aag gat agg tgt ctg 201 Lys Cys Ser Asp Arg Cys Ser Ser Ala Gly Val Lys Asp Arg Cys Leu 35 40 45 50 agg tac tgt gga ata tgc tgt get gag tgc aaa tgt gtt ect tct ggg 249 Arg Tyr Cys Gly He Cys Cys Ala Glu Cys Lys Cys Val Pro Ser Gly 55 60 65 ace tat ggg aac aag cac cag tgt ect tgc tac agg gac aag etc aac 297 Thr Tyr Gly Asn Lys His Gin Cys Pro Cys Tyr Arg Asp Lys Leu Asn 70 75 80 aag aag ggc aag ccc aaa tgc cca tga agtcttgaac tcaaagacca 344 Lys Lys Gly Lys Pro Lys Cys Pro * 85 90 agtcacatag agacttaaga gaataagaet ggtgtttgtg tttaeaatta categtgaat 404 teccaagcgt aatggttgga ctettgtttc eaatgtetgt tggatatatg ttagatctga 464 acgggaataa attacatatc ttggataaaa aaaaaaaaaa aaaaa 509 <210> 23 <211> 439 <212> DNA <213> Glycine max <220> <221> CDS <222> (17) ... (289) <400> 23 gtccttactt gcaaea atg aag ctt gtc ttt ggc ace eta eta tta tgt tct 52 Met Lys Leu Val Phe Gly Thr Leu Leu Leu Cys Ser 1 5 10 ctt ctt eta age ttc tct ttc ttg gag cca gtc ata gcc tat gaa gac 100 Leu Leu Leu Ser Phe Ser Phe Leu Glu Pro Val He Ala Tyr Glu Asp 15 20 25 tea tct tat tgc age aac aag tgt gcg gac aga tgc tea teg gca ggg 148 Ser Ser Tyr Cys Ser Asn Lys Cys Ala Asp Arg Cys Ser Ser Ala Gly 30 35 40 gtt aag gat agg tgt gtg aag tac tgt gga ata tgc tgt get gag tgc 196 Val Lys Asp Arg Cys Val Lys Tyr Cys Gly He Cys Cys Ala Glu Cys 45 50 55 60 aaa tgt gtt ect tct ggg ace tat ggg aac aag cac gag tgt ect tgc 244 Lys Cys Val Pro Ser Gly Thr Tyr Gly Asn Lys His Glu Cys Pro Cys 65 70 75 tac agg gac aag etc aac aag aag ggc aag ccc aaa tgc ect tga 289 Tyr Arg Asp Lys Leu Asn Lys Lys Gly Lys Pro Lys Cys Pro * 17 80 85 90 acttcaactc aaacaccaag tcgaatagag acttaagagt agtagttttt gcatgtggtt 349 gtattcttgt tttcaatgtc tgttgggtat gttagatctg aacaggaata aattacacat 409 cctctctgtc tcaaaaaaaa aaaaaaaaaa 439 <210> 24 <211> 783 <212> DNA <213> Glycine max <220> <221> CDS <222> (55) ... (345) <400> 24 tgtcactctc tctttgtctt aaaacctttg tttttgcttt gccactaatt aact atg 57 Met 1 gcc ate tea aaa age aca gtg gtc gta gtt att etc tgc ttc ate ctt 105 Ala He Ser Lys Ser Thr Val Val Val Val He Leu Cys Phe He Leu 5 10 15 ata caa gag ttg ggg ate tat ggt gaa gat cca cac atg gat get gcc 153 He Gin Glu Leu Gly He Tyr Gly Glu Asp Pro His Met Asp Ala Ala 20 25 30 aag aag ata gat tgc ggt ggc aag tgc aat tec agg tgc agt aag get 201 Lys Lys He Asp Cys Gly Gly Lys Cys Asn Ser Arg Cys Ser Lys Ala 35 40 45 agg agg caa aaa atg tgc att agg gca tgc aat agt tgc tgc aag aag 249 Arg Arg Gin Lys Met Cys He Arg Ala Cys Asn Ser Cys Cys Lys Lys 50 55 60 65 tgc agg tgc gtg cca ccc ggc act tct ggg aac cga gat ttg tgc ect 297 Cys Arg Cys Val Pro Pro Gly Thr Ser Gly Asn Arg Asp Leu Cys Pro 70 75 80 tgc tat get aga etc ace aca cat gga gga aag etc aag tgc cca tga 345 Cys Tyr Ala Arg Leu Thr Thr His Gly Gly Lys Leu Lys Cys Pro * 85 90 95 aatgatgact cgatcagaga egtctagcta agactagcac eatatgcatg eatgcagtta 405 aataaatgca attaataata ttttgtctga acgtaactac gtggtaatat ggtcgtcgat 465 egaggaatga ggeaecgagg gaagaaeata gatagcacea aattaaegag ctcettggcc 525 agcaaagtgg gaaaatggat gactaagatc ttgatgttgt ttttaatttt tatgctgcac 585 tatatttcot ttatcatata tatatatata tatatatata tatatgataa agcgaatgta 645 tgatgttaat ttgaggctta ataataatgt tagtcaatgt tagtactagt ttgcttcttt 705 aattagcata aaaatttcct ttatcatata tatatatata aataagtttg attttgtgca 765 aaaaaaaaaa aaaaaaaa 783 <210> 25 <211> 607 <212> DNA <213> Glycine max <220> <221> CDS <222> (39) ... (386) <400> 25 caaacactct agaatttgca tgcactgttc ttcataca atg gca tta cgc gag ctt 56 18 Met Ala Leu Arg Glu Leu 1 5 ctt atg atg ggg ata ttg ctg ctg gta tgt ctt get aag gtt tea tct 104 Leu Met Met Gly He Leu Leu Leu Val Cys Leu Ala Lys Val Ser Ser 10 15 20 gat gtt aac atg caa aag gaa gaa gat gaa gaa ctt cgc ttt ect aat 152 Asp Val Asn Met Gin Lys Glu Glu Asp Glu Glu Leu Arg Phe Pro Asn 25 30 35 cac ect ctt ate gtg aga gac ggg aac aga agg eta atg caa gac ata 200 His Pro Leu He Val Arg Asp Gly Asn Arg Arg Leu Met Gin Asp He 40 45 50 gat tgc gga gga ttg tgc aag aca agg tgc agt gcc cat teg agg cca 248 Asp Cys Gly Gly Leu Cys Lys Thr Arg Cys Ser Ala His Ser Arg Pro 55 60 65 70 aac gtg tgc aac agg get tgt ggc acg tgt tgt gtg agg tgc aag tgt 296 Asn Val Cys Asn Arg Ala Cys Gly Thr Cys Cys Val Arg Cys Lys Cys 75 80 85 gtt ccc cca gga act tea ggc aac agg gag etc tgt ggg ace tgc tat 344 Val Pro Pro Gly Thr Ser Gly Asn Arg Glu Leu Cys Gly Thr Cys Tyr 90 95 100 act gat atg ate act cac ggc aac aag ace aag tgt ccg tag 386 Thr Asp Met He Thr His Gly Asn Lys Thr Lys Cys Pro * 105 110 115 agcccggeec attgaaggtc ageectatcc aattgggcee ttcacaeaec gagttgatta 446 caccaagcaa agttagtcta gtttagtaaa taataaatat gggttatgta cacttttatg 506 gatttggatt ttgcatetta agatcgtgtt ctagttttta cctttgttat aatgtatcgt 566 attgttggag ccaagtttat aaaaaaaaaa aaaaaaaaaa a 607 <210> 26 <211> 788 <212> DNA <213> Glycine max <220> <221> CDS <222> (160) ... (513) <400> 26 ceagtgetge attttetttc gtctatataa tgctgctatg ccagtaatgt gtgaactgtg 60 aagtgtattg gtcactgacc tatcttggaa gagttttgaa gtttaaacct tcaaaccctt 120 ttgcctttag attctgattc tgagtctctg ctgctatat atg gcg cca cgc gta 174 Met Ala Pro Arg Val 1 5 ttt ctt gtg ttg ggg atg ttg ctg atg gtg tgc ctt gtt aag gtt teg 222 Phe Leu Val Leu Gly Met Leu Leu Met Val Cys Leu Val Lys Val Ser 10 15 20 tct gat cca aag aga gaa gaa gaa ata ctg gaa gaa gaa eta cat ttt 270 Ser Asp Pro Lys Arg Glu Glu Glu He Leu Glu Glu Glu Leu His Phe 25 30 35 ccc gat aac gag cca ctt att gtg aga gac ggg aac aga agg eta atg 318 Pro Asp Asn Glu Pro Leu He Val Arg Asp Gly Asn Arg Arg Leu Met 40 45 50 19 caa gac ata gat tgt ggt ggg ttg tgc aag acg agg tgc agt gca cat 366 Gin Asp He Asp Cys Gly Gly Leu Cys Lys Thr Arg Cys Ser Ala His 55 60 65 teg aga ccc aac ttg tgc act agg gcg tgt ggc acg tgc tgt gtg agg 414 Ser Arg Pro Asn Leu Cys Thr Arg Ala Cys Gly Thr Cys Cys Val Arg 70 75 80 85 tgt aag tgt gtc cca ect ggc aca tct gga aat agg gaa eta tgt gga 462 Cys Lys Cys Val Pro Pro Gly Thr Ser Gly Asn Arg Glu Leu Cys Gly 90 95 100 act tgc tac act gat atg act ace cat ggc aac aag ace aag tgc ect 510 Thr Cys Tyr Thr Asp Met Thr Thr His Gly Asn Lys Thr Lys Cys Pro 105 110 115 tag agaaaaaacc cattgggaaa tttgtgcttc attgattatg caccgaagtt 563 eaagtgtaet agtatgtggt ggttcaattc tgtttactat agegatgtgt gtgeaetact 623 ttggctatat tattagacta atagtatgtt tatttagaat gtgtaagttc tagtttgtgt 683 ctgtattatt tteggtgatg ggteatgtaa acttttgtgc ctttgtttgc etgaaeataa 743 agatagtagt acattacctt tttattaaaa aaaaaaaaaa aaaaa 788 <210> 27 <211> 996 <212> DNA <213> Glycine max <220> <221> CDS <222> (314) ... (673) <400> 27 tttttttttt ttttagacaa gtggcagtaa aaccacaaaa acatttaaat gttcaaaagc 60 caccggaaga ggtttaccac aattaagttc aacaaaaata aaaatagaaa aaacaaatga 120 catgctagtc accattaaga agaaaacagc aacaaggaat gtgacatcgg agtaaaataa 180 ccagagagct catgccatta tcttggcaga cctaacgtaa agactgtcca cgactttccc 240 aacatttgaa gtttaaacet tcaaattaat caaaeeattt taatttgcet atagattetg 300 agtcactgct get atg gcg eta cgc gta ctt ctt gtg ttg ggg atg ttg 349 Met Ala Leu Arg Val Leu Leu Val Leu Gly Met Leu 1 5 10 ctg atg ttg tgc ctt gtt aag gtt tea tct gat cca aag ata gaa gaa 397 Leu Met Leu Cys Leu Val Lys Val Ser Ser Asp Pro Lys He Glu Glu 15 20 25 gaa ata ctg gaa gca gaa gaa gaa ctg cag ttt ccc gat aac gag cca 445 Glu He Leu Glu Ala Glu Glu Glu Leu Gin Phe Pro Asp Asn Glu Pro 30 35 40 ctt ate gtg aga gac gcg aac aga agg eta atg caa gat atg gat tgt 493 Leu He Val Arg Asp Ala Asn Arg Arg Leu Met Gin Asp Met Asp Cys 45 50 55 60 gg ggg ttg tgc aag acg agg tgc agt gca cat teg agg ccc aac ttg 541 Gly Gly Leu Cys Lys Thr Arg Cys Ser Ala His Ser Arg Pro Asn Leu 65 70 75 tgc act agg gcg tgt ggc acg tgc tgt gtg agg tgc aag tgt gtc cca 589 Cys Thr Arg Ala Cys Gly Thr Cys Cys Val Arg Cys Lys Cys Val Pro 80 85 90 20 ct ggt aca tct gga aat agg gaa eta tgt gga ace tgc tac act gat 637 Pro Gly Thr Ser Gly Asn Arg Glu Leu Cys Gly Thr Cys Tyr Thr Asp 95 100 105 atg ace ace cat ggc aac aag ace aag tgc ect tag agaaacaaaa 683 Met Thr Thr His Gly Asn Lys Thr Lys Cys Pro * 110 115 agcttcatta gattggccaa tttgtgcttc gttcattatg catcaaagtt taagtgtact 743 cctatgtggg gtgcaattct gtttactata gcgatggatt tgtgtgcact actatggcta 803 tattaattga ctgttagtgt ttttatttag ggtgtgcctg tatgattgat gtgatgagct 863 agtcatgtaa actttgtgcc tttgtttgcg ttaatataaa atgtagtaca tcactgtacc 923 tttttatttc caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 983 aaaaaaaaaa aaa 996 <210> 28 <211> 615 <212> DNA <213> Glycine max <220> <221> CDS <222> (64) . ... (363) <400> 28 aateaaaaea tteecaataa caataatata cacatcttca attaagctec ttctcetata 60 gcc atg get ctt tct aag ctt ata att get tec ctt ctt gcg teg ctt 108 Met Ala Leu Ser Lys Leu He He Ala Ser Leu Leu Ala Ser Leu 1 5 10 15 etc ctt ctt cat ttc gtt gat get gat caa teg gca cat gca caa acg 156 Leu Leu Leu His Phe Val Asp Ala Asp Gin Ser Ala His Ala Gin Thr 20 25 30 cag ggg tct ctt ctt cag cag ata gat tgt aac gga gca tgt get gcg 204 Gin Gly Ser Leu Leu Gin Gin He Asp Cys Asn Gly Ala Cys Ala Ala 35 40 45 agg tgc cgt tta tea tct cgt cca cgc etc tgc caa aga get tgt gga 252 Arg Cys Arg Leu Ser Ser Arg Pro Arg Leu Cys Gin Arg Ala Cys Gly 50 55 60 act tgt tgt aga cgc tgt aac tgc gtg cca ect ggc act get gga aac 300 Thr Cys Cys Arg Arg Cys Asn Cys Val Pro Pro Gly Thr Ala Gly Asn 65 70 75 caa gaa gtg tgt ccc tgc tat gca agt ttg act act cat ggt ggc aaa 348 Gin Glu Val Cys Pro Cys Tyr Ala Ser Leu Thr Thr His Gly Gly Lys 80 85 90 95 cgc aag tgc ect tag acttaattgg accactatcc tatgcatgcc tttgatttat 403 Arg Lys Cys Pro * attataaaat aaaaataata etatatataa catgttaatt gcttaatatg tgctttaaga 463 gtaaagaata acatcgtgaa atcaaattac ccctttttca atacgtgttg aatcatcgat 523 ettggtttgt aatttggttg tatattcaea aaattaataa gtatattgtg atgtgattaa 583 ttcccttctc aaaaaaaaaa aaaaaaaaaa aa 615 <210> 29 <211> 628 <212> DNA <213> Zea mays 21 <220> <221> CDS <222> (49) ... (396) <400> 29 tcctcctcat atacagtaca aacttcagct ggtagatagt gcttccaa atg gag aag 57 Met Glu Lys 1 aaa agg aag act tta eta ttg ctg ctg etc atg get gca act etc ttc 105 Lys Arg Lys Thr Leu Leu Leu Leu Leu Leu Met Ala Ala Thr Leu Phe 5 10 15 tgc atg cca att gtg teg tat get gtt tct agt gtc aac att caa ggt 153 Cys Met Pro He Val Ser Tyr Ala Val Ser Ser Val Asn He Gin Gly 20 25 30 35 cat etc ace cat tct gag ctg gta aaa ggt ccc aat aga agg ctt ttg 201 His Leu Thr His Ser Glu Leu Val Lys Gly Pro Asn Arg Arg Leu Leu 40 45 50 cca ttt gtg gat tgt gga gcg agg tgc agg gtg agg tgc agt ttg cac 249 Pro Phe Val Asp Cys Gly Ala Arg Cys Arg Val Arg Cys Ser Leu His 55 60 65 tea agg cca aaa att tgc tea aga get tgc ggg aca tgc tgt ttc agg 297 Ser Arg Pro Lys He Cys Ser Arg Ala Cys Gly Thr Cys Cys Phe Arg 70 75 80 tgc agg tgt gtt ect cca ggc act tac ggg aac aga gag atg tgt ggc 345 Cys Arg Cys Val Pro Pro Gly Thr Tyr Gly Asn Arg Glu Met Cys Gly 85 90 95 aag tgt tac act gac atg ate act cat ggc aac aaa ect aag tgc ccc 393 Lys Cys Tyr Thr Asp Met He Thr His Gly Asn Lys Pro Lys Cys Pro 100 105 110 115 taa acctgtgcat gcatgcccat gtgtgtctac accttatgat gtttatcact 446 * agttaacaca aatttgaatt cccatttttt tgttttttct accttaattt cttaatgcat 506 tgtgtttctc ataatttgta accatcagtt ttgtgttttt tttcttctga acatcatcag 566 ttttgtgtat tgctgegatt taatgeatet atatataatg caaaaaaaaa aaaaaaaaaa 626 aa 628 <210> 30 <211> 1066 <212> DNA <213> Glycine max <220> <221> CDS <222> (189) . (764) <400> 30 aggattacgc caagctcgaa attaaccctc actaaaggga acaaaagctg gagctccacc 60 gcggtggcgg ecgctctaga actagtggat ececcgggct geaggtggaa etaaeacaca 120 etgaagaata gcageaagta gtagctcttg aecettcttt ccaeetttte tggtcectee 180 ctccagaa atg get tct aat tec att ctt ctt ctt tgt ate ttt ctt gtg 230 Met Ala Ser Asn Ser He Leu Leu Leu Cys He Phe Leu Val 1 5 10 gtt gcc act aag gtt ttt tec tat gat gaa gat etc aag aca gtg gtt 278 22 Val Ala Thr Lys Val Phe Ser Tyr Asp Glu Asp Leu Lys Thr Val Val 15 20 25 30 ect gca ect get cca cca gtg aag gca cca act ctt gcc ect cca gtg 326 Pro Ala Pro Ala Pro Pro Val Lys Ala Pro Thr Leu Ala Pro Pro Val 35 40 45 aaa tea cca tct tac ect cca ggg cca gtg ace aca cca aca gtt cca 374 Lys Ser Pro Ser Tyr Pro Pro Gly Pro Val Thr Thr Pro Thr Val Pro 50 55 60 aca ccc act gtt aag gta ccc ect ccc ect cag tct cca gta gtt aag 422 Thr Pro Thr Val Lys Val Pro Pro Pro Pro Gin Ser Pro Val Val Lys 65 ' 70 75 cca cca aca cca aca gtt cca cca ccc act gtt aag gta ccc ect ccc 470 Pro Pro Thr Pro Thr Val Pro Pro Pro Thr Val Lys Val Pro Pro Pro 80 85 90 ect cag tct cca gta gta aag cca cca act cca aca cca act tec cca 518 Pro Gin Ser Pro Val Val Lys Pro Pro Thr Pro Thr Pro Thr Ser Pro 95 100 105 110 gtg gtg tac ect ect ect gtt get cca tct cca cca get ect gta gtg 566 Val Val Tyr Pro Pro Pro Val Ala Pro Ser Pro Pro Ala Pro Val Val 115 120 125 aaa tea aac aag gat tgc att cca eta tgt gat tat agg tgc tea tta 614 Lys Ser Asn Lys Asp Cys He Pro Leu Cys Asp Tyr Arg Cys Ser Leu 130 135 . 140 cac tea agg aag aaa ttg tgc atg aga gca tgc ata ace tgt tgt gac 662 His Ser Arg Lys Lys Leu Cys Met Arg Ala Cys He Thr Cys Cys Asp 145 150 155 cga tgc aaa tgt gtc ect ect gga act tat ggt aac agg gaa aag tgt 710 Arg Cys Lys Cys Val Pro Pro Gly Thr Tyr Gly Asn Arg Glu Lys Cys 160 165 170 ggc aag tgc tac act gac atg ctg act cac ggc aac aaa ttc aag tgc 758 Gly Lys Cys Tyr Thr Asp Met Leu Thr His Gly Asn Lys Phe Lys Cys 175 180 185 190 cca tag aagaagccta atatctagta acttacctaa gcttttttgt taatcaagtt 814 Pro * tgaatcatga gtaatgtggt ttgagttgct agtgtattta ataacegaga gtgataatca 874 taattgtaca agctatcgtg ttaatcaaaa tagtcaacac tgtttgtgtt gtctatagga 934 tecatttgtg gtecatgaag aagtttatat tcataatgat taatataagg atgtattgct 994 gtacgaaatt cagaactata attaaatatg aatatgaeet tgetaaattt gattcaaaaa 1054 aaaaaaaaaa aa 1066 <210> 31 <211> 697 <212> DNA <213> Glycine max <220> <221> CDS <222> (110) ... (433) <400> 31 caaaactcaa gcattgcatc cctcttgatt tgtagtttgt tttgtgcttt agataaaagt 60 23 tctgccaaat caagaggggt tttaagatca tagtgtgtgt tttgcaaca atg get aag 118 Met Ala Lys 1 ttc ttt get get atg ate ttg gca etc ttt gcc att tec ata ctt caa 166 Phe Phe Ala Ala Met He Leu Ala Leu Phe Ala He Ser He Leu Gin 5 10 15 aca gtg gta atg get get aat gaa caa gga ggc cac ttg tat gac aac 214 Thr Val Val Met Ala Ala Asn Glu Gin Gly Gly His Leu Tyr Asp Asn 20 25 30 35 aag age aaa tat gga agt gga agt gtc aag agt tac caa tgc cca tea 262 Lys Ser Lys Tyr Gly Ser Gly Ser Val Lys Ser Tyr Gin Cys Pro Ser 40 45 50 caa tgc teg agg aga tgt age cag ace caa tac cac aag ccc tgc atg 310 Gin Cys Ser Arg Arg Cys Ser Gin Thr Gin Tyr His Lys Pro Cys Met 55 60 65 ttt ttc tgt cag aag tgc tgc agg aca tgc ctg tgt gtg ccc ccg ggg 358 Phe Phe Cys Gin Lys Cys Cys Arg Thr Cys Leu Cys Val Pro Pro Gly 70 75 80 tat tat ggt aat aaa get gtg tgc ect tgc tac aac aac tgg aag ace 406 Tyr Tyr Gly Asn Lys Ala Val Cys Pro Cys Tyr Asn Asn Trp Lys Thr 85 90 95 aag gaa gga gga ccc aag tgc ect tga gcttcaactt gttcaacttc 453 Lys Glu Gly Gly Pro Lys Cys Pro * 100 105 aattgtcgct ttcctacatt tttattgctt ccttccttgt gccaatttaa tgcactagct 513 accaaatgct aetagtcect tttggtggca ttctatgata ttatgttttt atgtattttg 573 gtgtatcact cettgggect tgtttgcctt taatgagagt ggcttattaa tatcaatata 633 tcaectacca aacttattge tggcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 693 aaaa 697 <210> 32 <211> 692 <212> DNA <213> Glycine max <220> <221> CDS <222> (114) ... (437) <400> 32 ctcaaacaca aacatccctc ttgatttgaa ggttgttttg tgcttataga taaaagttct 60 gccaaatcaa gaggggtttt cagatcatag tgtgtgtgtg tgtgtgttaa aca atg 116 Met 1 get aag ttc ttt get get atg ate ttg gca etc att gcc att tec atg 164 Ala Lys Phe Phe Ala Ala Met He Leu Ala Leu He Ala He Ser Met 5 10 15 ctt caa aca gtg gtt atg get get aat gag caa gga ggc cac ttg tat 212 Leu Gin Thr Val Val Met Ala Ala Asn Glu Gin Gly Gly His Leu Tyr 20 25 30 gac aac aag age aaa tat gga agt ggg agt gtc aag aga tac caa tgc 260 ' Asp Asn Lys Ser Lys Tyr Gly Ser Gly Ser Val Lys Arg Tyr Gin Cys 35 40 45 24 cca tea caa tgc teg agg aga tgt age cag ace caa tac cac aag ccc 308 Pro Ser Gin Cys Ser Arg Arg Cys Ser Gin Thr Gin Tyr His Lys Pro 50 55 60 65 tgc atg ttt ttc tgt cag aag tgc tgc agg aaa tgc ctg tgt gtg ccc 356 Cys Met Phe Phe Cys Gin Lys Cys Cys Arg Lys Cys Leu Cys Val Pro 70 75 80 ccg ggg tat tat ggt aat aaa get gtg tgc ect tgc tac aac aac tgg 404 Pro Gly Tyr Tyr Gly Asn Lys Ala Val Cys Pro Cys Tyr Asn Asn Trp 85 90 95 aag ace aag gaa gga gga ccc aag tgc ect tga aettcaaett eateaaattg 457 Lys Thr Lys Glu Gly Gly Pro Lys Cys Pro * 100 105 ttgcttttca ctatattttt atcatctccc ttgggccaat ttaatgcact agcttacttt 517 ccctactatt ttacccgtcc taaccaaatg ctcccctttt ggtggcactc tacgatatat 577 gtttttatgt attttggtgt atcctcetta ggecttgttt gectttaatg agagtggtta 637 ttaatatcaa tatateaact ataaaactta ttgctagcaa aaaaaaaaaa aaaaa 692 <210> 33 <211> 702 <212> DNA <213> Glycine max <220> <221> CDS <222> (87) ... (419) <400> 33 atctetettt gataceettt tgttcttttt ggtgetttaa tttgcactag caagggggtt 60 ggttttattt ctgtttgctt gcaaea atg get gtg get aat aag tta ctt tct 113 Met Ala Val Ala Asn Lys Leu Leu Ser 1 5 gtt ttg ate att gcc etc att gcc att tec atg ctt caa aca gtg gtt 161 Val Leu He He Ala Leu He Ala He Ser Met Leu Gin Thr Val Val 10 15 20 25 atg gca tct cat gga cat gga ggc cac cac tae aat gac aag aaa aaa 209 Met Ala Ser His Gly His Gly Gly His His Tyr Asn Asp Lys Lys Lys 30 35 40 tat gga ect ggc agt etc aaa age ttc caa tgc cca tea caa tgc tea 257 Tyr Gly Pro Gly Ser Leu Lys Ser Phe Gin Cys Pro Ser Gin Cys Ser 45 50 55 agg agg tgt ggc aag ace cag tac cac aag ccc tgc atg ttt ttc tgt 305 Arg Arg Cys Gly Lys Thr Gin Tyr His Lys Pro Cys Met Phe Phe Cys 60 65 70 cag aag tgt tgt agg aag tgc eta tgt gtg cca ccg ggg tat tat ggg 353 Gin Lys Cys Cys Arg Lys Cys Leu Cys Val Pro Pro Gly Tyr Tyr Gly 75 80 85 aac aaa gca gtg tgc ect tgc tac aac aac tgg aag ace aag gaa gga 401 Asn Lys Ala Val Cys Pro Cys Tyr Asn Asn Trp Lys Thr Lys Glu Gly 90 95 100 105 gga ccc aaa tgc ect taa taaccttatg ctatgttctt catcaaatta 449 Gly Pro Lys Cys Pro * 110 25 acaaagatat aatatagctt taatttatta tatccatatc atataatttt cttggtcctt 509 tctatgtctt aattaaccaa aaaatgtatg tccattttgg tcttagtaat actttgttgt 569 attgaagatg ccttttggag atagtgtgtg tgtgggctcc tctgcatcat accactcctt 629 attatggcat tgttggcttt taaatgaagt gtgtctaata etgttgctgt caaaaaaaaa 689 aaaaaaaaaa aaa 702 <210> 34 <211> 783 <212> DNA <213> Glycine max <220> <221> CDS <222> (121) (441) <400> 34 atttaggctc tcttaaaaca aaggtccctc aaaccacttt ccccacactc tttagtgtgt 60 catttttttt tttgctcttt ccccacaaag aggtcttgga cccttcttct gtgtagtgca 120 atg gcc atg get aag gtt ttc tgt gtt ctg ctt ctg gca etc ctt ggc 168 Met Ala Met Ala Lys Val Phe Cys Val Leu Leu Leu Ala Leu Leu Gly 1 5 10 15 att tec atg ate aca act cag gtt atg gca aca gat tct get tat cac 216 He Ser Met He Thr Thr Gin Val Met Ala Thr Asp Ser Ala Tyr His 20 25 30 ttg gat gga agg aat tat gga ect ggg agt etc aag age tea cag tgc 264 Leu Asp Gly Arg Asn Tyr Gly Pro Gly Ser Leu Lys Ser Ser Gin Cys 35 40 45 ect tct gaa tgc aca aga aga tgt age cag aca cag tac cac aag ccc 312 Pro Ser Glu Cys Thr Arg Arg Cys Ser Gin Thr Gin Tyr His Lys Pro 50 55 60 tgc atg gtc ttc tgc aaa caa tgc tgc aaa agg tgc ctt tgt gtt ect 360 Cys Met Val Phe Cys Lys Gin Cys Cys Lys Arg Cys Leu Cys Val Pro 65 70 75 80 ect ggc tac tat ggg aac aag tct gtg tgc ccc tgc tac aat aac tgg 408 Pro Gly Tyr Tyr Gly Asn Lys Ser Val Cys Pro Cys Tyr Asn Asn Trp 85 90 95 aag ace aag cgt gga gga ccc aaa tgc ccc tga aaattgaaaa tataagcata 461 Lys Thr Lys Arg Gly Gly Pro Lys Cys Pro * 100 105 atttcaccta caatttcata tatactactc aaagtggaac tataaactat atatatatat 521 atatatatat ggccatttct atgttttggg cagcacctac tacagttggg ttgtcactag 581 actaatacca tcttgttctc taccatgaaa ttagttcaat tattaatttc atgaagaaac 641 ctatatgtta ctccctttcc taaacaggta tgagaggggt gttctactaa ttagtcaatt 701 atctttgtea ttgtactttt tttagtttta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 761 aaaaaaaaaa aaaaaaaaaa aa 783 <210> 35 <211> 742 <212> DNA < 13> Glycine max <220> <221> CDS <222> (207) ... (578) <400> 35 26 acgccaagct cgaaattaac cctcactaaa gggaacaaaa gctggagctc caccgcggtg 60 gcggecgctc tagaactagt ggateccceg ggetgeagga atteggeacg aggctaactt 120 ctetetattt cttettttct ctgtgtgagg tceatttttg ageaatggeg agaaaactaa 180 gcattgttgt actctgcctt gttcaa atg ctg ctt ctt etc gtg gaa aac cat 233 Met Leu Leu Leu Leu Val Glu Asn His 1 5 gcc gag att gtt gtg tec ace gtt gag get tea get ccg cag ect cac 281 Ala Glu He Val Val Ser Thr Val Glu Ala Ser Ala Pro Gin Pro His 10 15 20 25 aag aac ace ace cac ace ctg tec cac get cca get ccg cag ect cac 329 Lys Asn Thr Thr His Thr Leu Ser His Ala Pro Ala Pro Gin Pro His 30 35 40 aaa aac ace aag tec ect gtt ccc aat ttg cag cat ggc ate ace gaa 377 Lys Asn Thr Lys Ser Pro Val Pro Asn Leu Gin His Gly He Thr Glu 45 50 55 ggc agt ctt aaa cca caa gaa tgt ggg cca cgt tgc ace get aga tgc 425 Gly Ser Leu Lys Pro Gin Glu Cys Gly Pro Arg Cys Thr Ala Arg Cys 60 65 70 tea aac aca caa tac aag aaa ccg tgc ctg ttc ttc tgc caa aag tgc 473 Ser Asn Thr Gin Tyr Lys Lys Pro Cys Leu Phe Phe Cys Gin Lys Cys 75 80 85 tgt gcc aag tgc tta tgt gtg ect ect gga act tat ggc aac aag caa 521 Cys Ala Lys Cys Leu Cys Val Pro Pro Gly Thr Tyr Gly Asn Lys Gin 90 95 100 105 gtt tgc ect tgc tac aac aac tgg aag ace aaa agg gga ggg cca aaa 569 Val Cys Pro Cys Tyr Asn Asn Trp Lys Thr Lys Arg Gly Gly Pro Lys 110 115 120 tgc ccc tga aactataaat tttacctatt aagtctctta attaatgcgt 618 Cys Pro * tgctagttgc taccagcact ccatgtattt atatatgtac ccaccagatt gaaattaagt 678 atcttaattt taatttgaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 738 aaaa 742 <210> 36 <211> 652 <212> DNA <213> Glycine max <220> <221> CDS <222> (94) ... (387) <400> 36 tatatattca tetttetett ttttagettt tetttteete taaaagtgag tccttcctte 60 ttegatcact tgttaaattc acatatcata gca atg gca gca cgt tec tac age 114 Met Ala Ala Arg Ser Tyr Ser 1 5 ccc ate atg gtt gcc etc tct ttg ctt ctt ttg gtc aca ttc tct aat 162 Pro He Met Val Ala Leu Ser Leu Leu Leu Leu Val Thr Phe Ser Asn 10 15 20 gta get gag get tat aca cgc agt gga aca ctt cgt ect tea gat tgt 210 Val Ala Glu Ala Tyr Thr Arg Ser Gly Thr Leu Arg Pro Ser Asp Cys 27 25 30 35 aaa cca aag tgt act tac cgt tgc tct gca act tea cac aag aag cca 258 Lys Pro Lys Cys Thr Tyr Arg Cys Ser Ala Thr Ser His Lys Lys Pro 40 45 50 55 tgc atg ttt ttc tgc cag aag tgt tgt get aaa tgc eta tgc gtt ect 306 Cys Met Phe Phe Cys Gin Lys Cys Cys Ala Lys Cys Leu Cys Val Pro 60 65 70 cct ggt aca tat ggc aac aag caa att tgc ect tgc tac aac age tgg 354 Pro Gly Thr Tyr Gly Asn Lys Gin He Cys Pro Cys Tyr Asn Ser Trp 75 80 85 aag ace aag gaa gga gga ccc aaa tgc cct taa aeceettaat tgeetaatat 407 Lys Thr Lys Glu Gly Gly Pro Lys Cys Pro * 90 95 ataaataatt taataageaa tgtaateeta tatgactctt eatgageaat tttttatetc 467 tacatagata agcaatgctc ttttaattgt ttagttgata gcacctgggg acacatttag 527 ttatgttccc ttcagttttc agagggaaaa cttttttttt agcaaattgt attttgtgtt 587 ggtatatatt atatatattg tttatatttt tttaaaaaaa aaaaaaaaaa aaaaaaaaaa 647 aaaaa 652 <210> 37 <211> 114 <212> PRT <213> Zea mays <400> 37 Met Val Thr Lys Val He Cys Phe Leu Val Leu Ala Ser Val Leu Leu 1 5 10 15 Ala Val Ala Phe Pro Val Ser Ala Leu Arg Gin Gin Val Lys Lys Gly 20 25 30 Gly Gly Gly Glu Gly Gly Gly Gly Gly Ser Val Ser Gly Ser Gly Gly 35 40 45 Gly Asn Leu Asn Pro Trp Glu Cys Ser Pro Lys Cys Gly Ser Arg Cys 50 55 60 Ser Lys Thr Gin Tyr Arg Lys Ala Cys Leu Thr Leu Cys Asn Lys Cys 65 70 75 80 Cys Ala Lys Cys Leu Cys Val Pro Pro Gly Phe Tyr Gly Asn Lys Gly 85 90 95 Ala Cys Pro Cys Tyr Asn Asn Trp Lys Thr Lys Glu Gly Gly Pro Lys 100 105 110 Cys Pro <210> 38 <211> 95 <212> PRT <213> Zea mays <400> 38 Met Lys Leu Gin Ala Thr Ala Arg Val Ala Gly Leu Leu Phe Leu Val 1 5 10 15 Leu Leu Leu Ala Leu Pro Ser Leu Arg Val Ser Met Ala Gly Ser Gly 20 25 30 Phe Cys Asp Gly Lys Cys Ala Val Arg Cys Ser Lys Ala Ser Arg His 35 40 45 Asp Asp Cys Leu Lys Tyr Cys Gly He Cys Cys Ala Thr Cys Asn Cys 50 55 60 Val Pro Ser Gly Thr Ala Gly Asn Lys Asp Glu Cys Pro Cys Tyr Arg 65 70 75 80 28 Asp Met Thr Thr Gly His Gly Asn Arg Thr Arg Pro Lys Cys Pro 85 90 95 <210> 39 <211> 115 <212> PRT <213> Zea mays <400> 39 Met Ala Pro Ser Lys Leu Ala Val Val Val Ala Leu Val Ala Ser Leu 1 5 10 15 Leu Leu Leu Thr Thr Ser Asn Thr Lys Leu Gly Leu Phe Val Leu Gly 20 25 30 Gin Ala Ala Pro Gly Ala Tyr Pro Pro Arg Ala Pro Pro Pro His Gin 35 40 45 He Val Asp Leu Ala Lys Asp Cys Gly Gly Ala Cys Asp Val Arg Cys 50 55 60 Gly Ala His Ser Arg Lys Asn He Cys Thr Arg Ala Cys Leu Lys Cys 65 70 75 80 Cys Gly Val Cys Arg Cys Val Pro Ala Gly Thr Ala Gly Asn Gin Gin 85 90 95 Thr Cys Gly Lys Cys Tyr Thr Asp Trp Thr Thr His Gly Asn Lys Thr 100 105 110 Lys Cys Pro 115 <210> 40 <211> 100 <212> PRT <213> Zea mays <400> 40 Met Ala Val Ala Lys Pro Pro Leu Gin Thr Ala Ala Val Leu Leu Leu 1 5 10 15 Leu Leu Leu Val Val Ala Ala Ala Ser Trp Leu Gin Thr Val Asp Ala 20 25 30 Ala Ser Gly Phe Cys Ser Ser Lys Cys Ser Val Arg Cys Gly Arg Ala 35 40 45 Ala Ser Ala Arg Ala Arg Gly Ala Cys Met Arg Ser Cys Gly Leu Cys 50 55 60 Cys Glu Glu Cys Asn Cys Val Pro Thr Arg Pro Pro Arg Asp Val Asn 65 70 75 80 Glu Cys Pro Cys Tyr Arg Asp Met Leu Thr Ala Gly Pro Arg Lys Arg 85 90 95 Pro Lys Cys Pro 100 <210> 41 <211> 128 <212> PRT <213> Zea mays <400> 41 Met Met Thr Thr Met Lys Lys Lys Lys Gin Gin Gin Gin Leu Leu Leu 1 5 10 15 Leu Ser Leu Met Phe Leu Val Ala Val Thr Ala Ala Ala Val Ala Ala 20 25 30 Asp Pro His Pro Gin Gin Val Gin Val Gin Gin Gin Gin Gin Ala Gin 35 40 45 Met Arg He Asn Arg Ala Thr Arg Ser Leu Leu Pro Gin Pro Pro Pro 50 55 60 29 Lys Leu Asp Cys Pro Ser Thr Cys Ser Val Arg Cys Gly Asn Asn Trp 65 70 75 80 Lys Asn Gin Met Cys Asn Lys Met Cys Asn Val Cys Cys Asn Lys Cys 85 90 95 Ser Cys Val Pro Pro Gly Thr Gly Gin Asp Thr Arg His Leu Cys Pro 100 105 110 Cys Tyr Asp Thr Met Leu Asn Pro His Thr Gly Lys Leu Lys Cys Pro 115 120 125 <210> 42 <211> 96 <212> PRT <213> Zea mays <400> 42 Met Lys Ala He Pro Val Ala Leu Leu Leu Leu Val Leu Val Ala Ala 1 5 10 15 Ala Ser Ser Phe Lys His Leu Ala Glu Ala Ala Asp Gly Gly Ala Val 20 25 30 Pro Asp Gly Val Cys Asp Gly Lys Cys Arg Ser Arg Cys Ser Leu Lys 35 40 45 Lys Ala Gly Arg Cys Met Gly Leu Cys Met Met Cys Cys Gly Lys Cys 50 55 60 Gin Gly Cys Val Pro Ser Gly Pro Tyr Ala Ser Lys Asp Glu Cys Pro 65 70 75 80 Cys Tyr Arg Asp Met Lys Ser Pro Lys Asn Gin Arg Pro Lys Cys Pro 85 90 95 <210> 43 <211> 129 <212> PRT <213> Zea mays <400> 43 Met Ala Ser Arg Asn Lys Ala Ala Ala Leu Leu Leu Cys Phe Leu Phe 1 5 10 15 Leu Ala Ala Val Ala Ala Ser Ala Ala Glu Met He Ala Gly Ser Gly 20 25 30 He Gly Asp Gly Glu Gly Glu Glu Leu Asp Lys Gly Gly Gly Gly Gly 35 40 45 Gly Gly His His Lys His Glu Gly Tyr Lys Asn Lys Asp Gly Lys Gly 50 55 60 Asn Leu Lys Pro Ser Gin Cys Gly Gly Glu Cys Arg Arg Arg Cys Ser 65 70 75 80 Lys Thr His His Lys Lys Pro Cys Leu Phe Phe Cys Asn Lys Cys Cys 85 90 95 Ala Lys Cys Leu Cys Val Pro Pro Gly Thr Tyr Gly Asn Lys Glu Thr 100 105 110 Cys Pro Cys Tyr Asn Asn Trp Lys Thr Lys Lys Gly Gly Pro Lys Cys 115 120 125 Pro <210> 44 <211> 94 <212> PRT <213> Zea mays <400> 44 Met Ala Lys Ala Ser Ser Arg Leu Leu Phe Ser Leu Ser Leu Val Val 1 5 10 15 30 Leu Leu Leu Leu Val Glu Thr Thr Thr Ser Pro His Gly Gin Ala Asp 20 25 30 Ala He Asp Cys Gly Ala Ser Cys Ser Tyr Arg Cys Ser Lys Ser Gly 35 40 45 Arg Pro Lys Met Cys Leu Arg Ala Cys Gly Thr Cys Cys Gin Arg Cys 50 55 60 Gly Cys Val Pro Pro Gly Thr Ser Gly Asn Glu Asp Val Cys Pro Cys 65 70 75 80 Tyr Ala Asn Met Lys Thr His Asp Gly Gin His Lys Cys Pro 85 90 <210> 45 <211> 145 <212> PRT <213> Zea mays <400> 45 Met Glu Ser Lys Ser Pro Trp Ser Leu Arg Leu Leu He Cys Cys Ala 1 5 10 15 Ala Met Val Ala He Ala Leu Leu Pro Gin Gin Gly Gly Gin Ala Ala 20 25 30 Cys Phe Val Pro Thr Pro Gly Pro Ala Pro Ala Pro Pro Gly Ser Ser 35 40 45 Ala Thr Asn Thr Asn Ala Ser Ser Ala Ala Pro Arg Pro Ala Lys Pro 50 55 60 Ser Ala Phe Pro Pro Pro Met Tyr Gly Gly Val Thr Pro Gly Thr Gly 65 70 75 80 Ser Leu Gin Pro His Glu Cys Gly Gly Arg Cys Ala Glu Arg Cys Ser 85 90 95 Ala Thr Ala Tyr Gin Lys Pro Cys Leu Phe Phe Cys Arg Lys Cys Cys 100 105 110 Ala Ala Cys Leu Cys Val Pro Pro Gly Thr Tyr Gly Asn Lys Asn Thr 115 120 125 Cys Pro Cys Tyr Asn Asn Trp Lys Thr Lys Arg Gly Gly Pro Lys Cys 130 135 140 Pro 145 <210> 46 <211> 77 <212> PRT <213> Triticum aestivum <400> 46 Met Gly Gly Gly Asn Gly Gly Ala Gly Gly Gly Gly Lys Leu Lys Pro 1 5 10 15 Trp Glu Cys Ser Ser Lys Cys Ser Ser Arg Cys Ser Gly Thr Gin Tyr 20 25 30 Lys Lys Ala Cys Leu Thr Tyr Cys Asn Lys Cys Cys Ala Thr Cys Leu 35 40 45 Cys Val Pro Pro Gly Thr Tyr Gly Asn Lys Gly Ala Cys Pro Cys Tyr 50 55 60 Asn Asn Trp Lys Thr Lys Glu Gly Gly Pro Lys Cys Pro 65 70 75 <210> 47 <211> 94 <212> PRT <213> Triticum aestivum <400> 47 31 Met Lys Lys Leu Arg Thr Thr Thr Leu Ala Leu Leu Leu Leu Leu Val 1 5 10 15 Phe Leu Ala Ala Ser Ser Leu Arg Ala Ala Met Ala Gly Ser Ala Phe 20 25 30 Cys Asp Gly Lys Cys Gly Val Arg Cys Ser Lys Ala Ser Arg His Asp 35 40 45 Asp Cys Leu Lys Tyr Cys Gly He Cys Cys Ala Glu Cys Asn Cys Val 50 55 60 Pro Ser Gly Thr Ala Gly Asn Lys Asp Glu Cys Pro Cys Tyr Arg Asp 65 70 75 80 Lys Thr Thr Gly His Gly Ala Arg Lys Arg Pro Lys Cys Pro 85 90 <210> 48 <211> 98 <212> PRT <213> Triticum aestivum <400> 48 Met Lys Lys Leu Arg Thr Thr Thr Ala Thr Thr Thr Leu Ala Leu He 1 5 10 15 Leu Leu Leu Val Leu He Ala Ala Thr Ser Leu Arg Val Ala Met Ala 20 25 30 Gly Ser Ala Phe Cys Asp Ser Lys Cys Gly Val Arg Cys Ser Lys Ala 35 40 45 Gly Arg His Asp Asp Cys Leu Lys Tyr Cys Gly He Cys Cys Ala Glu 50 55 60 Cys Asn Cys Val Pro Ser Gly Thr Ala Gly Asn Lys Asp Glu Cys Pro 65 70 75 80 Cys Tyr Arg Asp Lys Thr Thr Gly His Gly Ala Arg Thr Arg Pro Lys 85 90 95 Cys Pro <210> 49 <211> 107 <212> PRT <213> Triticum aestivum <400> 49 Met Lys Pro Leu Pro Val Thr Leu Ala Leu Leu Ala Leu Phe Leu Val 1 5 10 15 Ala Ser Tyr Gin Asp Leu Thr Val Ala Ala Asp Ala Asp Ala Asp Ala 20 25 30 Ala Gly Ala Gly Asp Val Gly Ala Val Pro Val Pro Asp Ser Val Cys 35 40 45 Glu Gly Lys Cys Lys Asn Arg Cys Ser Gin Lys Val Ala Gly Arg Cys 50 55 60 Met Gly Leu Cys Met Met Cys Cys Gly Lys Cys Ala Gly Cys Val Pro 65 70 75 80 Ser Gly Pro Leu Ala Pro Lys Asp Glu Cys Pro Cys Tyr Arg Asp Met 85 90 95 Lys Ser Pro Lys Ser Gly Arg Pro Lys Cys Pro 100 105 <210> 50 <211> 98 <212> PRT <213> Triticum aestivum <220> 32 <221> VARIANT <222> (64) ... (64) <223> The amino acid at position 64 can be any amino acid <400> 50 Met Ser Lys Pro Ser Arg Cys Arg Ala Val Gin Thr Gin Val Ala Leu 1 5 10 15 Leu Leu Leu Leu Leu Val Ala Ala Ser Leu Leu Gin Ala Gly Asp Ala 20 25 30 Ala Ser Gly Phe Cys Ala Gly Lys Cys Ala Val Arg Cys Gly Arg Ser 35 40 45 Arg Ala Lys Arg Gly Ala Cys Met Lys Tyr Cys Gly Leu Cys Cys Xaa 50 55 60 Glu Cys Ala Cys Val Pro Thr Gly Arg Ser Gly Ser Arg Asp Glu Cys 65 70 75 80 Pro Cys Tyr Arg Asp Met Leu Thr Ala Gly Pro Arg Lys Arg Pro Lys 85 90 95 Cys Pro <210> 51 <211> 114 <212> PRT <213> Triticum aestivum <400> 51 Met Val Thr Lys Val He Cys Phe Leu Val Leu Ala Ser Val Leu Leu 1 5 10 15 Ala Val Ala Phe Pro Val Ser Ala Leu Arg Gin Gin Val Lys Lys Gly 20 25 30 Gly Gly Gly Glu Gly Gly Gly Gly Gly Ser Val Ser Gly Ser Gly Gly 35 40 45 Gly Asn Leu Asn Pro Trp Glu Cys Ser Pro Lys Cys Gly Ser Arg Cys 50 55 60 Ser Lys Thr Gin Tyr Arg Lys Ala Cys Leu Thr Leu Cys Asn Lys Cys 65 70 75 80 Cys Ala Lys Cys Leu Cys Val Pro Pro Gly Phe Tyr Gly Asn Lys Gly 85 90 95 Ala Cys Pro Cys Tyr Asn Asn Trp Lys Thr Arg Glu Gly Gly Pro Lys 100 105 110 Cys Pro <210> 52 <211> 103 <212> PRT <213> Triticum aestivum <400> 52 Met Leu Leu Leu Ala Leu Ala Ala His His Gin Ala Ala Ser Asp Pro 1 5 10 15 Pro Ala Thr His Gly Gly Met Arg Ala Ser Gly Thr Arg Ser Leu Leu 20 25 30 Gin Gin Gin Pro Pro Pro Pro Arg Leu Asp Cys Pro Lys Val Cys Ala 35 40 45 Gly Arg Cys Ala Asn Asn Trp Arg Lys Glu Met Cys Asn Asp Lys Cys 50 55 60 Asn Val Cys Cys Gin Arg Cys Asn Cys Val Pro Pro Gly Thr Gly Gin 65 0 75 80 Asp Thr Arg His He Cys Pro Cys Tyr Ala Thr Met Thr Asn Pro His 85 90 95 33 Asn Gly Lys Leu Lys Cys Pro 100 <210> 53 <211> 105 <212 > PRT <213 > Triticum aestivum <400> 53 Met Ala Pro Gly Lys Leu Ala Val Phe Ala Leu Leu Ala Ser Leu Leu 1 5 10 15 Leu Leu Asn Thr He Lys Ala Ala Asp Tyr Pro Pro Ala Pro Pro Leu 20 25 30 Gly Pro Pro Pro His Lys He Val Asp Pro Gly Lys Asp Cys Val Gly 35 40 45 Ala Cys Asp Ala Arg Cys Ser Glu His Ser His Lys Lys Arg Cys Ser 50 55 60 Arg Ser Cys Leu Thr Cys Cys Ser Ala Cys Arg Cys Val Pro Ala Gly 65 70 75 80 Thr Ala Gly Asn Arg Glu Thr Cys Gly Arg Cys Tyr Thr Asp Trp Val 85 90 95 Ser His Asn Asn Met Thr Lys Cys Pro 100 105 <210> 54 <211> 84 <212> PRT <213> Triticum aestivum <400> 54 Met Ala Gly Gly Arg Gly Arg Gly Gly Gly Gly Gly Gly Gly Val Ala 1 5 10 15 Gly Gly Gly Asn Leu Arg Pro Trp Glu Cys Ser Pro Lys Cys Ala Gly 20 25 30 Arg Cys Ser Asn Thr Gin Tyr Lys Lys Ala Cys Leu Thr Phe Cys Asn 35 40 45 Lys Cys Cys Ala Lys Cys Leu Cys Val Pro Pro Gly Thr Tyr Gly Asn 50 55 60 Lys Gly Ala Cys Pro Cys Tyr Asn Asn Trp Lys Thr Lys Glu Gly Gly 65 70 75 80 Pro Lys Cys Pro <210> 55 <211> 88 <212> PRT <213> Glycine max <400> 55 Met Lys Val Ala Phe Val Ala Val Leu Leu He Cys Leu Val Leu Ser 1 5 10 15 Ser Ser Leu Phe Glu Val Ser Met Ala Gly Ser Ala Phe Cys Ser Ser 20 25 30 Lys Cys Ala Lys Arg Cys Ser Arg Ala Gly Met Lys Asp Arg Cys Thr 35 40 45 Arg Phe Cys Gly He Cys Cys Ser Lys Cys Arg Cys Val Pro Ser Gly 50 55 60 Thr Tyr Gly Asn Lys His Glu Cys Pro Cys Tyr Arg Asp Met Lys Asn 65 70 75 80 Ser Lys Gly Lys Pro Lys Cys Pro 34 85 <210> 56 <211> 88 <212> PRT <213> Glycine max <400> 56 Met Lys Val Ala Phe Ala Ala Val Leu Leu He Cys Leu Val Leu Ser 1 5 10 15 Ser Ser Leu Phe Glu Val Ser Met Ala Gly Ser Ala Phe Cys Ser Ser 20 25 30 Lys Cys Ser Lys Arg Cys Ser Arg Ala Gly Met Lys Asp Arg Cys Met 35 40 45 Lys Phe Cys Gly He Cys Cys Ser Lys Cys Asn Cys Val Pro Ser Gly 50 55 60 Thr Tyr Gly Asn Lys His Glu Cys Pro Cys Tyr Arg Asp Met Lys Asn 65 70 75 80 Ser Lys Gly Lys Ala Lys Cys Pro 85 <210> 57 <211> 88 <212> PRT <213> Glycine max <400> 57 Met Lys Leu Glu Phe Ala Asn Val Leu Leu Leu Cys Leu Val Leu Ser 1 5 10 15 Ser Ser Phe Leu Glu He Ser Met Ala Gly Ser Pro Phe Cys Asp Ser 20 25 30 Lys Cys Ala Gin Arg Cys Ala Lys Ala Gly Val Gin Asp Arg Cys Leu 35 40 45 Arg Phe Cys Gly He Cys Cys Glu Lys Cys Asn Cys Val Pro Ser Gly 50 55 60 Thr Tyr Gly Asn Lys Asp Glu Cys Pro Cys Tyr Arg Asp Met Lys Asn 65 70 75 80 Ser Lys Gly Lys Asp Lys Cys Pro 85 <210> 58 <211> 90 <212> PRT <213> Glycine max <400> 58 Met Lys Leu Val Phe Ala Thr Leu Leu Leu Cys Ser Leu Leu Leu Ser 1 5 10 15 Ser Ser Phe Leu Glu Pro Val He Ala Tyr Glu Asp Ser Ser Tyr Cys 20 25 30 Ser Asn Lys Cys Ser Asp Arg Cys Ser Ser Ala Gly Val Lys Asp Arg 35 40 45 Cys Leu Arg Tyr Cys Gly He Cys Cys Ala Glu Cys Lys Cys Val Pro 50 55 60 Ser Gly Thr Tyr Gly Asn Lys His Gin Cys Pro Cys Tyr Arg Asp Lys 65 70 75 80 Leu Asn Lys Lys Gly Lys Pro Lys Cys Pro 85 90 <210> 59 35 <211> 90 <212> PRT <213> Glycine max <400> 59 Met Lys Leu Val Phe Gly Thr Leu Leu Leu Cys Ser Leu Leu Leu Ser 1 5 10 15 Phe Ser Phe Leu Glu Pro Val He Ala Tyr Glu Asp Ser Ser Tyr Cys 20 25 30 Ser Asn Lys Cys Ala Asp Arg Cys Ser Ser Ala Gly Val Lys Asp Arg 35 40 45 Cys Val Lys Tyr Cys Gly He Cys Cys Ala Glu Cys Lys Cys Val Pro 50 55 60 Ser Gly Thr Tyr Gly Asn Lys His Glu Cys Pro Cys Tyr Arg Asp Lys 65 70 75 80 Leu Asn Lys Lys Gly Lys Pro Lys Cys Pro 85 90 <210> 60 <211> 96 <212> PRT <213> Glycine max <400> 60 Met Ala He Ser Lys Ser Thr Val Val Val Val He Leu Cys Phe He 1 5 10 15 Leu He Gin Glu Leu Gly He Tyr Gly Glu Asp Pro His Met Asp Ala 20 25 30 Ala Lys Lys He Asp Cys Gly Gly Lys Cys Asn Ser Arg Cys Ser Lys 35 40 45 Ala Arg Arg Gin Lys Met Cys He Arg Ala Cys Asn Ser Cys Cys Lys 50 55 60 Lys Cys Arg Cys Val Pro Pro Gly Thr Ser Gly Asn Arg Asp Leu Cys 65 70 75 80 Pro Cys Tyr Ala Arg Leu Thr Thr His Gly Gly Lys Leu Lys Cys Pro 85 90 95 <210> 61 <211> 108 <212> PRT <213> Glycine max <400> 61 Met Met Gly He Leu Leu Leu Val Cys Leu Ala Lys Val Ser Ser Asp 1 5 10 15 Val Asn Met Gin Lys Glu Glu Asp Glu Glu Leu Arg Phe Pro Asn His 20 25 30 Pro Leu He Val Arg Asp Gly Asn Arg Arg Leu Met Gin Asp He Asp 35 40 45 Cys Gly Gly Leu Cys Lys Thr Arg Cys Ser Ala His Ser Arg Pro Asn 50 55 60 Val Cys Asn Arg Ala Cys Gly Thr Cys Cys Val Arg Cys Lys Cys Val 65 70 75 80 Pro Pro Gly Thr Ser Gly Asn Arg Glu Leu Cys Gly Thr Cys Tyr Thr 85 90 95 Asp Met He Thr His Gly Asn Lys Thr Lys Cys Pro 100 105 <210> 62 <211> 117 <212> PRT 36 <213> Glycine max <400> 62 Met Ala Pro Arg Val Phe Leu Val Leu Gly Met Leu Leu Met Val Cys 1 5 10 15 Leu Val Lys Val Ser Ser Asp Pro Lys Arg Glu Glu Glu He Leu Glu 20 25 30 Glu Glu Leu His Phe Pro Asp Asn Glu Pro Leu He Val Arg Asp Gly 35 40 45 Asn Arg Arg Leu Met Gin Asp He Asp Cys Gly Gly Leu Cys Lys Thr 50 55 60 Arg Cys Ser Ala His Ser Arg Pro Asn Leu Cys Thr Arg Ala Cys Gly 65 70 75 80 Thr Cys Cys Val Arg Cys Lys Cys Val Pro Pro Gly Thr Ser Gly Asn 85 90 95 Arg Glu Leu Cys Gly Thr Cys Tyr Thr Asp Met Thr Thr His Gly Asn 100 105 110 Lys Thr Lys Cys Pro 115 <210> 63 <211> 119 <212> PRT < 13> Glycine max <400> 63 Met Ala Leu Arg Val Leu Leu Val Leu Gly Met Leu Leu Met Leu Cys 1 5 10 15 Leu Val Lys Val Ser Ser Asp Pro Lys He Glu Glu Glu He Leu Glu 20 25 30 Ala Glu Glu Glu Leu Gin Phe Pro Asp Asn Glu Pro Leu He Val Arg 35 40 45 Asp Ala Asn Arg Arg Leu Met Gin Asp Met Asp Cys Gly Gly Leu Cys 50 55 60 Lys Thr Arg Cys Ser Ala His Ser Arg Pro Asn Leu Cys Thr Arg Ala 65 70 75 80 Cys Gly Thr Cys Cys Val Arg Cys Lys Cys Val Pro Pro Gly Thr Ser 85 90 95 Gly Asn Arg Glu Leu Cys Gly Thr Cys Tyr Thr Asp Met Thr Thr His 100 105 110 Gly Asn Lys Thr Lys Cys Pro 115 <210> 64 <211> 99 <212> PRT < 13> Glycine max <400> 64 Met Ala Leu Ser Lys Leu He He Ala Ser Leu Leu Ala Ser Leu Leu 1 5 10 15 Leu Leu His Phe Val Asp Ala Asp Gin Ser Ala His Ala Gin Thr Gin 20 25 30 Gly Ser Leu Leu Gin Gin He Asp Cys Asn Gly Ala Cys Ala Ala Arg 35 40 45 Cys Arg Leu Ser Ser Arg Pro Arg Leu Cys Gin Arg Ala Cys Gly Thr 50 55 60 Cys Cys Arg Arg Cys Asn Cys Val Pro Pro Gly Thr Ala Gly Asn Gin 65 70 75 80 Glu Val Cys Pro Cys Tyr Ala Ser Leu Thr Thr His Gly Gly Lys Arg 85 90 95 Lys Cys Pro 37 <210> 65 <211> 115 <212> PRT <213> Glycine max <400> 65 Met Glu Lys Lys Arg Lys Thr Leu Leu Leu Leu Leu Leu Met Ala Ala 1 5 10 15 Thr Leu Phe Cys Met Pro He Val Ser Tyr Ala Val Ser Ser Val Asn 20 25 30 He Gin Gly His Leu Thr His Ser Glu Leu Val Lys Gly Pro Asn Arg 35 40 45 Arg Leu Leu Pro Phe Val Asp Cys Gly Ala Arg Cys Arg Val Arg Cys 50 55 60 Ser Leu His Ser Arg Pro Lys He Cys Ser Arg Ala Cys Gly Thr Cys 65 70 75 80 Cys Phe Arg Cys Arg Cys Val Pro Pro Gly Thr Tyr Gly Asn Arg Glu 85 90 95 Met Cys Gly Lys Cys Tyr Thr Asp Met He Thr His Gly Asn Lys Pro 100 105 110 Lys Cys Pro 115 <210> 66 <211> 191 <212> PRT <213> Glycine max <220> <221> VARIANT <222> (1) ... (48) <223> Xaa = Any Amino Acid <400> 66 Met Ala Ser Asn Ser He Leu Leu Leu Cys He Phe Leu Val Val Ala 1 5 10 15 Thr Lys Val Phe Ser Tyr Asp Glu Asp Leu Lys Thr Val Val Pro Ala 20 25 30 Pro Ala Pro Pro Val Lys Ala Pro Thr Leu Ala Pro Pro Val Lys Ser 35 40 45 Pro Ser Tyr Pro Pro Gly Pro Val Thr Thr Pro Thr Val Pro Thr Pro 50 55 60 Thr Val Lys Val Pro Pro Pro Pro Gin Ser Pro Val Val Lys Pro Pro 65 70 75 80 Thr Pro Thr Val Pro Pro Pro Thr Val Lys Val Pro Pro Pro Pro Gin 85 90 95 Ser Pro Val Val Lys Pro Pro Thr Pro Thr Pro Thr Ser Pro Val Val 100 105 110 Tyr Pro Pro Pro Val Ala Pro Ser Pro Pro Ala Pro Val Val Lys Ser 115 120 125 Asn Lys Asp Cys He Pro Leu Cys Asp Tyr Arg Cys Ser Leu His Ser 130 135 140 Arg Lys Lys Leu Cys Met Arg Ala Cys He Thr Cys Cys Asp Arg Cys 145 150 155 160 Lys Cys Val Pro Pro Gly Thr Tyr Gly Asn Arg Glu Lys Cys Gly Lys 165 170 175 Cys Tyr Thr Asp Met Leu Thr His Gly Asn Lys Phe Lys Cys Pro 180 185 190 38 <210> 67 <211> 107 <212> PRT <213> Glycine max <400> 67 Met Ala Lys Phe Phe Ala Ala Met He Leu Ala Leu Phe Ala He Ser 1 5 10 15 He Leu Gin Thr Val Val Met Ala Ala Asn Glu Gin Gly Gly His Leu 20 25 30 Tyr Asp Asn Lys Ser Lys Tyr Gly Ser Gly Ser Val Lys Ser Tyr Gin 35 40 45 Cys Pro Ser Gin Cys Ser Arg Arg Cys Ser Gin Thr Gin Tyr His Lys 50 55 60 Pro Cys Met Phe Phe Cys Gin Lys Cys Cys Arg Thr Cys Leu Cys Val 65 70 75 80 Pro Pro Gly Tyr Tyr Gly Asn Lys Ala Val Cys Pro Cys Tyr Asn Asn 85 90 95 Trp Lys Thr Lys Glu Gly Gly Pro Lys Cys Pro 100 105 <210> 68 <211> 107 <212> PRT <213> Glycine max <400> 68 Met Ala Lys Phe Phe Ala Ala Met He Leu Ala Leu He Ala He Ser 1 5 10 15 Met Leu Gin Thr Val Val Met Ala Ala Asn Glu Gin Gly Gly His Leu 20 25 30 Tyr Asp Asn Lys Ser Lys Tyr Gly Ser Gly Ser Val Lys Arg Tyr Gin 35 40 45 Cys Pro Ser Gin Cys Ser Arg Arg Cys Ser Gin Thr Gin Tyr His Lys 50 55 60 Pro Cys Met Phe Phe Cys Gin Lys Cys Cys Arg Lys Cys Leu Cys Val 65 70 75 80 Pro Pro Gly Tyr Tyr Gly Asn Lys Ala Val Cys Pro Cys Tyr Asn Asn 85 90 95 Trp Lys Thr Lys Glu Gly Gly Pro Lys Cys Pro 100 105 <210> 69 <211> 110 <212> PRT <213> Glycine max <400> 69 Met Ala Val Ala Asn Lys Leu Leu Ser Val Leu He He Ala Leu He 1 5 10 15 Ala He Ser Met Leu Gin Thr Val Val Met Ala Ser His Gly His Gly 20 25 30 Gly His His Tyr Asn Asp Lys Lys Lys Tyr Gly Pro Gly Ser Leu Lys 35 40 45 Ser Phe Gin Cys Pro Ser Gin Cys Ser Arg Arg Cys Gly Lys Thr Gin 50 55 60 Tyr His Lys Pro Cys Met Phe Phe Cys Gin Lys Cys Cys Arg Lys Cys 65 70 75 80 Leu Cys Val Pro Pro Gly Tyr Tyr Gly Asn Lys Ala Val Cys Pro Cys 85 90 95 Tyr Asn Asn Trp Lys Thr Lys Glu Gly Gly Pro Lys Cys Pro 39 100 105 110 <210> 70 <211> 106 <212> PRT <213> Glycine max <400> 70 Met Ala Met Ala Lys Val Phe Cys Val Leu Leu Leu Ala Leu Leu Gly 1 5 10 15 He Ser Met He Thr Thr Gin Val Met Ala Thr Asp Ser Ala Tyr His 20 25 30 Leu Asp Gly Arg Asn Tyr Gly Pro Gly Ser Leu Lys Ser Ser Gin Cys 35 40 45 Pro Ser Glu Cys Thr Arg Arg Cys Ser Gin Thr Gin Tyr His Lys Pro 50 55 60 Cys Met Val Phe Cys Lys Gin Cys Cys Lys Arg Cys Leu Cys Val Pro 65 70 75 80 Pro Gly Tyr Tyr Gly Asn Lys Ser Val Cys Pro Cys Tyr Asn Asn Trp 85 90 95 Lys Thr Lys Arg Gly Gly Pro Lys Cys Pro 100 105 <210> 71 <211> 123 <212> PRT <213> Glycine max <400> 71 Met Leu Leu Leu Leu Val Glu Asn His Ala Glu He Val Val Ser Thr 1 5 10 15 Val Glu Ala Ser Ala Pro Gin Pro His Lys Asn Thr Thr His Thr Leu 20 25 30 Ser His Ala Pro Ala Pro Gin Pro His Lys Asn Thr Lys Ser Pro Val 35 40 45 Pro Asn Leu Gin His Gly He Thr Glu Gly Ser Leu Lys Pro Gin Glu 50 55 60 Cys Gly Pro Arg Cys Thr Ala Arg Cys Ser Asn Thr Gin Tyr Lys Lys 65 70 75 80 Pro Cys Leu Phe Phe Cys Gin Lys Cys Cys Ala Lys Cys Leu Cys Val 85 90 95 Pro Pro Gly Thr Tyr Gly Asn Lys Gin Val Cys Pro Cys Tyr Asn Asn 100 105 110 Trp Lys Thr Lys Arg Gly Gly Pro Lys Cys Pro 115 120 <210> 72 <211> 97 <212> PRT <213> Glycine max <400> 72 Met Ala Ala Arg Ser Tyr Ser Pro He Met Val Ala Leu Ser Leu Leu 1 5 10 15 Leu Leu Val Thr Phe Ser Asn Val Ala Glu Ala Tyr Thr Arg Ser Gly 20 25 30 Thr Leu Arg Pro Ser Asp Cys Lys Pro Lys Cys Thr Tyr Arg Cys Ser 35 40 45 Ala Thr Ser His Lys Lys Pro Cys Met Phe Phe Cys Gin Lys Cys Cys 50 55 60 Ala Lys Cys Leu Cys Val Pro Pro Gly Thr Tyr Gly Asn Lys Gin He 40 65 70 75 80 Cys Pro Cys Tyr Asn Ser Trp Lys Thr Lys Glu Gly Gly Pro Lys Cys 85 90 95 Pro <210> 73 <211> 66 <212> PRT <213> Oryza sativa <400> 73 His Glu Val Gin His He Asp Cys Asn Ala Ala Cys Ala Ala Arg Cys 1 5 10 15 Arg Leu Ala Ser Arg Gin Arg Met Cys His Arg Ala Cys Gly Thr Cys 20 25 30 Cys Arg Arg Cys Asn Cys Val Pro Pro Gly Thr Ser Gly Asn Gin Glu 35 40 45 Val Cys Pro Cys Tyr Ala Ser Leu Ala Thr His Gly Gly Arg Arg Lys 50 55 60 Cys Pro 65 <210> 74 <211> 88 <212> PRT <213> Solanum tuberosum <400> 74 Met Lys Leu Phe Leu Leu Thr Leu Leu Leu Val Thr Leu Val He Thr 1 5 10 15 Pro Ser Leu He Gin Thr Thr Met Ala Gly Ser Asn Phe Cys Asp Ser 20 25 30 Lys Cys Lys Leu Arg Cys Ser Lys Ala Gly Leu Ala Asp Arg Cys Leu 35 40 45 Lys Tyr Cys Gly Val Cys Cys Glu Glu Cys Lys Cys Val Pro Ser Gly 50 55 60 Thr Tyr Gly Asn Lys His Glu Cys Pro Cys Tyr Arg Asp Lys Lys Asn 65 70 75 80 Ser Lys Gly Lys Ser Lys Cys Pro 85 <210> 75 <211> 63 <212> PRT <213> Gerbera hybrida <400> 75 Ser Lys He Asn Cys Gly Ala Ala Cys Lys Ala Arg Cys Arg Leu Ser 1 5 10 15 Ser Arg Pro Asn Leu Cys His Arg Ala Cys Gly Thr Cys Cys Ala Arg 20 25 30 Cys Arg Cys Val Pro Pro Gly Thr Ser Gly Asn Gin Lys Val Cys Pro 35 40 45 Cys Tyr Tyr Asn Met Thr Thr His Gly Gly Arg Arg Lys Cys Pro 50 55 60 <210> 76 <211> 63 <212> PRT 41 <213> Arabidopsis thaliana <400> 76 Lys Ser Tyr Gin Cys Gly Gly Gin Cys Thr Arg Arg Cys Ser Asn Thr 1 5 10 15 Lys Tyr His Lys Pro Cys Met Phe Phe Cys Gin Lys Cys Cys Ala Lys 20 25 30 Cys Leu Cys Val Pro Pro Gly Thr Tyr Gly Asn Lys Gin Val Cys Pro 35 40 45 Cys Tyr Asn Asn Trp Lys Thr Gin Gin Gly Gly Pro Lys Cys Pro 50 55 60 <210> 77 <211> 96 <212> PRT <213> Solanum lycopersicum <400> 77 Met Ala Lys Ser Gly Tyr Asn Ala Ser Phe Leu Leu Leu He Ser Met 1 5 10 15 Phe Leu He Leu Leu Thr Phe Ser Asn Val Val Glu Gly Tyr Asn Lys 20 25 30 Leu Arg Pro Thr Asp Cys Lys Pro Arg Cys Thr Tyr Arg Cys Ser Ala 35 40 45 Thr Ser His Lys Lys Pro Cys Met Phe Phe Cys Gin Lys Cys Cys Ala 50 55 60 Thr Cys Leu Cys Val Pro Lys Gly Val Tyr Gly Asn Lys Gin Ser Cys 65 70 75 80 Pro Cys Tyr Asn Asn Trp Lys Thr Gin Glu Gly Lys Pro Lys Cys Pro 85 90 95 <210> 78 <211> 106 <212> PRT <213> Arabidopsis thaliana <400> 78 Met Ala Lys Ser Tyr Gly Ala He Phe Leu Leu Thr Leu He Val Leu 1 5 10 15 Phe Met Leu Gin Thr Met Val Met Ala Ser Ser Gly Ser Asn Val Lys 20 25 30 Trp Ser Gin Lys Arg Tyr Gly Pro Gly Ser Leu Lys Arg Thr Gin Cys 35 40 45 Pro Ser Glu Cys Asp Arg Arg Cys Lys Lys Thr Gin Tyr His Lys Ala 50 55 60 Cys He Thr Phe Cys Asn Lys Cys Cys Arg Lys Cys Leu Cys Val Pro 65 70 75 80 Pro Gly Tyr Tyr Gly Asn Lys Gin Val Cys Ser Cys Tyr Asn Asn Trp 85 90 95 Lys Thr Gin Glu Gly Gly Pro Lys Cys Pro 100 105 <210> 79 <211> 106 <212> PRT <213> Arabidopsis thaliana <400> 79 Met Ala Lys Ser Tyr Gly Ala He Phe Leu Leu Thr Leu He Val Leu 1 5 10 15 Phe Met Leu Gin Thr Met Val Met Ala Ser Ser Gly Ser Asn Val Lys 42 20 25 30 Trp Arg Gin Lys Arg Tyr Gly Pro Gly Ser Leu Lys Arg Thr Gin Cys 35 40 45 Pro Ser Glu Cys Asp Arg Arg Cys Lys Lys Thr Gin Tyr His Lys Ala 50 55 60 Cys He Thr Phe Cys Asn Lys Cys Cys Arg Lys Cys Leu Cys Val Pro 65 70 75 80 Pro Gly Tyr Tyr Gly Asn Lys Gin Val Cys Ser Cys Tyr Asn Asn Trp 85 90 95 Lys Thr Gin Glu Gly Gly Pro Lys Cys Pro 100 105 <210> 80 <211> 97 <212> PRT <213> Arabidopsis thaliana <400> 80 Met Ala Asn Cys He Arg Arg Asn Ala Leu Phe Phe Leu Thr Leu Leu 1 5 10 15 Phe Leu Leu Ser Val Ser Asn Leu Val Gin Ala Ala Arg Gly Gly Gly 20 25 30 Lys Leu Lys Pro Gin Gin Cys Asn Ser Lys Cys Ser Tyr Arg Cys Ser 35 40 45 Ala Thr Ser His Lys Lys Pro Cys Met Phe Phe Cys Leu Lys Cys Cys 50 55 60 Lys Lys Cys Leu Cys Val Pro Pro Gly Thr Phe Gly Asn Lys Gin Thr 65 70 75 80 Cys Pro Cys Tyr Asn Asn Trp Lys Thr Lys Glu Gly Arg Pro Lys Cys 85 90 95 Pro <210> 81 <211> 112 <212> PRT <213> Lycopersicon esculentum <400> 81 Met Ala Gly Lys Met Ser He Val Leu Phe Val Leu Leu Val Val Phe 1 5 10 15 Leu Thr Gin Asn Gin Val Ser Arg Ala Asn He Met Arg Asp Glu Gin 20 25 30 Gin Gin Gin Gin Arg Asn Asn Gin Leu Tyr Gly Val Ser Glu Gly Arg 35 40 45 Leu His Pro Gin Asp Cys Gin Pro Lys Cys Thr Tyr Arg Cys Ser Lys 50 55 60 Thr Ser Tyr Lys Lys Pro Cys Met Phe Phe Cys Gin Lys Cys Cys Ala 65 70 75 80 Lys Cys Leu Cys Val Pro Ala Gly Thr Tyr Gly Asn Lys Gin Ser Cys 85 90 95 Pro Cys Tyr Asn Asn Trp Lys Thr Lys Arg Gly Gly Pro Lys Cys Pro 100 105 110 <210> 82 <211> 99 <212> PRT <213> Arabidopsis thaliana <400> 82 43 Met Ala He Phe Arg Ser Thr Leu Val Leu Leu Leu He Leu Phe Cys 1 5 10 15 Leu Thr Thr Phe Glu Leu His Val His Ala Ala Glu Asp Ser Gin Val 20 25 30 Gly Glu Gly Val Val Lys He Asp Cys Gly Gly Arg Cys Lys Gly Arg 35 40 45 Cys Ser Lys Ser Ser Arg Pro Asn Leu Cys Leu Arg Ala Cys Asn Ser 50 55 60 Cys Cys Tyr Arg Cys Asn Cys Val Pro Pro Gly Thr Ala Gly Asn His 65 70 75 80 His Leu Cys Pro Cys Tyr Ala Ser He Thr Thr Arg Gly Gly Arg Leu 85 90 95 Lys Cys Pro <210> 83 <211> 99 <212> PRT <213> Arabidopsis thaliana <400> 83 Met Ala Val Phe Arg Ser Thr Leu Val Leu Leu Leu He He Val Cys 1 5 10 15 Leu Thr Thr Tyr Glu Leu His Val His Ala Ala Asp Gly Ala Lys Val 20 25 30 Gly Glu Gly Val Val Lys He Asp Cys Gly Gly Arg Cys Lys Asp Arg 35 40 45 Cys Ser Lys Ser Ser Arg Thr Lys Leu Cys Leu Arg Ala Cys Asn Ser 50 55 60 Cys Cys Ser Arg Cys Asn Cys Val Pro Pro Gly Thr Ser Gly Asn Thr 65 70 75 80 His Leu Cys Pro Cys Tyr Ala Ser He Thr Thr His Gly Gly Arg Leu 85 90 95 Lys Cys Pro <210> 84 <211> 98 <212> PRT <213> Arabidopsis thaliana <400> 84 Met Ala He Ser Lys Ala Leu He Ala Ser Leu Leu He Ser Leu Leu 1 5 10 15 Val Leu Gin Leu Val Gin Ala Asp Val Glu Ser Ser Gin Lys Lys Asn 20 25 30 Gly Tyr Ala Lys Lys He Asp Cys Gly Ser Ala Cys Val Ala Arg Cys 35 40 45 Arg Leu Ser Arg Arg Pro Arg Leu Cys His Arg Ala Cys Gly Thr Cys 50 55 60 Cys Tyr Arg Cys Asn Cys Val Pro Pro Gly Thr Tyr Gly Asn Tyr Asp 65 70 75 80 Lys Cys Gin Cys Tyr Ala Ser Leu Thr Thr His Gly Gly Arg Arg Lys 85 90 95 Cys Pro <210> 85 <211> 112 <212> PRT <213> Petunia x hybrida 44 <400> 85 Met Ala Gly Lys Leu Ser He Val Leu Phe Val Leu Leu Val Val Leu 1 5 10 15 Leu Ala Gin Asn Gin Val Ser Arg Ala Lys Met Val Leu Asp Ser Lys 20 25 30 Val Gin Arg Arg Gly Asn Asp Gin He Tyr Gly Val Ser Gin Gly Ser 35 40 45 Leu His Pro Gin Asp Cys Gin Pro Lys Cys Thr Tyr Arg Cys Ser Lys 50 55 60 Thr Ser Phe Lys Lys Pro Cys Met Phe Phe Cys Gin Lys Cys Cys Ala 65 70 75 80 Lys Cys Leu Cys Val Pro Ala Gly Thr Tyr Gly Asn Lys Gin Thr Cys 85 90 95 Pro Cys Tyr Asn Asn Trp Lys Thr Lys Glu Gly Gly Pro Lys Cys Pro 100 105 110 <210> 86 <211> 102 <212> PRT <213> Lavatera thuringiaca <400> 86 Met Ala He Ser Lys Ala Leu He Ala Ser Leu Leu He Ser Leu Leu 1 5 10 15 He He Gin He Val Glu Ala Asp His Gin Leu Val Thr Ser Ala Gly 20 25 30 Lys Gly Asn Ser Ser Pro Lys Lys He Asp Cys Gly Gly Ala Cys Ala 35 40 45 Ala Arg Cys Gin Leu Ser Ser Arg Pro His Leu Cys Lys Arg Ala Cys 50 55 60 Gly Thr Cys Cys Ala Arg Cys Ala Cys Val Pro Pro Gly Thr Ala Gly 65 70 75 80 Asn Gin Glu Met Cys Pro Lys Cys Tyr Ala Ser Leu Thr Thr His Gly 85 90 95 Gly Lys Arg Lys Cys Pro 100 <210> 87 <211> 91 <212> PRT <213> Fragaria x ananassa <400> 87 Met Met Met He Ser Leu Leu Val Phe Asn Pro Val Glu Ala Asp Gly 1 5 10 15 Val Val Val Asn Tyr Gly Gin His Ala Ser Leu Leu Ala Lys He Asp 20 25 30 Cys Gly Gly Ala Cys Lys Ala Arg Cys Arg Leu Ser Ser Arg Pro His 35 40 45 Leu Cys Lys Arg Ala Cys Gly Thr Cys Cys Gin Arg Cys Ser Cys Val 50 55 60 Pro Pro Gly Thr Ala Gly Asn Tyr Asp Val Cys Pro Cys Tyr Ala Thr 65 70 75 80 Leu Thr Thr His Gly Gly Lys Arg Lys Cys Pro 85 90 <210> 88 <211> 101 <212> PRT <213> Lavatera thuringiaca 45 <400> 88 Met Ala He Ser Lys Ala Leu He Ala Ser Leu Leu He Ser Leu Leu 1 5 10 15 He He Gin He Val Glu Ala Asp His Gin Leu Val Thr Ser Ala Ser 20 25 30 Lys Gly Ser Ser Phe Pro Lys Lys He Asp Cys Gly Gly Ala Cys Ala 35 40 45 Ala Arg Cys Gin Leu Ser Ser Arg Pro His Leu Cys Lys Arg Ala Cys 50 55 60 Gly Thr Cys Cys Ala Arg Ser Arg Cys Val Pro Pro Gly Thr Ala Gly 65 70 75 80 Asn Gin Glu Met Cys Pro Cys Tyr Ala Ser Leu Thr Thr His Gly Gly 85 90 95 Lys Arg Lys Cys Pro 100 <210> 89 <211> 103 <212> PRT <213> Arabidopsis thaliana <400> 89 Met He Tyr Glu Phe Arg Glu He Lys Phe Phe Phe Leu Cys Val Tyr 1 5 10 15 Val Gin Gly Asp Glu Leu Glu Ser Gin Ala Gin Ala Pro Ala He His 20 25 30 Lys Asn Gly Gly Glu Gly Ser Leu Lys Pro Glu Glu Cys Pro Lys Ala 35 40 45 Cys Glu Tyr Arg Cys Ser Ala Thr Ser His Arg Lys Pro Cys Leu Phe 50 55 60 Phe Cys Asn Lys Cys Cys Asn Lys Cys Leu Cys Val Pro Ser Gly Thr 65 70 75 80 Tyr Gly His Lys Glu Glu Cys Pro Cys Tyr Asn Asn Trp Thr Thr Lys 85 90 95 Glu Gly Gly Pro Lys Cys Pro 100 <210> 90 <211> 87 <212> PRT <213> Arabidopsis thaliana <400> 90 Met Lys Leu Val Val Val Gin Phe Phe He He Ser Leu Leu Leu Thr 1 5 10 15 Ser Ser Phe Ser Val Leu Ser Ser Ala Asp Ser Ser Cys Gly Gly Lys 20 25 30 Cys Asn Val Arg Cys Ser Lys Ala Gly Gin His Glu Glu Cys Leu Lys 35 40 45 Tyr Cys Asn He Cys Cys Gin Lys Cys Asn Cys Val Pro Ser Gly Thr 50 55 60 Phe Gly His Lys Asp Glu Cys Pro Cys Tyr Arg Asp Met Lys Asn Ser 65 70 75 80 Lys Gly Gly Ser Lys Cys Pro 85 <210> 91 <211> 110 <212> PRT <213> Picea mariana 46 <400> 91 Met Ala Arg Leu Gin Ser Phe Ala Val Leu Leu He Thr He Phe Ala 1 5 10 15 Leu Phe He Trp Asn He Glu Ala Ala Leu Pro His Ser Asn Val Asp 20 25 30 Pro Phe Met Glu Gin Lys Gin Gly Gin Tyr Gly Glu Gly Ser Leu Arg 35 40 45 Pro Ser Glu Cys Gly Gin Arg Cys Ser Tyr Arg Cys Ser Ala Thr Ser 50 55 60 His Lys Lys Pro Cys Met Phe Phe Cys Gin Lys Cys Cys Ala Lys Cys 65 70 75 80 Leu Cys Val Pro Pro Gly Thr Phe Gly Asn Lys Gin Val Cys Pro Cys 85 90 95 Tyr Asn Asn Trp Lys Thr Gin Gin Gly Gly Pro Lys Cys Pro 100 105 110 <210> 92 <211> 108 <212> PRT <213> Arabidopsis thaliana <400> 92 Met Lys He He Val Ser He Leu Val Leu Ala Ser Leu Leu Leu He 1 5 10 15 Ser Ser Ser Leu Ala Ser Ala Thr He Ser Asp Ala Phe Gly Ser Gly 20 25 30 Ala Val Ala Pro Ala Pro Gin Ser Lys Asp Gly Pro Ala Leu Glu Lys 35 40 45 Trp Cys Gly Gin Lys Cys Glu Gly Arg Cys Lys Glu Ala Gly Met Lys 50 55 60 Asp Arg Cys Leu Lys Tyr Cys Gly He Cys Cys Lys Asp Cys Gin Cys 65 70 75 80 Val Pro Ser Gly Thr Tyr Gly Asn Lys His Glu Cys Ala Cys Tyr Arg 85 90 95 Asp Lys Leu Ser Ser Lys Gly Thr Pro Lys Cys Pro 100 105 <210> 93 <211> 88 <212> PRT <213> Arabidopsis thaliana <400> 93 Met Ala Val Phe Arg Val Leu Leu Ala Ser Leu Leu He Ser Leu Leu 1 5 10 15 Val Leu Asp Phe Val His Ala Asp Met Val Arg Cys Ser Leu Ser Ser 20 25 30 Arg Pro Asn Leu Cys His Arg Ala Cys Gly Thr Cys Cys Ala Arg Cys 35 40 45 Asn Cys Val Ala Pro Gly Thr Ser Gly Asn Tyr Asp Lys Cys Pro Cys 50 55 60 Tyr Gly Ser Leu Thr Thr His Gly Gly Arg Arg Lys Glu Val Lys Glu 65 70 75 80 Phe Ser Phe Phe Thr His Gly Ser 85 <210> 94 <211> 98 <212> PRT <213> Arabidopsis thaliana 47 <400> 94 Met Ala He Ser Lys Ala Leu He Ala Ser Leu Leu He Ser Leu Leu 1 5 10 15 Val Leu Gin Leu Val Gin Ala Asp Val Glu Asn Ser Gin Lys Lys Asn 20 25 30 Gly Tyr Ala Lys Lys He Asp Cys Gly Ser Ala Cys Val Ala Arg Cys 35 40 45 Arg Leu Ser Arg Arg Pro Arg Leu Cys His Arg Ala Cys Gly Thr Cys 50 55 60 Cys Tyr Arg Cys Asn Cys Val Pro Pro Gly Thr Tyr Gly Asn Tyr Asp 65 70 75 80 Lys Cys Gin Cys Tyr Ala Ser Leu Thr Thr His Gly Gly Arg Arg Lys 85 90 95 Cys Pro <210> 95 <211> 93 <212> PRT <213> Oryza sativa <400> 95 Met Lys Leu Asn Thr Thr Thr Thr Leu Ala Leu Leu Leu Leu Leu Leu 1 5 10 15 Leu Ala Ser Ser Ser Leu Gin Val Ser Met Ala Gly Ser Asp Phe Cys 20 25 30 Asp Gly Lys Cys Lys Val Arg Cys Ser Lys Ala Ser Arg His Asp Asp 35 40 45 Cys Leu Lys Tyr Cys Gly Val Cys Cys Ala Ser Cys Asn Cys Val Pro 50 55 60 Ser Gly Thr Ala Gly Asn Lys Asp Glu Cys Pro Cys Tyr Arg Asp Met 65 70 75 80 Thr Thr Gly His Gly Ala Arg Lys Arg Pro Lys Cys Pro 85 90 <210> 96 <211> 106 <212> PRT <213> Arabidopsis thaliana <400> 96 Met Ala Lys Ser Tyr Gly Ala He Phe Leu Leu Thr Leu He Val Leu 1 5 10 15 Phe Met Leu Gin Thr Met Tyr Met Ala Ser Ser Gly Ser Asn Val Lys 20 25 30 Trp Arg Gin Lys Arg Val Gly Pro Gly Ser Leu Lys Arg Thr Gin Cys 35 40 45 Pro Ser Glu Cys Asp Arg Arg Cys Lys Lys Thr Gin Tyr His Lys Ala 50 55 60 Cys He Thr Phe Cys Asn Lys Cys Cys Arg Lys Cys Leu Cys Val Pro 65 70 75 80 Pro Gly Tyr Tyr Gly Asn Lys Gin Val Cys Ser Cys Tyr Asn Asn Trp 85 90 95 Lys Thr Gin Glu Gly Gly Pro Lys Cys Pro 100 105 <210> 97 <211> 18 <212> PRT <213> Artificial Sequence 48 <220> <223> consensus sequence <221> VARIANT <222> (2)... (2) <223> The amino acid at position 2 can be any amino acid. <221> VARIANT <222> (3) ... (3) <223> The amino acid at position 3 can be any amino acid. <221> VARIANT <222> (6) ... (6) <223> The amino acid at position 6 can be any amino acid. <221> VARIANT <222> (7) ... (7) <223> The amino acid at position 7 can be any amino acid. <221> VARIANT <222> (8) ... (8) <223> The amino acid at position 8 can be Cys or Ser. <221> VARIANT <222> (9) ... (9) <223> The amino acid at position 9 can be any amino acid. <221> VARIANT <222> (10) ... (10) <223> The amino acid at position 10 can be any amino acid, and can either be absent or present. <221> VARIANT <222> (14) ... (14) <223> The amino acid at position 14 can be Pro, Ser, Ala, Thr, or Lys. <221> VARIANT <222> (15) ... (15) <223> The amino acid at position 15 can be Gly or Arg. <221> VARIANT <222> (16) ... (16) <223> The amino acid at position 16 can be any amino acid. <221> VARIANT <222> (17) ... (17) <223> The amino acid at position 17 can be any amino acid. <221> VARIANT <222> (18) ... (18) <223> The amino acid at position 18 can be Gly, Ala, Gin, or Arg. <400> 97 Cys Xaa Xaa Cys Cys Xaa Xaa Xaa Xaa Xaa Cys Val Pro Xaa Xaa Xaa 49 10 15 Xaa Xaa <210> 98 <211> 20 <212 > PRT <213 > Artificial Sequence <220> <223> consensus sequence <221> VARIANT <222> (1) ... (1) <223> The amino acid at position 1 can be Cys or Ser. <221> VARIANT <222> (2) ... (2) <223> The amino acid at position 2 can be Pro, Ser, Gin, Ala, or Gly. <221> VARIANT <222> (3) ... (3) <223> The amino acid at position 3 can be any amino acid, and can be absent or present. <221> VARIANT <222> (4) ... (4) <223> The amino acid at position 4 can be any amino acid, and can be absent or present. <221> VARIANT <222> (7) ... (7) <223> The amino acid at position 7 can be any amino acid. <221> VARIANT <222> (8) ... (8) <223> The amino acid at position 8 can be any amino acid. <221> VARIANT <222> (9) ... (9) <223> The amino acid at position 9 can be any amino acid. <221> VARIANT <222> (10) ... (10) <223> The amino acid at position 10 can be any amino acid. <221> VARIANT <222> (11) ... (11) <223> The amino acid at position 11 can be Thr, Asn, Ser, or Met. <221> VARIANT <222> (12) ... (12) <223> The amino acid at position 12 can be any amino acid. <221> VARIANT <222> (13) ... (13) 50 <223> The amino acid at position 13 can be any amino acid. <221> VARIANT <222> (14) ... (14) <223> The amino acid at position 14 can be any amino acid. <221> VARIANT <222> (15) ... (15) <223> The amino acid at position 15 can be any amino acid. <221> VARIANT <222> (16) ... (16) <223> The amino acid at position 16 can be any amino acid. <221> VARIANT <222> (17) ... (17) <223> The amino acid at position 17 can be any amino acid, and can be absent or present . <221> VARIANT <222> (18) ... (18) <223> The amino acid at position 18 can be any amino acid, and can be absent or present . <221> VARIANT <222> (19) ... (19) <223> The amino acid at position 19 can be any amino acid, and can be absent or present. <400> 98 Xaa Xaa Xaa Xaa Cys Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Lys 20 <210> 99 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide primer <400> 99 tcgacccacg cgtccgaaaa aaaaaaaaaa aaaaaa 36 51

Inventors: NAVARRO ACEVEDO PEDRO A, SIMMONS CARL R, NAVARRO ACEVEDO, PEDRO, A., SIMMONS, CARL, R.
Applicants: NAVARRO ACEVEDO PEDRO A, PIONEER HI BRED INT, SIMMONS CARL R, NAVARRO ACEVEDO, PEDRO, A., PIONEER HI-BRED INTERNATIONAL, INC., SIMMONS, CARL, R.
Application year: 2001
Main classification: C12N15
IPC codes: C07K14, C12N15